Innophos Holdings Inc Annual Report 2017

FY2017 Annual Report · Innophos Holdings Inc

Loading PDF…

Transformation
inACTION
n

2017 Annual Report

Innophos is a global specialty ingredients provider with strong cash delivery, an attractive
EBITDA proﬁle and $722m of revenue in 2017. We provide specialty ingredient solutions that
deliver versatile beneﬁts for the Food, Health, Nutrition and Industrial markets.

2017
Highlights

$722m
Revenue

$22m
Net Income

17%
Adjusted
EBITDA Margin*

Vision 2022:
A Clear Path to
Proﬁtable Growth

Strategic Pillars: Provide Focus and Drive Performance

Operational Excellence
• Phase 1 delivered $16m of savings
• On track to achieve $13m Phase 2 savings

Commercial Excellence
• Market focused global sales organization
• ‘3-in-the-box’ model in place

Strategic Growth
• Completed two strategic acquisitions –
Novel Ingredients and NutraGenesis
• Actively evaluating robust pipeline to

further build upon FHN platform

Solid Cash Generation Supports
Investments in Strategic Priorities
and Strong Shareholder Returns
Over 5 Year Period 2013-2017

$537m
Cash From Ops

$366m
Free Cash Flow
(Excludes acquisitions)

$345m
Dividends and
Share Buyback

50%
Dividend Payout
Ratio (% of FCF)

Strengthen the core

Pursue inorganic
growth

Forge strategic
partnerships

Continuous
improvement

$1.25bn
Sales

20%
Adjusted
EBITDA Margin*

Enhanced growth
proﬁle with asset light
investment needs

Cumulative Return Comparison

IPHS
S&P 500

500%

400%

300%

200%

100%

-100%

*For GAAP to non-GAAP reconciliations, please see the tables in the Company’s latest Earnings Results Press Release available at www.innophos.com.

Safe Harbor for Forward-Looking and Cautionary Statements
This 2017 Annual Report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncer-
tainties. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be
materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking
statement contained in this 2017 Annual Report, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations
of the future, about which we cannot be certain. The forward-looking statements in this 2017 Annual Report may include, among other things, statements about our plans, objectives,
goals, strategies, future events, future revenues or performance, capital expenditures, ﬁnancing needs, plans or intentions relating to acquisitions, the demand for our products and
services, the markets in which we compete and other information that is not historical information. You should read this 2017 Annual Report in conjunction with our Annual Report on
Form 10-K provided herewith. You should refer to “Forward-Looking Statements” and “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for a discussion of important
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you
that the forward-looking statements in this 2017 Annual Report will prove to be accurate. If our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In
light of the signiﬁcant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we
will achieve our objectives and plans in any speciﬁed time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law. We qualify all of our forward-looking statements by these cautionary statements.

Unless the context otherwise indicates, all references in this 2017 Annual Report to the “Company,” “Innophos,” “we,” “us” or “our” or similar words are to Innophos Holdings, Inc. and its
consolidated subsidiaries.
For more information please visit www.innophos.com.

To Our Valued Shareholders:
2017 was a year of great progress for Innophos as we further strengthened our foundation,

delivered operational improvements, advanced our efforts to drive commercial excellence, and

set our strategic transformation into motion.

We delivered sales and adjusted EBITDA margins in line with the
prior year, as the beneﬁts of our two strategic acquisitions and
Operational Excellence initiatives largely offset the effects of our
proactive pruning of lower margin, less differentiated business in
the second half of 2016. We grew our higher margin Food, Health
and Nutrition (FHN) segment to 55% of the overall business and
we exited the year with base business selling prices and volumes
beginning to stabilize. In addition, we had solid free cash ﬂow of
$39 million for 2017 and maintained a strong balance sheet to
support our ongoing strategic priorities.

Vision 2022: Transformation in Action
In April, we introduced our Vision 2022 strategic roadmap to
transform the growth and earnings proﬁle of the company,
increase our presence in attractive FHN end markets, strengthen
our competitive position in the North American phosphate market
and develop innovative solutions that better serve our customers.
Vision 2022 sets the goal of delivering enhanced shareholder value
by achieving $1.25 billion in revenue and 20% Adjusted EBITDA
margin by 2022.

Our team has been relentlessly focused on executing against the
Vision 2022 strategy. In the second half of the year, we closed on
two strategic acquisitions – Novel Ingredients and NutraGenesis
– creating a nearly $0.5 billion FHN platform and strengthening
our foothold in high growth end-markets. These acquisitions are
important steps forward in strengthening our growth proﬁle and
enhancing the value that we offer our customers. The integrations

of both companies are well underway, and we remain conﬁdent in
our ability to improve EBITDA margins by delivering on acquisition
cost synergies. It is clear that our customers value the more
differentiated and innovative solutions that we now offer, and we
have made excellent progress in growing our existing customer
relationships and capitalizing on new business opportunities.

In the fourth quarter, we initiated a strategic value chain
repositioning and manufacturing optimization initiative. We
expect this program, which will be phased throughout 2018, to
meaningfully strengthen our competitive position in the North
America phosphate market and improve earnings, free cash ﬂow
and return on invested capital in future years.

The Strategic Pillars: A Blueprint for
Excellence and Success
Throughout the year, we remained steadfastly committed to our
Strategic Pillars, a framework that was introduced in 2016 and is
now woven into the fabric of everything that we do at Innophos.

We delivered bottom-line beneﬁts through our Operational
Excellence initiatives. This included the completion of our Phase 1
program, which delivered a total of $16 million in savings. In addition,
we are on track to achieve $13 million of Phase 2 cost savings.

We advanced our efforts to be viewed as a partner-of-choice with
our focus on Commercial Excellence. We reorganized our global
commercial team into market-focused verticals and hired key

commercial leaders to drive changes. In addition, we implemented
a new customer engagement strategy with differentiated levels of
service, and a new “3-in-the-box” go-to-market model that aligns
our sales, technology and marketing teams to drive customer
intimacy.

Delivering growth via further M&A remains a top priority for
Innophos under our Strategic Growth pillar. Our team is actively
engaged in identifying opportunities that meet our ﬁnancial
criteria and advance our strategic objectives of expanding
our presence in attractive FHN markets. Our Integration
Management Ofﬁce is fully established with a deep bench of in-
house talent in place and an intricate M&A playbook that covers
every aspect of due diligence and integration. Finding the next
right opportunity is of the utmost importance and we continue to
take a methodical and strategic approach to the process. We are
conﬁdent that we have the balance sheet and internal resources
to act swiftly and efﬁciently.

Organizational and Cultural
Transformation
At the foundation of our successful execution of our three
Strategic Pillars and Vision 2022 roadmap is advancing our
organizational and cultural transformation. 2017 was another
year of accomplishment as we strengthened the organization
by acquiring external talent that brings new skillsets and
expertise to Innophos. In addition, we have remained focused on
having a positive social impact as an organization through our
commitment to diversity in the workplace and giving back to our
community as a champion of STEM education.

Leveraging Momentum, Putting Strategy
to Action
We are excited about the opportunities that are ahead for our
shareholders, partners and employees. In 2018, we are focused
on leveraging the momentum at our backs and continuing to put
our strategy to action as we execute against our top priorities for
the year, which are to:
• Capitalize on inorganic growth opportunities in high-growth

FHN end-markets

• Execute on our value chain repositioning and manufacturing

optimization program

• Develop new and innovative science-backed solutions that

leverage our recently acquired assets, deliver enhanced value
to our customers and address FHN mega trends

• And, complete our Phase 2 Operational Excellence program

We are conﬁdent that the actions we have taken this past year, and
those that are in our pipeline, position Innophos to deliver double
digit top and bottom-line growth in 2018. I would like to thank our
shareholders for your continued support, our customers for their
ongoing partnership and our nearly 1,400 employees for their
relentless commitment to realizing the full potential of Innophos.
2018 will be an important step forward in our transformative
journey toward our Vision 2022 goals and we look forward to
sharing our accomplishments with you along the way.

Sincerely,

Kim Ann Mink, Ph.D.
Chairman, President and Chief Executive Ofﬁcer
April 11, 2018

The higher-margin Food,
Health and Nutrition
segment grew to 55% of
the overall business in 2017,
a signiﬁcant step towards
our Vision 2022 goals

2017

36%

$722m
Revenue

55%

Vision 2022

20%

2022
Projected
Revenue
Mix

75%

(cid:2) Food, Health & Nutrition (FHN) (cid:2) Industrial Specialties (IS) (cid:2) Other

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON DC, 20549
_______________________________________________________________________________________________
FORM 10-K
_______________________________________________________________________________________________

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2017

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

_______________________________________________________________________________________________
INNOPHOS HOLDINGS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
_______________________________________________________________________________________________

Delaware
(state or other jurisdiction of incorporation)

001-33124
(Commission File number)

20-1380758
(IRS Employer Identification No.)

259 Prospect Plains Road
Cranbury, New Jersey 08512
(Address of Principal Executive Officer, including Zip Code)

(609) 495-2495
(Registrants’ Telephone Number, Including Area Code)

Not Applicable
(Former name or former address, if changed since last report)
_______________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class
Common Stock, par value $.001 per share

Name of Each Exchange on Which Registered

Nasdaq Global Select Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act

of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.

Yes

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit and post such files). Yes

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained
herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company

or an emerging growth company. See definition of “accelerated filer,” “large accelerated filer,” “smaller reporting company” and “emerging growth
company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with

any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

The aggregate market value of the voting common equity held by non-affiliates of the registrant was approximately $0.8 billion as of

June 30, 2017, the last business day of the Registrant’s most recently completed second quarter (based on the Nasdaq Global Select Market
closing price on that date).

As of February 21, 2018, the registrant had 19,540,029 shares of common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of Innophos Holdings, Inc. Proxy Statement to be filed for its Annual
Meeting of Stockholders to be held May 15, 2018

Document

Incorporated By Reference In Part No.

III (Items 10, 11, 12, 13 and 14)

Page 1 of 85

TABLE OF CONTENTS

Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures

Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of
Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Consolidated Financial Statements and Supplementary Data
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information

Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions and Director Independence
Principal Accounting Fees and Services

PART I

Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.

PART II

Item 5.

Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.

PART III

Item 10.
Item 11.
Item 12.
Item 13.
Item 14.

PART IV

Item 15.

Exhibits, Financial Statement Schedules

Item 16.

Form 10-K Summary

Signatures

Page

4
11
19
19
19
19

20
21
22
37
38
80
80
80

81
81
81
81
81

Page 2 of 85

FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities
Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking
statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,”
“objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and/or the negative of these
terms, or other comparable terminology intended to identify statements about the future. These statements involve known and
unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements
to be materially different from the information expressed or implied by these forward-looking statements.

Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report
on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and
our expectations of the future, about which we cannot be certain. The forward-looking statements in this Annual Report on
Form 10-K may include, among other things, statements about: (1) global macroeconomic conditions and trends; (2) the
behavior of financial markets, including fluctuations in foreign currencies, interest rates and turmoil in capital markets; (3)
changes in regulatory controls regarding tariffs, duties, taxes and income tax rates; (4) our ability to implement and refine our
Vision 2022 growth plan; (5) our ability to successfully identify and complete acquisitions in line with our Vision 2022 growth
plan and effectively operate and integrate acquired businesses to realize the anticipated benefits of those acquisitions; (6) our
ability to realize expected cost savings and efficiencies from our performance improvement and other optimization initiatives;
(7) our ability to effectively compete in our markets, and to successfully develop new and competitive products that appeal to
our customers; (8) changes in consumer preferences and demand for our products or a decline in consumer confidence and
spending; (9) our ability to benefit from our investments in assets and human capital and the ability to complete projects
successfully and on budget; (10) economic, regulatory and political risks associated with our international operations, most
notably Mexico and China; (11) volatility and increases in the price of raw materials, energy and transportation, and
fluctuations in the quality and availability of raw materials and process aids; (12) the impact of a disruption in our supply chain
or our relationship with our suppliers; (13) our ability to comply with, and the costs associated with compliance with, U.S. and
foreign environmental protection laws; (14) our ability to meet quality and regulatory standards in the various jurisdictions in
which we have operations or conduct business; and (15) other information that is not historical information.

You should refer to “Part I, Item 1A. Risk Factors” of this Annual Report on Form 10-K for a discussion of important

factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report on
Form 10-K will prove to be accurate. You should understand that it is not possible to predict or identify all such factors.
Consequently, you should not consider any such list to be a complete discussion of all potential risks or uncertainties that may
substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors
emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition
or results of operations.

Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the
significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or
warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We
undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.

You should read this Annual Report on Form 10-K and any documents that we reference in this report completely and
with the understanding that our actual future results may be materially different from what we expect. We qualify all of our
forward-looking statements by these cautionary statements.

_______________________________________________________________________________________________

Unless the context otherwise indicates, all references in this Annual Report on Form 10-K to the “Company,”

“Innophos,” “we,” “us” or “our” or similar words are to Innophos Holdings, Inc. and its consolidated subsidiaries. Innophos
Holdings, Inc. is a Delaware corporation and was incorporated on July 15, 2004.

_______________________________________________________________________________________________

This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies.

All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their
respective owners.

Page 3 of 85

ITEM 1.

BUSINESS

Our Company

PART I

Innophos is a leading international producer of specialty ingredient solutions that deliver versatile benefits for the food,
health, nutrition and industrial markets. We leverage our expertise in the science and technology of blending and formulating
phosphate, mineral, enzyme and botanical based ingredients to help our customers offer products that are tasty, healthy, nutritious
and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in
Canada, Mexico and China.

Innophos combines more than a century of experience in specialty phosphate manufacturing with a broad range of other
specialty nutritional ingredients. Utilizing our capabilities in consumer insight, research and product development and application
expertise, we partner with our customers to provide differentiated product offerings that respond to consumer preferences and
megatrends. We utilize this collaborative approach in order to attempt to generate market share gains for our customers.

Many of Innophos’ products are application-specific compounds engineered to meet customer performance requirements
and are often critical to the taste, texture, performance or nutritional content of foods, beverages, pharmaceuticals, oral care products
and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture
additives in cheeses, leavening agents in baked goods, pharmaceutical excipients and cleaning agents in toothpaste, and they also
provide a wide range of nutritional fortification solutions for food, beverage and nutritional supplement manufacturers.

Innophos’ product offering includes a wide array of botanical, enzyme and mineral based nutritional ingredients. These
products have various applications in the food, beverage and dietary supplement end markets such as weight management, men
and women health, digestive health, and cognitive health among others. Innophos’ 2017 acquisitions of Novel Ingredients and
NutraGenesis substantially expanded Innophos’ portfolio of nutritional ingredients, which is a market that Innophos intends to
continue to target for future growth of its food, health and nutrition segment.

Innophos commenced operations as an independent company in August 2004 after purchasing its North American
specialty phosphates business from affiliates of Rhodia, S.A., or Rhodia, which has been a part of Solvay S.A. since 2011. In
November 2006, Innophos completed an initial public offering and listed its common stock for trading on the Nasdaq Global
Select Market under the symbol “IPHS”.

Our Segments and Products

We report our business in three segments: Food, Health and Nutrition; Industrial Specialties; and Other. We have three
principal product lines within these reporting segments: (i) Specialty Ingredients; (ii) Core Ingredients; and (iii) Co-Products
and Other. Our Food, Health and Nutrition reporting segment as well as our Industrial Specialties reporting segment consists of
products in the Specialty Ingredients and Core Ingredients product lines. The Other reporting segment consists of products in
the Co-Products and Other product line.

In 2017, we achieved sales of $722.0 million, of which 55% can be attributed to our Food, Health and Nutrition segment,

36% can be attributed to our Industrial Specialties segment, and 9% can be attributed to our Other segment. For financial
information about our segments and geographic areas, please see Note 21 (Segment Reporting) of the Notes to Financial
Statements in “Part II, Item 8. Consolidated Financial Statements and Supplemental Data” included elsewhere in this Annual
Report on Form 10-K.

Specialty Ingredients

Specialty Ingredients are the most value adding products in our portfolio. Specialty Ingredients consist of specialty
phosphate products, specialty phosphoric acids, including polyphosphoric acid, and a range of other mineral, enzyme and
botanical based specialty ingredients. With our recent acquisitions of Novel Ingredients and NutraGenesis, we have a growing
portfolio of nutritional ingredients, including a growing portfolio of branded nutritional ingredients. Our Specialty Ingredients
products have a wide range of applications, including:

flavor enhancers in beverages;
electrolytes in sports drinks;
texture modifiers in cheeses;
leavening agents in baked goods;
calcium and phosphorus fortification in food and beverages;

•
•
•
•
•
• moisture and color retention in seafood, poultry and meat;

Page 4 of 85

• mineral, enzyme and botanical sources for a wide variety of fortified foods, beverages and dietary supplements;
•
•

excipients in vitamins, minerals, nutritional supplements and pharmaceuticals; and
abrasives in toothpaste.

Each product typically has a number of different applications and end uses. For example, our dicalcium phosphate

product can be used as an excipient for pharmaceutical and dietary supplements, a leavening agent in bakery products and as an
abrasive in oral care products. We often work directly with customers to tailor products to their required specifications for their
finished product application.

Core Ingredients

Our Core Ingredients product line includes food grade purified phosphoric acid, or PPA, technical grade PPA, sodium
tripolyphosphate, or STPP, and detergent grade PPA. Food grade PPA can be used to produce phosphate salts and has a variety of
applications in food and beverages. Technical grade PPA has applications in water treatment. We also sell technical grade PPA in
the merchant market to third-party phosphate derivative producers. STPP is a key ingredient in cleaning products, including
industrial and institutional cleaners and automatic dishwashing detergents and consumer laundry detergents outside the United
States. In addition to its use in cleaning products, STPP is also used in water treatment, clay processing, and copper ore processing.
The end use market for STPP is largely derived from consumer product applications. Detergent Grade PPA is a lower grade form
of PPA used primarily in the production of STPP.

Co-Products and Other

Our Co-Products and Other product line includes granular triple super phosphate, or GTSP, and merchant green phosphoric
acid, or MGA. GTSP is generated at our Coatzacoalcos facility in Mexico as a co-product of our purified wet acid manufacturing
process described further below under “Manufacturing”. GTSP is a fertilizer product used throughout Latin America for increasing
crop yields in a wide range of agricultural sectors. We sell MGA in the merchant market to third party manufacturers of fertilizer
products.

Our Industry

Each of the industries in which we have a presence is competitive in nature.

In connection with our Specialty Ingredients products, we face competition with respect to our phosphate products, as well
as our botanical, enzyme and mineral based nutritional ingredients. Many of our phosphate products are viewed as basic ingredients
that compete with virtually identical products and derivatives manufactured by other companies in the industry, including companies
that utilize the thermal acid method of production described below under “Manufacturing.” North America is a competitive market
for phosphates with several competitors importing products from overseas. Our major competitor in the downstream specialty
phosphates industry is Israel Chemicals Limited, or ICL. We also compete in the specialty phosphates industry with imports from
Germany, Belgium, Israel, Russia, North Africa and China. In recent years, we have faced increasing competition from imports,
including domestically located production facilities owned by foreign based organizations. In addition, in recent years, we have
experienced pricing pressure from overseas imports, which we expect to continue for the foreseeable future.

Our major PPA competitor is Nutrien Ltd., or Nutrien, formed on January 1, 2018 by the merger of Potash Corporation of
Saskatchewan Inc., a global fertilizer company for which specialty phosphates represents only a small part of its business, with
Agrium Inc. We consume the majority of our PPA production in our downstream operations and sell the remainder externally,
where we compete with Nutrien. We also compete with PPA imports from China, Belgium and Israel.

Our major North American STPP competitor is Mexichem, S.A.B. de C.V., or Mexichem, in Mexico. We also compete with
STPP imports from North Africa, Europe, Russia and China. Over the past several decades, there have been regulatory-driven
efforts to reduce the use of STPP in consumer and institutional cleaners and it was essentially eliminated in consumer automatic
dishwashing applications in the United States and Canada in 2010. The industrial and institutional cleaner market has also
reformulated some of its products to reduce STPP content.

We are not a significant supplier to the GTSP or MGA fertilizer markets, and sell our GTSP co-product via a tolling

arrangement that was established in December 2016.

Our nutritional ingredients business faces competition from a larger number of competitors as the industries in which we

compete in connection with this business are highly fragmented. Our competitors in the nutritional ingredients space are
multiple, and include Balchem Corporation, Jost Chemical Company, Naturex Inc. and BI Nutraceuticals Inc. to name a few.

Page 5 of 85

For a discussion of the risks associated with the competition that we face in our markets, see “Part I, Item 1A. Risk

Factors-Risks Related to Our Business Operations-Competition -The success of our business depends on our ability to
successfully compete in competitive markets.” appearing elsewhere in this Annual Report on Form 10-K.

Our Customers

We supply a broad range of customers in over 70 countries worldwide. No customer accounted for more than ten percent

of our net sales in 2017, 2016 or 2015. For the years ended December 31, 2017, 2016 and 2015, we generated net sales of
$722.0, $725.3 million and $789.1 million, respectively.

Our customer base is principally composed of consumer goods manufacturers, specialty chemical manufacturers and
distributors. Our customers manufacture products such as soft drinks, sports drinks and juices, various food products and dietary
supplements, oral care products, petroleum and petrochemical products, and various cleaners and detergents. Our customers include
major consumer goods manufacturers with global market recognition in the food, beverage, pharmaceutical and cleaning product
markets. We have maintained long-term relationships with the majority of our key customers, with the average customer relationship
having lasted over 15 years, and some relationships spanning many decades. Because our Specialty Ingredient products provide
critical functionality and typically represent only a small percentage of our customers’ total end-product cost, our customers
generally tend not to frequently change key raw materials or suppliers, especially in highly recognized brands in the food, health
and nutrition markets.

Manufacturing

We currently have twelve manufacturing plants located in the United States, Canada, Mexico and China supporting our

phosphates and nutrition ingredients products.

The production of specialty phosphates begins with phosphate rock, which can be processed in two alternative ways to
produce PPA: (i) the thermal acid method, in which elemental phosphorus is combusted in a furnace and subsequently hydrated
to produce PPA; or (ii) the purified wet acid method utilized by Innophos, in which mined phosphate rock is reacted with an acid
(most often sulfuric acid) to produce MGA, which is then purified through solvent-based extraction into PPA. The conversion of
MGA into PPA is a technically complex and a capital-intensive process. PPA can be sold or reacted with appropriate mineral salts
or inorganic compounds to produce various specialty phosphate products as required.

We also produce a wide range of botanical, enzyme and mineral based ingredients as part of our nutrition business through

a variety of customized production processes resulting in an extensive suite of product formulations.

Raw Materials and Energy

We purchase a range of raw materials and energy sources on the open market, including phosphate rock, sulfur and sulfuric
acid, MGA, PPA, nutritional ingredients, natural gas and electricity. To help secure supply, we purchase several of our key raw
materials under long-term contracts generally providing for fixed or minimum quantities of materials, or purchase of our full
requirements, and predetermined pricing formulae based on various market indices and other factors. We do not engage in any
significant futures or other derivative contracts to hedge against fluctuations of raw materials. We rely on unaffiliated third parties
to provide our raw materials, a result of which is that raw materials acquisition at economical price levels is an important risk of
our business. See “Part I, Item 1A. Risk Factors - Raw Materials Availability and Pricing - The success of our business depends
on our ability to successfully source sufficient amounts of the raw materials used in our products at competitive prices, often from
a limited number of suppliers, some of whom with we do not have a long-term contract in place.” in this Annual Report on Form
10-K for a discussion of the risks associated with our sourcing raw materials.

Phosphate Rock and MGA. MGA, which is purified to produce PPA, is the main raw material for the creation of our
downstream salts and acids. We currently purchase all of the MGA for processing at our Geismar, Louisiana facility through a
long-term agreement for MGA with Nutrien. At our Coatzacoalcos facility in Mexico, we typically purchase phosphate rock in
order to produce MGA internally; however, we can also process externally purchased MGA available from various suppliers
globally. In addition to our primary sources, we have options for other spot suppliers and will continue to qualify and develop
additional sources for potential future supply.

Sulfur and Sulfuric Acid. Sulfur is the key raw material used in the production of sulfuric acid, a key raw material used in
the production of MGA by the wet method. We produce the vast majority of the sulfuric acid required to operate our Coatzacoalcos
facility. The majority of the sulfuric acid required for the production of MGA by Nutrien supplied to our Geismar, Louisiana
facility is supplied by Solvay. Our U.S. needs for sulfuric acid and our Mexican needs for sulfur are handled through contracts
with Solvay and Pemex-Gas y Petroquimica Basica, respectively.

Page 6 of 85

Purified Phosphoric Acid. The key raw material input for all of our downstream specialty phosphate salt and specialty
phosphoric acid operations is PPA. In addition to purifying MGA to produce PPA internally, we also purchase certain quantities
of our PPA supply from third parties to optimize our consumption and net sales, including from Nutrien with whom we have a
supply contract for PPA (distinct from the supply contract for MGA) which will expire in July 2018. We continue to qualify and
develop additional sources of PPA. In 2017, we produced approximately 70% and purchased approximately 30% of our total PPA
supply.

Nutritional Ingredients. We purchase a variety of botanicals, enzymes and minerals on the international open market for
distribution, further processing, packaging and/or branding for our chosen food, beverages and dietary supplement end markets.
We typically rely on spot suppliers, and in certain limited cases, short-term contracts, for our botanical, enzyme and mineral needs.

Natural Gas and Electricity. Natural gas and electricity are used to operate our facilities and generate heat and steam for
the various manufacturing processes. We typically purchase natural gas and electricity on the North American open market at so-
called “spot rates.” From time to time, we may enter into longer term natural gas and electricity supply contracts in an effort to
eliminate some of the volatility in our energy costs. We did not enter into any economic hedges in the past three years.

Research and Development

Our new product and application development activities are aimed at developing and enhancing products, processes and
applications by offering differentiated, technology-based solutions to our customers and thereby strengthening our position in the
markets we serve. We focus on:

•

•
•

•

•
•

developing new or improved application-specific specialty ingredients based on our existing product line and
identified or anticipated customer needs;
creating new products to be used in new applications or to serve new markets;
providing customers with premier technical services as they integrate our ingredients into their products and
manufacturing processes;
ensuring that our products are manufactured in accordance with our stringent regulatory, health and safety policies
and objectives and applicable law;
developing more efficient and lower cost manufacturing processes; and
expanding existing, and developing new, relationships with customers to meet their product application needs.

Our research expenditures were $3.7 million, $3.7 million and $4.5 million for the years ended December 31, 2017, 2016

and 2015, respectively.

Environmental and Regulatory Compliance

Certain of our operations involve manufacturing and marketing ingredients for use in food, nutritional supplement and
pharmaceutical excipient products, and therefore must comply with U.S. Food and Drug Administration, or FDA, or the U.S.
Department of Agriculture, or USDA, regulatory controls and similar regulatory controls of foreign jurisdictions where we have
operations or conduct business, as well as good manufacturing practices and the quality requirements of our customers. The
regulation of, and legal requirements for, the manufacture and sale of our products is a changing environment, and those changes
may require increased operating costs to develop and implement additional product safety measures. Although there is some
harmonization among the regulatory requirements of various jurisdictions, each country’s specific regulatory requirements apply
to products imported and sold in that country. Regulatory systems throughout the world vary in complexity and transparency, as
well as the time required to navigate such system in order to enter the subject market. Our growth that involves expansion of
existing products into new markets or new products into current or new markets is affected by our ability to obtain necessary
regulatory approvals and achieve and maintain compliance with regulatory requirements. In addition, public perception in the
United States, Europe and other markets of products we offer for sale in relation to their safety and other market and legal trends
related to “natural”, “organic“ and “clean labeling” in foods also may affect our sales and operations.

In addition, our operations that involve the use, handling, processing, storage, transportation and disposal of hazardous
materials are subject to extensive and frequently changing environmental regulation by federal, state, and local authorities,
including, but not limited to, the U.S. Environmental Protection Agency and the U.S. Federal Railroad Administration, or FRA,
as well as regulatory authorities with jurisdiction over our operations in Canada, Mexico and China. Our operations also expose
us to the risk of claims for environmental remediation and restoration or for exposure to hazardous materials. Our production
facilities require operating permits that are subject to renewal or modification. Violations of health and safety and environmental
laws, regulations, or permits may result in restrictions being imposed on operating activities, substantial fines, penalties, damages,
the rescission of an operating permit, third-party claims for property damage or personal injury, or other costs, any of which could
have a material adverse effect on our business, financial condition, results of operations, or cash flows. Due to changes in health
and safety and environmental laws and regulations, the time frames when those laws and regulations might be applied, and
Page 7 of 85

developments in environmental control technology, we cannot predict with certainty the amount of capital expenditures to be
incurred for environmental purposes.

Some environmental laws and regulations impose liability and responsibility on present and former owners, operators or
users of facilities, and sites for contamination at such facilities and sites without regard to causation or knowledge of contamination.
Many of our sites have an extended history of industrial use. Soil and groundwater contamination have been detected at some of
our sites, and additional contamination might occur or be discovered at these sites or other sites in the future (including sites to
which we may have sent hazardous waste). We continue to investigate, monitor or cleanup contamination at most of these sites.
The potential liability for all these sites will depend on several factors, including the extent of contamination, the method of
remediation, future developments and increasingly stringent regulation, the outcome of discussions with regulatory agencies, the
liability of third parties, potential natural resource damage and insurance coverage. Liabilities for environmental matters are
recorded in the accounting period in which our responsibility is established and the cost can be reasonably estimated. Due to the
uncertainties associated with environmental investigations, cleanups and other obligations, as well as the ongoing nature of the
investigations, cleanups and other obligations at our sites, we are unable to predict precisely the nature, cost and timing of our
future remedial obligations with respect to our sites and, as a result, our actual environmental costs and liabilities could significantly
exceed our accruals.

Further information, including the current status of significant environmental matters and the financial impact incurred for
the remediation of such environmental matters, is included in Note 17 (Commitments and Contingencies) of the Notes to Financial
Statements in "Part II, Item 8. Consolidated Financial Statements and Supplementary Data" and in “Part I, Item 1A. Risk Factors
- Legal and Regulatory Risks - We are subject to a wide variety of laws, regulations and government policies, including with
respect to product quality and labeling and the environment, which may change in significant ways.” appearing elsewhere in this
Annual Report on Form 10-K.

Intellectual Property

We rely on a combination of patent, copyright and trademark laws to protect certain key intellectual aspects of our business.
In addition, our pool of proprietary information, consisting of manufacturing know-how, trade secrets and unregistered copyrights
relating to the design and operation of our facilities and systems, is considered particularly important and valuable. Accordingly,
we seek to protect proprietary information through all legal means practicable. However, monitoring the unauthorized use of our
intellectual property is difficult, and the steps we have taken may not prevent all unauthorized use by others.

Insurance

In the normal course of business, we are subject to numerous operating risks, including risks associated with environmental
contamination, health and safety issues and compliance with food safety laws, while manufacturing, developing, marketing and
supplying products.

We currently have in force insurance policies covering property, general liability, excess liability, workers’ compensation,
employer’s liability, product liability, product recall, fiduciary and other coverages. We seek to maintain coverages consistent with
market practices and required by those customers with whom we do business. Where appropriate for the protection of our property
and interests, we also require others with whom we do business to provide certain coverages for our benefit. We believe that we
are appropriately insured for the insurable risks associated with our business.

Employees

As of December 31, 2017, we had 1,373 employees at our facilities worldwide, of whom 747 were unionized hourly
wage employees. We currently employ both union and non-union employees at most of our facilities. We have experienced no
work stoppages or strikes at any of our unionized facilities since acquiring them in 2004. We are a party to a collective
bargaining agreement with the United Steel, Paper and Forestry, Rubber, Manufacturing, Energy, Allied Industrial and Service
Workers International Union, Local No. 7-765 through January 16, 2020 at the Chicago Heights, Illinois facility; International
Union of Operating Engineers, Local No. 369 through April 18, 2019 at the Nashville, Tennessee facility; the Health Care,
Professional, Technical, Office, Warehouse and Mail Order Employees Union, affiliated with the International Brotherhood of
Teamsters, Local 743 through June 17, 2020 at the Chicago (Waterway), Illinois facility; the United Steelworkers, Local
No. 6304 through April 30, 2020 at the Port Maitland, Ontario Canada facility; and the Sindicato de Trabajadores de la
Industria Química, Petroquímica, Carboquímica, Gases, Similares y Conexos de la República Mexicana, at the Mexico
facilities. The agreement at the Coatzacoalcos, Mexico facility is for an indefinite period, but wages are reviewed every year
and the rest of the agreement is subject to negotiation every two years (next scheduled for June 2018).

Page 8 of 85

Executive Officers

The following table and biographical material present information about the persons serving as our executive officers:

Name
Kim Ann Mink
Han Kieftenbeld
Charles Brodheim
Sherry Duff
Amy Hartzell
Joshua Horenstein
Mark Santangelo
Robert Sklans

Position
Chairman, Chief Executive Officer and President
Senior Vice President and Chief Financial Officer

Age
58
52
54 Vice President, Corporate Controller and Chief Accounting Officer
50
42
41
60
52

Senior Vice President, Chief Marketing and Technology Officer
Senior Vice President, Supply Chain and Purchasing
Senior Vice President, Chief Legal Officer and Corporate Secretary
Senior Vice President, Manufacturing, Engineering, and EH&S
Senior Vice President, Chief Human Resources Officer

Biographical Material

Kim Ann Mink, Ph.D. has been the Chief Executive Officer and President of Innophos since December 2015, a director of
Innophos since January 2016 and Chairman since February 2017. Prior to joining Innophos, she served as Business President of
Elastomers, Electrical and Telecommunications at The Dow Chemical Company, or Dow Chemical, from September 2012 to
December 2015. Dr. Mink joined Dow Chemical in April 2009 as Global General Manager, Performance Materials and President
and Chief Executive Officer of ANGUS Chemical Co. (then a fully owned subsidiary of Dow Chemical). Prior to joining Dow
Chemical, Dr. Mink was Corporate Vice President and Global General Manager, Ion Exchange Resins at the Rohm and Haas
Company (now a fully owned subsidiary of Dow Chemical), where she spent more than 20 years serving in numerous senior roles
with increasing responsibilities. From September 2012 to December 2015, Dr. Mink served as a member of the Board of Advisors
of Catalyst Inc. From November 2012 to December 2016, she served as a member of the National Board of Trustees of the ALS
Association. In addition, in 2014, Dr. Mink was named to STEMconnector's 100 Diverse Corporate Leaders in STEM. Since
March 2017, Dr. Mink has served as a director of PolyOne Corporation, a publicly-traded global provider of specialized polymer
materials, services and solutions. Dr. Mink received her B.A. in Chemistry from Hamilton College and a Ph.D. in Analytical
Chemistry from Duke University. She is a graduate of the Wharton School of Business Management Program.

Han Kieftenbeld has been the Senior Vice President and Chief Financial Officer of Innophos since April 2016. From June
2014 to July 2015, Mr. Kieftenbeld served as the Global Chief Financial Officer at AB Mauri, a worldwide producer of bakery
ingredients. From December 2010 to June 2014, Mr. Kieftenbeld served as the Global Chief Procurement Officer of Ingredion
Incorporated, a global ingredient solutions provider. Mr. Kieftenbeld served as Chief Financial Officer at AkzoNobel N.V. from
2007 to 2010 and, before that, at ICI PLC from 1997 to 2007. Mr. Kieftenbeld held various roles of increasing responsibility at
Unilever N.V. from 1988 to 2007. From 2006 to 2017, Mr. Kieftenbeld served as a non-executive advisor and board member at
Themis Analytics, an international sales and marketing decision analytics solutions provider to the pharmaceutical industry. Mr.
Kieftenbeld earned a master’s degree from New York University Stern School of Business, London School of Economics and
Political Science, as well as the HEC School of Management, Paris. He holds a B.S. in Business Economics and Accounting from
Windesheim University in the Netherlands.

Charles Brodheim is the Vice President, Corporate Controller and Chief Accounting Officer of Innophos. Mr. Brodheim
has been Corporate Controller of Innophos since its formation and a Vice President since 2011. Mr. Brodheim joined Rhodia in
1988 and held various tax, accounting and business analyst positions within Rhodia. Mr. Brodheim was the North American
Finance Director for Specialty Phosphates from 2000 to 2002. After 2002, Mr. Brodheim was a Finance Director for various
Rhodia North American Enterprises, including its Eco-Services enterprise. Mr. Brodheim earned a B.B.A. degree in Finance/
Accounting from Temple University and is a certified public accountant.

Sherry Duff is the Senior Vice President, Chief Marketing and Technology Officer of Innophos, a position that she has
held since May 2017. Ms. Duff joined Innophos as Vice President, Chief Marketing Officer in July 2016. Previously, from
November 2011 to June 2015, Ms. Duff served as the President and Managing Director of Arista Laboratories, Inc., a U.S.
subsidiary of Molins, PLC that provides tobacco testing services. From 1997 to October 2011, Ms. Duff held a series of
positions of increasing responsibility at Arch Chemicals, Inc., global biocides company, including most recently as its Director,
Strategic Planning, Business Development & Government Affairs. Ms. Duff received BS degree in Chemistry from the
University of Connecticut and her MBA degree from Rensselaer Polytechnic Institute at Hartford.

Page 9 of 85

Amy Hartzell is the Senior Vice President, Supply Chain and Purchasing at Innophos, a position that she has held since
May 2017. Ms. Hartzell joined Innophos as Vice President, Supply Chain and Purchasing in April 2016. She worked at Dow
Chemical Company from 2009 to March 2016, serving in positions of increasing responsibility, including most recently as its
Global Director, Corporate Supply Chain Center of Excellence. Ms. Hartzell began her career at Rohm and Haas Company in
1997, serving in positions of increasing responsibility until Rohm and Haas Company was acquired by Dow Chemical
Company. Ms. Hartzell earned a BS from Lehigh University and an MBA from La Salle University.

Joshua Horenstein is the Senior Vice President, Chief Legal Officer and Corporate Secretary of Innophos, a position he

has held since May 2017. Mr. Horenstein was Vice President, Chief Legal Officer and Corporate Secretary from September
2016 to May 2017, and acting Vice President, Chief Legal Officer and Corporate Secretary from March 2016 to September
2016. Mr. Horenstein served as interim Chief Human Resources Officer from September 2017 through February 2018. Mr.
Horenstein joined Innophos in 2010 as Corporate Counsel and M&A Attorney and has since held various legal positions of
increasing responsibility. Before joining Innophos, Mr. Horenstein practiced law at several leading law firms, including Ballard
Spahr, LLP, Pepper Hamilton, LLP and Flaster/Greenberg P.C. and was also Vice President and Chief Legal Officer at Rock
Your Phone, Inc., a technology start-up company. Mr. Horenstein received his law degree from the University of Pennsylvania
Law School and he holds bachelor degrees in Economics and Political Science from Penn State University.

Mark Santangelo is the Senior Vice President, Manufacturing, Engineering, and EH&S of Innophos, a position he has held

since May 2017. At the time of joining Innophos, Mr. Santangelo was serving as an independent operations and supply chain
consultant to the specialty chemical industry. Previously, from December 2014 to May 2016, Mr. Santangelo held the position
of Vice President, Global Operations and Supply Chain at Arizona Chemical Company, an international specialty chemical
company. Prior to Arizona Chemical, Mr. Santangelo spent more than 30 years at Ashland Inc., an international specialty
chemical company serving in positions of increasing responsibility with the last 8 years as Vice President Global Supply Chain.
Mr. Santangelo earned his BS and MS degrees, each in chemical engineering, from Villanova University.

Robert Sklans has been the Senior Vice President, Chief Human Resources Officer of Innophos since February 2018.
Prior to joining Innophos, Mr. Sklans served as Chief Human Resources Officer of Elementis PLC, a global specialty chemicals
company, from July 2015 through December 2017, Vice President, Human Resources - North America Division of DSM, a
global food and nutrition company, from January 2014 through July 2015, and Director, Talent Management & Employee
Development - North America Region of Evonik Corporation, a global specialty chemicals company, from June 2011 through
January 2014. Prior to that, Mr. Sklans held various human resources positions at Johnson & Johnson (2002-2011) and Casio,
Inc. (1998-2002). Mr. Sklans holds a BA degree in Psychology from Connecticut College and a Masters in Organizational
Psychology from Columbia University.

Available Information

The Securities and Exchange Commission, or the SEC, maintains a website that contains reports, proxy and information
statements, and other information regarding issuers, including Innophos, that file electronically with the SEC. The public can
obtain any documents that the Company files with the SEC at http://www.sec.gov. Innophos files annual reports, quarterly
reports, proxy statements and other documents with the SEC under the Securities Exchange Act of 1934, as amended, or the
Exchange Act. The public may read and copy any materials that the Company files with the SEC at the SEC’s Public Reference
Room at 100 F Street, N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public
Reference Room by calling the SEC at 1-800-SEC-0330.

Innophos also makes available free of charge through its website (www.innophos.com) its Annual Report on Form 10-K,

Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or
furnished pursuant to the Exchange Act as soon as reasonably practicable after Innophos electronically files such material with,
or furnishes it to, the SEC. The information contained on Innophos’ website is not included in, or incorporated by reference
into, this Annual Report on Form 10-K.

Page 10 of 85

ITEM 1A. RISK FACTORS

The following discussion of risk factors contains "forward-looking statements," as discussed in the Forward-Looking
Statements section of this Annual Report on Form 10-K. Investing in Innophos involves a significant degree of risk. We are providing
the following cautionary discussion of risk factors, uncertainties and assumptions that we believe are relevant to our business.
These are factors that, individually or in the aggregate, we think could cause our actual results to differ materially from expected
and historical results and our forward-looking statements. You should understand that it is not possible to predict or identify all
such factors. Consequently, you should not consider this section to be a complete discussion of all potential risks or uncertainties
that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors
emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or
results of operations.

Risks Related to Our Business Operations

External Factors Impacting Profitability - Our profitability may be affected by factors beyond our control.

Our ability to maintain and increase profitability depend to a large extent upon our ability to price finished products at a level
that will cover manufacturing and raw material costs and provide an acceptable profit margin. Our ability to maintain appropriate
price levels is determined by a number of factors largely beyond our control, such as the economic conditions of the geographic
regions in which we conduct business, raw materials availability and pricing, competitive factors, adoption of new regulations in
the U.S. and other jurisdictions in which we do business and customer preferences impacting use of our ingredients, each of which
is discussed further below. Any of the foregoing factors may materially and negatively impact our ability to increase profitability
as part of our Vision 2022 growth plan.

Raw Materials Availability and Pricing - The success of our business depends on our ability to successfully source sufficient
amounts of the raw materials used in our products at competitive prices, often from a limited number of suppliers, some of
whom with we do not have a long-term contract in place.

We may not be able to source sufficient amounts of the raw materials used in our products at competitive prices, or at all,

which may materially and negatively impact our business.

We rely on unaffiliated third parties to provide our raw materials, and we do not engage in any significant futures or other
derivative contracts to hedge against fluctuations in the price of raw materials. Most of our raw materials are supplied to us by
either one or a small number of suppliers. Some of those suppliers rely, in turn, on sole or limited sources of supply for raw
materials included in their products. Failure of our suppliers to maintain sufficient capability to meet changes in demand or quality,
or to overcome unanticipated interruptions in their own sources of supply due to their own supplier’s performance failures or force
majeure conditions, such as disaster or political unrest, may prevent them from continuing to supply raw materials as we require
them, or at all. Our inability to obtain sufficient quantities of sole or limited source raw materials or to develop alternative sources
on a timely basis if required could result in increased costs in our operations, which may be material, and may negatively impact
our ability to properly maintain our existing level of operations.

Our raw materials are purchased under supply arrangements that vary from long-term multi-year supply agreements to short
term agreements. We also rely on spot suppliers. As a result, we are subject to risks that we may not be able to secure the raw
materials needed for our products on favorable terms, or at all. We cannot be sure that the annual or other periodic contracts we
have in place for our raw materials can be renewed at all or on similar terms to the current terms. In addition, with respect to those
suppliers with whom we do have long-term agreements, we cannot be certain that our suppliers will not seek to terminate, modify
or disrupt performance under such agreements. As previously disclosed, in 2016, Nutrien notified us that it is terminating our
supply agreement for PPA effective July 2018. As a result of such termination, we are continuing to develop alternatives for future
PPA supply needs after July 2018, which could affect our operating costs and adversely impact the competitive positions of some
of our products.

Various market conditions beyond our control can affect the price and supply of our raw materials. For example, the cost for
phosphate rock and sulfur is heavily influenced by the fertilizer market. Prices for both materials have historically experienced
periodic significant fluctuations. Likewise, the cost of natural gas is often positively correlated with petroleum prices. We typically
purchase natural gas at spot market prices for use at our facilities, and our business has, from time to time, been negatively impacted
by wide fluctuations in natural gas prices. Pricing within most of our supply arrangements is set according to predetermined
formulae dependent on price indices or market prices or, with respect to some shorter term contracts, by negotiation with reference
to market conditions. The prices we pay under these contracts will generally lag the underlying market prices of the raw material,

Page 11 of 85

which exposes us to risks in the event the cost of the raw materials decreases quickly. A minority percentage of our raw materials
are purchased under fixed annual pricing arrangements, which provides us price certainty and protection against increases in the
market cost of such materials but exposes us to risks in the event that the cost of such materials decreases. Increased raw material
pricing may adversely affect our margins if we are not able to offset costs with sales price increases. See “Competition - The
success of our business depends on our ability to successfully compete in competitive markets” below.

Our phosphates-based business can be affected by the availability and cost of phosphate rock. Although there are multiple
available global suppliers to supply phosphate rock to our Coatzacoalcos, Mexico site, in 2018, we expect the majority of our
phosphate rock requirements to come from a limited number of these suppliers, thus exposing us to risks if any such supplier
experiences a significant disruption. Although our Coatzacoalcos facility was upgraded to handle alternative grades of rock without
adversely affecting operating efficiency, further investment may be required to realize the full benefits of improved process
flexibility, including to address process efficiency issues which may arise over longer time periods as the plant processes rock
from various sources.

We are also subject to risks stemming from local social and political conditions in those jurisdictions where the phosphate
rock that supports our operations is sourced. The phosphate rock that it utilized by Nutrien to supply MGA to our Geismar, Louisiana
facility is subject to those social and political conditions in Western Sahara, where Nutrien sources the phosphate rock, which
territory has had a long history of social and political upheaval. If Nutrien is unable to source phosphate rock or sufficient amounts
of phosphate rock, our MGA supply would be disrupted and our ability to manufacture our products could be materially adversely
affected.

Competition - The success of our business depends on our ability to successfully compete in competitive markets.

We operate in a competitive environment. Our ability to grow our business depends on our ability to effectively compete in
each of our targeted markets. Some of our competitors have broader product portfolios, larger market shares, access to larger
customer bases, including as a result of a broader geographical footprint, and greater financial resources with respect to the markets
in which we compete. Our business will be materially and adversely affected if we are unable to effectively compete in those
markets that we target.

Our operations are subject to currency fluctuation transaction risks. We may from time to time be at a competitive disadvantage
as a result of the strengthening of the U.S. Dollar, which can place us at a competitive disadvantage with respect to our foreign
competitors selling competing products into the markets to which we sell our products.

With respect to our phosphates-based business, we face competition from lower-cost producers, including in connection with
import competition, which competition intensifies from time to time as a result of changing exchange rates and production
overcapacity. Import competition is heavily influenced by the actions of foreign governments, including the taxation and subsidy
policies of China, which actions are frequently unpredictable. Certain producers are integrated back to phosphate rock, which may
provide cost advantages to them depending on the markets in which they choose to compete. We also face competition from those
suppliers who utilize the “thermal” production method, a process more heavily dependent on energy that may be cost advantaged
compared to “wet” method producers (such as Innophos) during periods of low energy prices. In addition, we also face competition
from those competitors continuing to seek to develop improvements to the purified wet acid method to produce PPA, which, if
developed, may hurt our competitive position. In addition, new technologies are being developed to attempt to produce PPA at a
cheaper cost than the thermal acid method or the purified wet acid method. Any such new or improved technology that is developed
would be expected to reduce the barriers to entry and/or significantly increase competition in the markets in which we compete,
all of which would be expected to harm our competitive position and our business. Although we have a number of product quality
improvement and product enhancement initiatives underway, we cannot assure that our efforts in maintaining differentiation will
be successful. We also face competition from competitors offering non-phosphate alternatives to our phosphate-based products,
which may intensify as a result of evolving consumer preferences.

The nutritional ingredient market is also competitive in nature. In the nutritional ingredient market, competition is based
upon a number of considerations, including product differentiation and innovation, product quality, technical service, and supply
reliability. Our competitors continue to seek improvements to their products and manufacturing processes. Our success in the
nutritional ingredient market depends on our ability to grow our product portfolio, effectively differentiate our products, supply
quality products that comply with evolving regulations, source raw materials in sufficient quantities and at competitive prices and
provide customer service that meets or exceeds our customer’s expectations.

Food, Health and Nutrition Portfolio - we may not be able to continue to grow our growing nutritional ingredient portfolio

due to competitive factors or otherwise.

We are subject to commercial risks in connection with our focus on growing our Food, Health and Nutrition portfolio. Our
two acquisitions in 2017 focused on companies with significant nutritional ingredient portfolios. We expect to continue to evaluate

Page 12 of 85

opportunities to grow our nutritional ingredient portfolio. Our ability to acquire, develop and commercialize nutritional ingredients
depends on, among other factors, our ability to adjust to market and consumer trends, effectively compete in the competitive
dietary supplement market, generate and grow our brand recognition, conduct studies to generate the data needed to support noted
benefits and differentiate our nutritional ingredients and protect our associated intellectual property, including our trademarks. We
may not be able to fully commercialize and grow those nutritional ingredients that we acquire or develop internally as a result of
any of the foregoing factors, which could materially and negatively impact our business.

Consumer Preferences - Changes in consumer preferences and perceptions may lessen the demand for our products,

which could reduce our sales and profitability and harm our business.

Food products are often affected by changes in consumer tastes, national, regional and local economic conditions and
demographic trends. For instance, changes in prevailing health or dietary preferences causing consumers to avoid food products
containing phosphates in favor of foods that are perceived as being healthier could reduce our sales and profitability. Increasing
concern among consumers, public health professionals and government agencies about health and wellness issues represent a
significant challenge to some of our customers, including those engaged in the food and beverage industries.

Public perception in the United States, Europe and other markets, which may be driven by public opinions and publications
concerning phosphate products in relation to their safety, may affect our sales and operations. Regulators in the United States,
Europe and other jurisdictions may choose to change recommended daily intake levels for total phosphate in the diet or added
phosphates in food. Ongoing safety evaluation by European Union regulators of phosphate content in food may result in more
stringent regulations with respect to phosphates or otherwise influence public perception of the health risks associated with
phosphates. In addition, U.S. class action trends related to “natural” and “clean labeling” in foods, as well as public interest
organization spotlighting with respect to environmental impact, may affect our sales and operations. Also, additional demand
restrictions may arise from producers reformulating to reduce or eliminate phosphate content, as has been announced over the
past few years by major consumer packaged goods manufacturers and major food chains.

In addition, our growing nutritional ingredient portfolio is particularly subject to risks associated with consumer preferences.
Our ability to acquire, develop and commercialize nutritional ingredients depends on, among other factors, our ability to understand
evolving customer and market trends and our ability to translate these insights into commercially viable new products. If we are
unable to do so, in whole or in part, our customer relationships and product sales could be harmed. Furthermore, the nutritional
supplements industry is characterized by rapid and frequent changes in demand for products and new product introductions. Our
ineffectiveness in accurately predicting these trends could negatively impact consumer opinion of our products, which could harm
our customer relationships and cause losses to our market share.

Legal and Regulatory Risks - We are subject to a wide variety of laws, regulations and government policies, including

with respect to product quality and labeling and the environment, which may change in significant ways.

Our business is subject to regulation under a wide variety of laws, rules and regulations in each jurisdiction in which we
have operations (United States, Canada, Mexico and China) or conduct business, including the European Union. There can be no
assurance that laws, regulations and policies will not evolve in ways that will require us to modify our business models and
objectives or affect our returns on investments by restricting existing activities and products, subjecting them to escalating costs
or prohibiting them outright. Our inability to maintain compliance with these evolving regulations would adversely affect the
regulatory status of our products and facilities and adversely affect our results of operations, financial position and cash flows.

Our operations involve the use, handling, processing, storage, transportation and disposal of hazardous materials. In addition,
many of our products are ingredients in foods, nutritional supplements or pharmaceutical excipients that are used in finished
products consumed or used by humans or animals and accordingly are subject to applicable food safety laws. As a result, we are
subject to comprehensive and frequently changing food safety, environmental and other regulatory requirements and periodic
inspection by federal, state, local and foreign authorities with jurisdiction over our operations and product markets, including, but
not limited to the EPA, the FDA and their foreign counterparts. Moreover, as we increase operations in foreign jurisdictions, such
as in China where our facility became operational in 2013, and export existing products into new markets or new products into
markets where they have not previously been sold, we are subject to a variety of regulatory requirements in jurisdictions that may
have unique challenges or slow processes. Failure to comply with such regulations could lead to enforcement actions, fines and
penalties or the assertion of private litigation claims and damages. Currently, we are involved in several compliance and remediation
efforts and agency inspections concerning health, safety and environmental matters, the outcome of which cannot be predicted
with certainty.

We are subject to a number of risks if we are unable to achieve and maintain compliance with evolving food safety laws.
These risks are particularly prevalent as we continue to grow our Food, Health and Nutrition portfolio, including through
acquisitions. Worldwide regulatory trends towards increasing regulation of food safety factors to reduce risks, adoption of increased
food defense measures and prevention of economic adulteration of food particularly through supply chain management may
Page 13 of 85

increase our operating costs. For example, in 2011, the United States enacted the Food Safety Modernization Act, or FSMA, which
mandates comprehensive, prevention-based controls by food processors to protect the U.S. food supply and provides the FDA
with new enforcement authority. The FDA, pursuant to the FSMA, continues to promulgate and finalize the FSMA by implementing
regulations. We are subject to substantial risks if we fail to maintain compliance with evolving FSMA requirements and comparable
food regulatory requirements in other jurisdictions in which we do business, including enforcement actions, fines, the rescission
or denial of operating permits, and other penalties. We are also subject to the increased costs associated with maintaining compliance
with such regulatory requirements. In addition, in the United States and other jurisdictions, our products are subject to strict good
manufacturing practice, or GMP, regulations established by the FDA and comparable foreign authorities. Compliance with such
GMP regulations is costly, and failure to comply could lead to enforcement actions and harm our business.

Additional laws or regulations focused on phosphate-based products may be implemented in the future. As European Union
authorities continue to evaluate phosphate content safety considerations in food, any reduction in approved phosphate content
could harm our business. In addition, regulators in the United States, the European Union and other jurisdictions may choose to
no longer allow phosphates as a synthetic ingredient in products labeled with “organic” claims.

A number of states within the United States, and Canada (countrywide), have effectively banned the use of phosphate-based
products in consumer automatic dishwashing detergents. In addition, the European Union enacted legislation to effectively ban
phosphates in consumer detergents with a first phase that began in 2013, and in Australia an industry-led voluntary phosphate ban
took effect in 2014. These trends and related changes in consumer preferences have already reduced our requirements for automatic
dishwashing markets and we have responded with a shift in our capabilities to serve other food and industrial applications.
Furthermore, although phosphates are still permitted for consumer detergent applications in many Latin American countries and
other parts of the world, we cannot be sure that similar bans may not be implemented in some or all of these markets in the future
or that additional customers will not reformulate their products to reduce STPP content in an effort to market a reduced phosphate
content product line. We expect some detergent grade STPP reformulation in 2018, which will adversely affect our financial results.

Additional laws, regulations or distribution policies focused on reduced use of other phosphate-based products could occur
in the future, including new regulations restricting or banning the use of polyphosphoric acid in asphalt road construction. Several
states in the United States have regulations relating to the use of polyphosphoric acid in asphalt road construction, many of which
restrict such use or require approvals (which may include trials) before such use is permitted. If restrictions are instituted in
additional jurisdictions in the United States and Canada, a notable impact on our business could occur.

Changes in composition or permitted-use regulations in domestic or export countries may affect the regulatory status of our
products and our ability to sell these products into some markets. Such changes may in turn require us to reformulate or establish
alternative raw material sourcing, potentially incurring additional cost. If these measures are not successful, the available markets
for our products may be limited.

Our operations also expose us to the risk of claims for environmental remediation and restoration or for exposure to hazardous
materials. Our production facilities require various operating permits that are subject to renewal or modification. Violations of
environmental laws, regulations, or permits may result in restrictions being imposed on operating activities, substantial fines,
penalties, damages, the rescission or denial of operating permits, third-party claims for property damage or personal injury, or
other costs.

Some existing environmental laws and regulations impose liability and responsibility on present and former owners, operators
or users of facilities and sites for contamination at those locations without regard to causation or knowledge of contamination.
Many of our sites have an extended history of industrial use, which may expose us to liability. Soil and groundwater contamination
have been detected at some of our sites, and additional contamination might occur or be discovered at these sites or other sites
(including sites which we might acquire or to which we may have sent hazardous waste) in the future, which could expose us to
liability. For example, future environmental spending is probable at our site in Nashville, Tennessee, as discussed further in Note
17 (Commitments and Contingencies) of the audited financial statements appearing elsewhere in this Annual Report on Form 10-
K. We continue to investigate, monitor and/or clean-up contamination at most of these sites. In addition, in 2017 we reached an
agreement with federal and Louisiana authorities with respect to alleged non-compliance at our Geismar, Louisiana facility, as
discussed further in Note 17 (Commitments and Contingencies) of the audited financial statements appearing elsewhere in this
Annual Report on Form 10-K. This settlement agreement included a fine and subjects us to ongoing compliance obligations,
including with respect to our implementation of a government-approved deep well injection system at the plant to handle the co-
product separated at the site. If we fail to fully operationalize this deep well injection system and comply with the associated
ongoing compliance obligations, we could be forced to develop alternative solutions for handling the subject co-product, which
alternatives may be costly and time-consuming, and we could face additional fines and other penalties. Due to the uncertainties
associated with environmental investigations, clean-ups and other obligations, as well as the ongoing nature of the investigations,
clean-ups and other obligations at our sites, we cannot predict precisely the nature, cost, and timing of our future remedial obligations
with respect to our sites.

Page 14 of 85

International Operations - We are subject to a variety of risks with respect to our foreign operations.

We have production operations in China, Mexico and Canada. We evaluate business opportunities that may expand our
operations to other areas beyond our current operations. We believe that revenue from sales outside the United States will continue
to account for a material portion of our total revenue for the foreseeable future. There are inherent risks in international operations,
including currency fluctuations and devaluations, economic and business conditions that differ from U.S. cycles, divergent social
and political conditions that may become unsettled or even disruptive, communication and translation delays and errors due to
cultural and language barriers and less predictable outcomes from differing legal and judicial systems. Our risks in those regards
are likely to be greatest as we continue to grow our business in China, where we are subject to risks associated with complying
with China’s regulatory requirements, changes in local economic conditions, currency devaluations, and potential disruption from
socio-political activities in that country. Among the additional risks potentially affecting our Mexican operations are changes in
local economic conditions, currency devaluations, renegotiation of the North American Free Trade Agreement, potential disruption
from socio-political violence in that country, and difficulty in contract enforcement due to differences in the Mexican legal and
regulatory regimes compared to those of the United States. Risks to our Canadian operations include a differing federal and
provincial regulatory environment from that in the United States, currency fluctuations and devaluations. In the event that we
establish operations in additional regions, our exposures to risks from the noted causes and from other as yet unknown causes may
increase.

In addition, we are required to comply with the laws of each jurisdiction in which we have operations or sell our products,
including safety and quality laws, product and facility registration laws, marketing laws, environmental laws, antitrust laws, anti-
bribery laws and import and export control laws. The laws of these jurisdictions vary significantly, and we have limited experience
in complying with the laws of certain such jurisdictions. Violations of such laws may result in restrictions being imposed on our
operating activities, substantial fines, civil or criminal penalties, damages, the rescission of operating permits, third-party claims
for property damage or personal injury, or other costs.

Our overall success as a multinational business depends, in part, upon our ability to succeed in differing economic, social
and political conditions. Among other things, we are faced with potential difficulties in staffing and managing local workforces
and designing and effecting solutions to manage commercial risks posed by local customers and distributors. We may not continue
to succeed in developing and implementing policies and strategies that are effective in each location where we do business. These
risks are not limited to only those countries where we actually operate facilities, but may extend to areas and regions that supply
and service our facilities or are supplied and serviced by them.

As a U.S. corporation, we are subject to the regulations imposed by the U.S. Foreign Corrupt Practices Act, or FCPA, which
generally prohibit U.S. companies, their subsidiaries and their intermediaries from making improper payments to foreign officials
for the purpose of obtaining or keeping business. We are also subject to the comparable anti-corruption laws of other countries in
which we conduct business. We sell many of our products in developing countries through third-party sales agents and distributors
whose personnel are not subject to our disciplinary procedures. Although we and our subsidiaries are committed to conducting
business in a legal and ethical manner wherever we operate, and we communicate and seek to monitor compliance with our policies
by all who do business with us, we cannot be sure that all of our third party distributors or agents will remain in full compliance
with the FCPA or comparable foreign regulations at all times. Violations of the FCPA or similar anti-corruption laws by us or our
distributors or agents may result in severe criminal or civil sanctions, could disrupt our business, and could adversely affect our
reputation.

Labor Relations - Our profitability could be negatively impacted if we fail to maintain satisfactory labor relations.

A significant portion of our U.S. employees and a substantial majority of our non-U.S. employees are members of unions.
Strikes, lockouts or other work stoppages or slowdowns involving our unionized employees could have a material adverse effect
on our business.

Product Liability Exposure - We may be subject to costly product liability claims with respect to our products.

Many of our products are functional or fortification additives used in the food and beverage, consumer product, nutritional
supplement and pharmaceutical industries. The sale of these additives and our customers' products that include them involve the
risk of product liability and personal injury claims, which may be brought by our customers or end-users of our customers’ products.
Although we endeavor to adhere to stringent quality standards in the course of their production, storage and transportation, our
products could be subject to adverse effects from foreign matter such as moisture, dust, odors, insects, mold or other substances,
or from excessive temperature variations. Our products may also be susceptible to non-conformance resulting from the raw materials
we use to manufacture our products or other products supplied to us by third parties that we resell, as well as quality issues resulting
from contract manufacturers that we utilize. In addition, we could be subject to claims by end-users of our customers’ products
that incorporate our products that our customers have mislabeled or misrepresented the benefits of their products sold to such end-
users. Historically, we have not been subject to material product liability claims, and no material claims are outstanding. However,
Page 15 of 85

because our products are used in manufacturing a wide variety of our customers' products, including those ingested by humans,
and we have concentrated the recent growth of our business in those areas, we cannot be sure we will not be subject to material
product liability or recall claims in the future. Any product liability claim brought against us, with or without merit, could result
in: decreased demand for our products; regulatory investigations that could require costly recalls or product modifications; loss
of revenues; substantial costs of litigation; liabilities that substantially exceed our product liability insurance, which we would
then be required to pay ourselves; an increase in our product liability insurance rates; and damage to our reputation and the
reputation of our products.

Production Facility Operating Hazards - We may be subject to liability with respect to the operations of our production

facilities.

Our production facilities are subject to hazards associated with the manufacturing, handling, storage and transportation of
chemical substances and products, including failure of pipeline integrity, explosions, fires, inclement weather and natural disasters,
terrorist attacks, mechanical failures, unscheduled downtime, transportation or utility interruptions, remedial complications,
chemical spills, discharges or releases of toxic or hazardous substances, storage tank leaks and other environmental risks. Although
we have implemented and installed various management systems and engineering controls and procedures at all our production
facilities to enhance safety and minimize these risks and we insure our facilities to protect against a range of risks, these potential
hazards continue to exist and could cause personal injury and loss of life, severe damage to or destruction of property and equipment,
and environmental and natural resource damage, and may result in a suspension of operations (or extended shutdowns) and the
imposition of civil or criminal penalties, whose nature, timing, severity and non-insured exposures are unknown. In addition, we
do not have backup production capabilities in place for all of our production facilities. If we experience a disruption at any of our
production facilities, it could have a material and adverse effect on our operations.

Intellectual Property Rights - If we are unable to protect our intellectual property rights, our position in our markets may

be materially and adversely affected.

We rely on a combination of contractual provisions, confidentiality procedures and agreements, and patent, trademark,
copyright, unfair competition, trade secrecy, and other intellectual property laws to protect our intellectual property and other
proprietary rights on a worldwide basis. Nonetheless, we cannot be sure that any pending patent application or trademark application
will result in an issued patent or registered trademark, that any issued or registered patents or trademarks will not be challenged,
invalidated, circumvented or rendered unenforceable or that our confidentiality procedures will maintain the confidentiality of
our confidential information. In addition, with respect to the intellectual property rights that we license from a third party, we
cannot be certain that such third party will take all steps necessary to protect such rights from infringement by a third party. Our
ability to protect our intellectual property, including intellectual property that we license from third parties, is particularly important
as we seek to continue to grow our branded nutritional ingredient portfolio. The use of our intellectual property (owned or licensed
by us) by others could reduce any competitive advantage we have developed or otherwise harm our business. Failure to protect
the intellectual property associated with our branded nutritional ingredients in particular may have a material adverse effect on
the sales of such products. Moreover, we cannot be sure that our intellectual property rights can be asserted in all cases, particularly
in an international context, or that we can defend ourselves successfully or cost-effectively against the assertion of rights by others.

Contingency Planning - We may face operational challenges that could have a material adverse effect on our business.

We operate a number of manufacturing facilities in the United States, Mexico, Canada and China, and we coordinate company
activities, including our sales, customer service, information technology systems and administrative services and the like, through
headquarters operated in those countries.

Our sites and those of others who provide services to them are subject to varying risks of disaster and follow on consequences,
both manmade and natural, that could degrade or render inoperable one or more of our facilities for an extended period of time.
Such disaster related risks and effects are not predictable with certainty and, although they can be mitigated, they cannot be
completely prevented. Although we review and analyze risks applicable to our business, the factors that actually affect us may
not be those we have concluded are most likely to occur. Furthermore, although our reviews have led to more systematic contingency
planning, our plans are in varying stages of development and execution, such that they may not be adequate at the time of occurrence
for the magnitude of any particular disaster event that befalls us.

We depend on our information technology systems for the efficient functioning of our business, including accounting, sales
and order processing, data storage, compliance, purchasing and inventory management. Although we attempt to mitigate
interruptions to these systems, we may experience unanticipated interruptions, including in connection with implementing certain
upgrades to these systems. In addition, we may experience difficulties in operating our business during an upgrade. Any such
disruption to these systems could disrupt our business, including our ability to timely ship and track product orders, project
inventory requirements, manage our supply chain and otherwise adequately service our customers. In addition, we may not be
able to repair any disruption to our systems in an efficient and timely manner.

Page 16 of 85

Increased global cybersecurity vulnerabilities, threats and sophisticated and targeted cyber-related attacks pose a risk to the
security of our and our customers', partners', suppliers' and third-party service providers' respective products, systems and networks
and the confidentiality, availability and integrity of our and our customers' data. Although we attempt to mitigate these risks by
employing a number of measures, we remain potentially vulnerable to additional known or unknown threats. We may have access
to sensitive, confidential or personal data or information that is subject to privacy and security laws, regulations and customer-
imposed controls. Despite our efforts to protect sensitive, confidential or personal data or information, we may be vulnerable to
material security breaches, theft, misplaced or lost data, programming errors, employee errors and/or malfeasance that could
potentially lead to the compromising of sensitive, confidential or personal data or information, improper use of our systems,
software solutions or networks, unauthorized access, use, disclosure, modification or destruction of information, defective products,
production downtimes and operational disruptions. In addition, a cyber-related attack could result in other negative consequences,
including damage to our reputation or competitiveness, costly and time-consuming remediation or increased protection actions,
litigation or regulatory action.

Acquisition Risks - Any acquisitions or divestitures we make could disrupt our business and not produce the expected

benefits of such transaction.

In 2017, we completed two acquisitions. We will continue from time to time to consider certain acquisitions or divestitures.
Acquisitions and divestitures involve numerous risks, including identifying attractive target acquisitions, undisclosed risks affecting
the target, difficulties integrating acquired businesses, the assumption of unknown liabilities, potential adverse effects on existing
business relationships with current customers and suppliers and overall increased demand on our employees' time and resources.

We cannot provide assurance that any acquisitions or divestitures, including the two acquisitions that we consummated in
2017, will perform as planned or prove to be beneficial to our operations and cash flow, or that we will be able to successfully
integrate any acquisitions that we undertake. Any such failure could harm our financial condition, results of operations and cash
flows.

Certain Financial Risks

Impairment Charges - The recognition of impairment charges on goodwill or long-lived assets could adversely impact

our future financial position and results of operations.

We have approximately $257 million of total intangible assets at December 31, 2017, consisting of $153 million of goodwill
and $104 million of other intangible assets. Additionally, we have approximately $219 million of long-lived assets at December
31, 2017.

We perform an annual impairment assessment for goodwill and our indefinite-lived intangible assets, and as necessary, for
other long-lived assets. If the results of such assessments were to show that the fair value of these assets were less than the carrying
values, we could be required to recognize a charge for impairment of goodwill and/or long-lived assets and the amount of the
impairment charge could be material. Based on the results of the annual assessment, we concluded that as of December 31, 2017,
the fair value of all of our reporting units was greater than their carrying value.

Even though it was determined that there was no additional goodwill impairment as of December 31, 2017, the future
occurrence of a potential indicator of impairment, such as a significant adverse change in the business climate that would require
a change in our assumptions or strategic decisions made in response to economic or competitive conditions, could require us to
perform an assessment prior to the next required assessment date during the fourth quarter of 2018.

Tax Rates - Changes in our tax rates or exposure to additional income tax liabilities could impact our profitability.

We are subject to income taxes in the United States and in various other foreign jurisdictions. Our effective tax rates could
be adversely affected by changes in the mix of earnings by jurisdiction, changes in tax laws or tax rates including recent tax reform
in the United States to broaden the tax base and reduce deductions or credits, changes in the valuation of deferred tax assets and
liabilities, and material adjustments from tax audits.

The recoverability of deferred tax assets, which are predominantly applicable in the United States, is dependent upon our
ability to generate future taxable income in these jurisdictions. In addition, the amount of income taxes we pay is subject to ongoing
audits in various jurisdictions and a material assessment by a governing tax authority could affect our profitability.

Interest Rates - Increased interest rates could increase our borrowing costs.

From time to time we may issue securities or seek additional borrowings to finance acquisitions, capital expenditures, working
capital and for other general corporate purposes. An increase in our net leverage position, and an increase in interest rates in the

Page 17 of 85

general economy could result in an increase in our borrowing costs for these financings, as well as under any existing debt that
bears interest at an un-hedged floating rate.

Contingencies Affecting Dividends - Our ability to pay dividends in the future may be compromised.

After our common stock became publicly traded in 2006, our Board of Directors initiated a policy of paying regular quarterly
cash dividends, subject to the availability of funds, legal and contractual restrictions and prudent needs of our business. We have
maintained that policy and paid dividends continuously since that time, making payments that we believed were prudent and
promoted stockholder value. However, we are a holding company that does not conduct any business operations of our own. As
a result, we are normally dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly
Innophos, Inc., our primary operating subsidiary, and Innophos Investment Holdings, Inc., the direct subsidiary of Innophos
Holdings, Inc. and the direct parent company of Innophos, Inc., to make dividend payments on our common stock. The amounts
available to us to pay cash dividends are restricted by provisions of Delaware law and historically, and we expect for the future,
also by limitations in our debt facilities. As allowed by existing debt instruments, we may incur additional indebtedness that may
restrict to an even greater degree, or prohibit, the payment of dividends on stock. We cannot be sure the level of our operations or
agreements governing our current or future indebtedness will permit us to adhere to our current dividend policy, increase dividends,
or pay any dividends at all, or that continued payment of dividends will remain prudent for our business in the future judgment
of our Board of Directors.

Credit Facility Risks - Our credit facility restricts our current and future operations.

In December 2016, we entered into a credit agreement with a group of lenders to establish a credit facility, which credit
facility essentially replaced our existing credit facility at that time. This credit facility imposes operating and financial restrictions
on us, including affirmative and negative covenants that prohibit or limit a variety of actions by Innophos generally without the
lenders’ approval. These include covenants that affect our ability, among other things, to: incur or guarantee indebtedness; create
liens; enter into mergers, recapitalizations or assets purchases or sales; change names; make certain changes to our business; make
restricted payments that include dividends, purchases and redemptions of equity; make advances, investments or loans; effect
sales and leasebacks; enter into transactions with affiliates; allow negative pledges or limitations on the repayment abilities of
subsidiaries; or amend subordinated debt. In addition to these restrictions and covenants, our credit facility requires us to comply
with specified financial maintenance covenants. We cannot guarantee that we will be able to maintain compliance with these
covenants. In addition, any of these restrictions or covenants could limit our ability to plan for or react to market conditions or
meet certain capital needs and could otherwise restrict our corporate activities. For example, our results of operations may limit
our borrowing base to a level below that which we seek to establish. Any such limitation could harm our business.

Additional Funding - We may not have access to the funds required for future growth and expansion.

We may need additional funds to grow and expand our operations. We expect to fund our capital expenditures from
operating cash flow to the extent we are able to do so and from our credit facility. If our operating cash flow is insufficient to
fund our capital expenditures, we may either reduce our capital expenditures or further utilize our credit facility. For further
strategic growth through mergers or acquisitions, we may also seek to generate additional liquidity, including beyond our
existing credit facility, through the sale of debt or equity securities in private or public markets, through the sale of non-
productive assets or through additional borrowings under our existing credit facility and/or additional facilities. We cannot
provide any assurance that our cash flows from operations and our existing credit facility will be sufficient to fund anticipated
capital expenditures or that we will be able to obtain additional funds from financial markets or from the sale of assets at terms
favorable to us or at all. If we are unable to generate sufficient cash flows or raise sufficient additional funds to cover our
capital expenditures or other strategic growth opportunities, we may not be able to achieve our desired operating efficiencies
and expansion plans, which may adversely impact our competitiveness and, therefore, our results of operations.

Page 18 of 85

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2.

PROPERTIES

Our headquarters are located in Cranbury, New Jersey, with manufacturing facilities strategically located throughout the
United States, Canada, Mexico and China. We do not own and are not responsible for any closed U.S. or Canadian elemental
phosphorus or phosphate production sites. All of our properties located in the United States, Canada, Mexico, China and Brazil
are utilized in our Food, Health and Nutrition, Industrial Specialties and Other reporting segments, except for our China
property which are only utilized in our Food, Health and Nutrition segment.

Facility Type

Location

Owned or Leased

Corporate Headquarters / Research & Development

Cranbury, NJ

Manufacturing

Manufacturing
Manufacturing

Manufacturing

Manufacturing / Research & Development /
Administrative

Manufacturing

Warehouse

Administrative

Manufacturing

Administrative

Manufacturing

Administrative

Manufacturing

Administrative

Chicago Heights, IL

Nashville, TN

Port Maitland, Ontario, Canada
Geismar, LA

Ogden, UT
North Salt Lake, UT

Green Pond, SC

Chicago (Waterway), IL

Chicago Heights, IL

East Hanover, NJ

Brattleboro, VT

Coatzacoalcos, Veracruz, Mexico

Leased

Owned

Owned
Owned

Leased
Owned

Owned

Leased

Owned

Mission Hills, Guanajuato, Mexico

Leased

Mexico City, Mexico

Mississauga, Ontario, Canada

Taicang City, China

Xi'an, China

Sao Paulo, Brazil

Leased

ITEM 3.

LEGAL PROCEEDINGS

The information set forth in Note 17 of the Notes to Consolidated Financial Statements, “Commitments and
Contingencies,” in “Part II, Item 8. Consolidated Financial Statements and Supplementary Data” of this Annual Report on
Form 10-K is incorporated herein by reference.

ITEM 4. MINE SAFETY DISCLOSURES

None.

Page 19 of 85

PART II

ITEM 5. MARKET FOR THE REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS

AND ISSUER PURCHASES OF EQUITY SECURITIES

Certain Market Data

Our common stock has been listed and traded since November 2006 on the Nasdaq Global Select Market under the

symbol “IPHS.”

Stock price comparisons:

Quarter
First
Second
Third
Fourth

2017

2016

High

Low

55.20
53.97
49.36
50.50

47.44
42.29
41.77
42.60

Dividends
Paid
Per Share
0.48
0.48
0.48
0.48

High

Low

31.79
42.21
44.28
57.16

23.12
31.10
37.26
38.17

Dividends
Paid
Per Share
0.48
0.48
0.48
0.48

The Company declared a $0.48 per share dividend in the first quarter of 2018.The number of holders of record of our

common stock at February 15, 2018 was 7,589.

Dividends

Consistent with the determination our Board of Directors made in December 2006, we continue to declare and pay

quarterly dividends. The quarterly dividend has been $0.48 per share since August 2014. Subject to action by the Board of
Directors, management’s present policy is to recommend dividends be continued, reflecting its judgment at the present time
that stockholders are better served if we distribute to them, as quarterly dividends payable at the discretion of the Board of
Directors, a portion of the cash generated by our business in excess of our expected cash needs rather than retaining or using
the cash for other purposes. Our expected cash needs include operating expenses and working capital requirements, interest and
principal payments on our indebtedness, capital expenditures, costs associated with being a public company, taxes and other
costs. If our financial needs change, management’s recommendations concerning dividends may also change.

We are not required to pay dividends, and our stockholders will not be guaranteed, or have contractual or other rights, to

receive dividends. Our Board of Directors may decide, in its discretion at any time, to decrease or increase the amount of
dividends, otherwise modify or repeal the dividend policy or discontinue entirely the payment of dividends.

In addition to prudent business considerations, our ability to pay dividends is restricted by the laws of Delaware, our state

of incorporation, and certain restrictions in the credit agreement governing our credit facility.

Because we are a holding company, substantially all assets shown on our consolidated balance sheet are held by our
subsidiaries. Accordingly, our earnings and cash flow and our ability to pay dividends are largely dependent upon the earnings
and cash flows of our subsidiaries and the distribution or other payment of such earnings to us in the form of dividends. Our
ability to pay dividends on our common stock is limited by restrictions in the credit agreement governing our indebtedness
affecting the ability to pay dividends. See Note 10 of Notes to Consolidated Financial Statements in “Part II, Item 8.
Consolidated Financial Statements and Supplementary Data” and Part I, Item 1A. Risk Factors - Certain Financial Risks -
Contingencies Affecting Dividends - Our ability to pay dividends in the future may be compromised." appearing elsewhere in
this Annual Report on Form 10-K.

Issuer Purchases of Equity Securities

The Company did not have any share repurchases on the open market during 2017. From time to time, the Company

reacquires shares from employees in connection with the vesting, exercise and forfeiture of awards under its equity
compensation plans. In December 2017, the Company reacquired an aggregate of 9,766 shares at a price of $46.73 per share in
connection with the surrender of restricted shares by employees for tax purposes.

Page 20 of 85

ITEM 6.

SELECTED FINANCIAL DATA

The following table presents selected historical consolidated statements of operations, balance sheet and other data for the

periods presented and should only be read in conjunction with our audited consolidated financial statements and the related
notes thereto, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” which are
included elsewhere in this Annual Report on Form 10-K.

(Dollars in thousands, except per share amounts, share amounts or where
otherwise noted)

Year Ended December 31,

2017

2016

2015

2014

2013

Statement of operations data:

Net sales

Cost of goods sold

Gross profit

Operating expenses:

Selling, general and
administrative

Research and development

Total operating expenses

Operating income

Interest expense, net

Foreign exchange (gains) losses, net

Income before income taxes

Provision for income taxes

Net income

Allocation of net income to common
shareholders
Per share data:

Income per share:

Basic

Diluted

Cash dividends declared

Weighted average shares outstanding:

Basic
Diluted

Other data:

Cash flows provided from (used in):

Operating activities
Investing activities
Financing activities

Capital expenditures
Ratio of earnings to fixed charges (1)

722,024

725,345

789,147

839,186

572,995

149,029

574,953

150,392

645,818

143,329

651,722

187,464

82,229

3,733

85,962

63,067

7,008

(578)

56,637

34,192

22,445

22,369

1.15

1.13

1.92

67,555

3,739

71,294

79,098

7,669

1,111

70,318

22,347

47,971

47,683

2.47

2.44

1.92

87,304

4,502

91,806

51,523

7,518

3,882

40,123

13,777

26,346

26,274

1.31

1.29

1.92

76,020

4,649

80,669

106,795

4,354

5,085

97,356

32,895

64,461

64,324

2.96

2.91

1.76

844,129

685,830

158,299

70,501

3,928

74,429

83,870

4,426

3,197

76,247

26,741

49,506

49,442

2.25

2.21

1.45

19,444,795

19,271,448

20,032,300

21,753,270

21,933,843

19,733,410

19,581,476

20,323,385

22,121,903

22,345,980

(Dollars in thousands)

Year Ended December 31,

2017

2016

2015

2014

2013

80,617
(191,458)
86,542
41,487
6.9x

139,109
(36,599)
(67,072)
36,599
8.0x

98,926
(31,699)
(86,018)
31,699
5.1x

126,781
(29,398)
(94,042)
27,955
15.7x

91,677
(37,840)
(47,519)
33,415
11.1x

(1) For purposes of calculating the ratio of earnings to fixed charges, earnings represent income before income taxes
plus fixed charges. Fixed charges consist of interest expense and one-third of operating rental expenses which
management believes is representative of the interest component of rent expense.

Page 21 of 85

Balance sheet data:
Cash and cash equivalents
Accounts receivable, net
Inventories
Property, plant & equipment, net
Total assets
Total debt
Total stockholders’ equity

(Dollars in thousands)

Year Ended December 31,

2017

2016

2015

2014

2013

28,782
100,820
145,685
219,297
785,169
310,009
333,559

53,487
77,692
128,295
205,459
643,011
185,000
347,226

17,905
79,743
172,667
199,494
669,553
213,002
333,260

36,207
90,551
184,621
198,988
728,411
136,005
463,007

32,755
88,434
181,467
201,985
745,666
163,009
463,419

Items included in the preceding tables which had a significant impact on results are summarized as follows:

2017 included the acquisitions of Novel Ingredients and NutraGenesis (included in our Food, Health and Nutrition
segment), increasing investing activities by approximately $151.1 million, and $17.3 million tax expense due to the enactment
of the U.S. Tax Cuts and Jobs Act of 2017. 2016 included restructuring costs of approximately $1.5 million before tax ($0.2
million in cost of goods sold and $1.3 million in selling, general and administrative expense). 2015 included management
transition expenses and restructuring costs of approximately $20.4 million before tax ($3.3 million in cost of goods sold and
$17.1 million in selling, general and administrative expense) and the Company's stock repurchase program which increased
financing activities by $125.0 million, which was partially offset by increased borrowings. 2013 included the acquisition of
Chelated Minerals International, Inc. (now part of our Food, Heath and Nutrition segment), increasing investing activities by
approximately $5.0 million, and an after tax benefit of $5.4 million ($7.2 million before tax) for the settlement of the Mexican
Comision National del Agua, or CNA Fresh Water Claims.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF

OPERATIONS

This discussion contains forward-looking statements about our markets, the demand for our products and services and

our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially
from those suggested by our forward-looking statements for various reasons including those discussed in the “Risk Factors”
and “Forward-Looking Statements” sections of this Annual Report on Form 10-K.

Background

Innophos is a leading international producer of specialty ingredient solutions that deliver versatile benefits for the food,

health, nutrition and industrial markets. Innophos combines more than a century of experience in specialty phosphate
manufacturing with a broad range of other specialty nutritional ingredients. Many of Innophos' products are application-
specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and
performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products
act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods,
pharmaceutical excipients and cleaning agents in toothpaste, and they also provide a wide range of nutritional fortification
solutions for food, beverage and nutritional supplement manufacturers.

2017 Overview

Our financial performance in 2017 was highlighted by:

• Net sales of $722.0 million compared to $725.3 million for 2016, a decrease of $3.3 million mostly attributable to:

$36.7 million revenues from the Novel Ingredients and NutraGenesis acquisitions, offset by $28.3 million of
selling price declines in the base business and $11.7 million lower volumes;

• Reduced input and operating costs by $37.8 million during 2017 due to cost reduction actions to offset negative margin

impact due to revenue decreases;

• Net income of $22.4 million, a 53% decrease versus 2016 largely due to provisional U.S. tax reform charges;

• Capital expenditures of $41.5 million, up 13% versus 2016 primarily due to investment in and completion of the Geismar

deep well, with approximately 53% spent on strategic initiatives and 47% spent on plant maintenance;

Page 22 of 85

• Earnings per share of $1.13 (diluted), down 54% versus 2016 due primarily to non-recurring U.S. tax reform charges;

• Total year dividends of $1.92 per share paid on the common stock in 2017, same as 2016 dividend payments;

• Delivered 210 basis point reduction in working capital as a percent of sales through improvements in inventory planning

processes;

• Operating cash flow of $80.7 million, down 42% compared to 2016 when working capital was significantly reduced by

688 basis points; and

• Net debt more than doubled due to $151.1 million incurred in connection with the Novel Ingredients and NutraGenesis

acquisitions.

2018 Outlook

The Company expects full year 2018 revenues to grow 12% to 14% compared to 2017 due to the annualized

contributions from Novel Ingredients and NutraGenesis, favorable growth in the nutrition end-markets served, and stabilization
in the base business.

Due primarily to recently enacted U.S. tax reform, Innophos is lowering its estimated effective tax rate for 2018 from the

historical 32% to 34% range to 27% to 29% given the geographical mix in earnings. The Company is carefully reviewing all
aspects of tax reform and how they may impact 2018 financials.

Earnings before interest, taxes, depreciation and amortization, or EBITDA, is forecasted to be weighted 45% toward H1

and 55% toward H2 given the phasing of the benefits from the strategic value chain repositioning and manufacturing
optimization program as well as the integration of the acquisitions completed in 2017. The Company expects to only modestly
increase the use of cash to make targeted 2018 capital investments to support the aforementioned program.

The Company’s proactive selling price increase program that was implemented in Q4 2017 is well underway and

expected to sufficiently offset the impact of forecasted input cost increases in 2018.

The Company remains on track to realize $4 million of expected acquisition cost synergies in 2018, which will enhance

the Food, Health and Nutrition EBITDA margin profile.

Delivery of $10 million in Phase 2 Operational excellence savings is expected in 2018, compared with $3 million

recorded in 2017.

Page 23 of 85

Results of Operations

The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the

periods indicated (dollars in millions):

Net sales
Cost of goods sold
Gross profit
Operating expenses:

Selling, general and administrative
Research & development

Income from operations
Interest expense, net
Foreign exchange (gains) losses, net
Provision for income taxes
Net income

Year Ended December 31,

2017

Amount

722.0
573.0
149.0

82.2
3.7
63.1
7.0
(0.5)
34.2
22.4

%
100.0
79.4
20.6

11.4
0.5
8.7
1.0
(0.1)
4.7
3.1

2016

Amount

725.3
574.9
150.4

67.6
3.7
79.1
7.7
1.1
22.3
48.0

%
100.0
79.3
20.7

9.3
0.5
10.9
1.1
0.2
3.1
6.6

2015

Amount

789.1
645.8
143.3

87.3
4.5
51.5
7.5
3.9
13.8
26.3

%
100.0
81.8
18.2

11.1
0.6
6.5
1.0
0.5
1.7
3.3

Year Ended December 31, 2017 compared to the Year Ended December 31, 2016

Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items

invoiced to customers. Net sales for the year ended December 31, 2017 were $722.0 million, a decrease of $3.3 million, or
0.5%, as compared to $725.3 million for 2016 with prices down 3.9%, partially offset by higher volumes of 3.4%. Food, Health
and Nutrition sales were up 5.5%, or $20.6 million, with selling prices lower by 2.9%, or $11.1 million, but volume higher by
8.4%, or 31.7 million. Results from the newly acquired Novel Ingredients and NutraGenesis businesses had sales totaling $36.7
million in 2017. Industrial Specialties sales were down 5.6%, or $15.6 million, due to lower selling prices and flat sales
volumes. Other sales were lower by 11.9%, or $8.3 million, with volume lower by 9.5%, or $6.6 million, due to higher
commodity fertilizer sales in the prior year period, and prices lower by 2.4%, or $1.7 million.

The Company calculates pure selling price dollar variances as the selling price for the current year period minus the

selling price for the prior year period, and then multiplies the resulting selling price difference by the prior year period
volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue
effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The
following table illustrates for the year ended December 31, 2017 the percentage changes in net sales by reportable segment
compared with the prior year, including the effect of price and volume/mix changes upon revenue:

Food, Health and Nutrition
Industrial Specialties
Other
Total

Gross Profit

Price

Volume/Mix

Total

(2.9)%
(5.6)%
(2.4)%
(3.9)%

8.4 %
— %
(9.5)%
3.4 %

5.5 %
(5.6)%
(11.9)%
(0.5)%

Gross profit represents net sales less cost of goods sold. Gross profit for the year ended December 31, 2017 was $149.0

million, a decrease of $1.4 million, or 0.9%, as compared to $150.4 million for 2016. Gross profit percentage was 20.6% for the
year ended December 31, 2017, essentially unchanged from 20.7% for 2016. Gross profit in 2017 was unfavorably affected by
$28.4 million lower selling prices, $6.8 million lower sales volumes, $4.3 million planned maintenance outage expense at our
Coatzacoalcos, Mexico and Geismar, Louisiana manufacturing facilities, $3.2 million expenses for the implementation of Phase
2 Operational Excellence initiatives, and $1.3 million higher depreciation expenses. These unfavorable effects were partially
offset by $34.9 million lower raw material costs, mainly phosphate rock and MGA, and $2.2 million lower manufacturing
costs. Results from the newly acquired Novel Ingredients and NutraGenesis businesses favorably affected gross profit by $2.4

Page 24 of 85

million in 2017, which includes a charge of $4.3 million for fair value inventory purchase accounting. Included in 2016 gross
profit was $2.4 million planned maintenance outage expense at our Coatzacoalcos, Mexico manufacturing facility and a $0.9
million charge for a GTSP lower of cost or market reserve.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative expenses and research and development
expenses. Operating expenses for the year ended December 31, 2017 were $85.9 million, an increase of $14.6 million, or
20.5%, as compared to $71.3 million for 2016. The increase was due to $5.2 million of Novel Ingredients and NutraGenesis
operating expenses for the current period, $5.2 million of transaction and integration costs related to the Novel Ingredients and
NutraGenesis acquisitions, $3.4 million of such expenses for strategic initiatives and $1.4 million higher severance costs.
Included in 2016 was $0.6 million of costs from the refinancing of our credit facility.

Operating Income

Operating income for the year ended December 31, 2017 was $63.1 million, a decrease of $16.0 million, or 20.2%, as

compared to $79.1 million for 2016. Operating income percentages decreased to 8.7% for 2017 from 10.9% for 2016.

Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the year ended December 31, 2017 was $7.0

million, a decrease of $0.7 million, or 9.1%, as compared to $7.7 million for 2016. The decrease was primarily due to lower
applicable margins on our December 2016 credit facility, lower deferred financing expense and prior year interest charges from
U.S. federal and state amended tax returns from prior periods which did not reoccur in 2017.

Foreign Exchange

Foreign exchange for the year ended December 31, 2017 was a gain of $0.5 million as compared to a loss of $1.1 million
for 2016. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange
gain or loss is recorded on remeasurement of non-U.S. Dollar denominated monetary assets and liabilities. Such gains and
losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. Dollar and the amount of
non-U.S. Dollar denominated assets and liabilities increases or decreases.

The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as value

added tax, or VAT, receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability
balances. As the U.S. Dollar strengthened throughout 2016 versus the Mexican Peso and the Canadian Dollar, the
remeasurement of the net foreign asset denominated balances contributed to a net foreign exchange loss for 2016. Conversely,
as the Mexican Peso was strengthening in 2017, the Company realized a net foreign exchange gain.

Provision for Income Taxes

The effective income tax rate was 60% for the year ended December 31, 2017 compared to 32% for 2016. The most

significant variance in the effective tax rate was due to the provisions of the U.S. Tax Cuts and Jobs Act of 2017 which
increased the tax rate by 31% year over year. The two primary components of this 31% increase in the tax rate were: (1) the
one-time transition tax on the mandatory deemed repatriation of foreign earnings of certain non-U.S. subsidiaries which
increased the tax rate by 25%, and (2) the remeasurement of certain U.S. deferred tax assets and liabilities, based on the enacted
rates, which increased the tax rate by 6%. The 31% increase in the effective income tax rate due to this legislation was partially
offset by increased income, including non-taxable interest income, in lower tax rate jurisdictions which decreased the effective
tax rate by 3%.

Net Income

Net income for the year ended December 31, 2017 was $22.4 million, a decrease of $25.6 million, as compared to $48.0

million for 2016, due to the factors described above.

Page 25 of 85

Year Ended December 31, 2016 compared to the Year Ended December 31, 2015

Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items

invoiced to customers. Net sales for the year ended December 31, 2016 were $725.3 million, a decrease of $63.8 million, or
8.1%, as compared to $789.1 million for 2015 with prices down 3.0% and volumes down 5.1%. Food, Health and Nutrition
sales were down 4.6%, or $18.2 million, with selling prices lower by 0.6%, or $2.2 million, and volume lower by 4.0%, or
$16.0 million. Industrial Specialties sales were down 12.9%, or $41.3 million, with selling prices lower by 2.1%, or $6.6
million, and sales volumes lower by 10.8%, or $34.7 million due to product pruning. Other sales were lower by 5.8%, or $4.3
million, with selling prices lower by 20.2%, or $15.1 million, due to low-value fertilizer market sales, partially offset by higher
volumes of $10.8 million, or 14.4%.

The Company calculates pure selling price dollar variances as the selling price for the current year period minus the

selling price for the prior year period, and then multiplies the resulting selling price difference by the prior year period
volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue
effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix. The
following table illustrates for the year ended December 31, 2016 the percentage changes in net sales by reportable segment
compared with the prior year, including the effect of price and volume/mix changes upon revenue:

Food, Health and Nutrition
Industrial Specialties
Other

Total

Gross Profit

Price

Volume/Mix

Total

(0.6)%
(2.1)%
(20.2)%

(3.0)%

(4.0)%
(10.8)%
14.4 %

(5.1)%

(4.6)%
(12.9)%
(5.8)%

(8.1)%

Gross profit represents net sales less cost of goods sold. Gross profit for the year ended December 31, 2016 was $150.4

million, an increase of $7.1 million, or 5.0%, as compared to $143.3 million for 2015. Gross profit percentage increased to
20.7% for the year ended December 31, 2016 versus 18.2% for 2015. Gross profit in 2016 was favorably affected by $21.7
million lower raw material costs, largely phosphate rock and sulfur, $9.4 million lower manufacturing costs due to savings from
the 2015 restructuring program and focus on cost controls, $6.2 million favorable exchange effects from our Mexican peso and
Canadian dollar based costs, and $1.1 million lower depreciation expenses. These favorable effects were partially offset by
$23.9 million lower selling prices and $16.1 million lower sales volume. Included in 2015 gross profit was $3.4 million
increase in inventory reserves, $3.3 million restructuring and management transition costs, and $2.0 million cost due to a
supplier revision of their 2014 costs.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative expenses and research and development
expenses. Operating expenses for the year ended December 31, 2016 were $71.3 million, a decrease of $20.5 million, or 22.3%,
as compared to $91.8 million for 2015. The decrease was primarily due to $8.9 million lower costs related to savings from the
2015 restructuring program, $4.5 million lower restructuring costs, and $1.1 million favorable exchange rate from Mexican
peso based costs, partially offset by $3.7 million higher employee related expenses for short-term incentive accruals and stock
compensation expense, $1.0 million of strategy consulting fees and first quarter 2016 CEO transition costs, and $0.6 million
costs from the refinancing of our credit facility. Included in 2015 was $11.3 million of management transition costs.

Operating Income

Operating income for the year ended December 31, 2016 was $79.1 million, an increase of $27.6 million, or 53.6%, as

compared to $51.5 million for 2015. Operating income percentages increased to 10.9% for 2016 from 6.5% for 2015.

Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the year ended December 31, 2016 was $7.7

million, an increase of $0.2 million, or 2.7%, as compared to $7.5 million for 2015. The increase was primarily due to higher
average interest rates on borrowings, mostly offset by lower interest charges from U.S. federal and state amended tax returns
from prior periods.

Page 26 of 85

Foreign Exchange

Foreign exchange for the year ended December 31, 2016 was a loss of $1.1 million as compared to a loss of $3.9 million

for 2015. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign
denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in
foreign jurisdictions, than offsetting foreign denominated liability balances. As the U.S. Dollar strengthened throughout 2016
versus the Mexican Peso and the Canadian Dollar, the remeasurement of the net foreign asset denominated balances
contributed to a net foreign exchange loss for 2016. Consequently, foreign exchange gain or loss is recorded on remeasurement
of non-U.S. Dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the
foreign currencies strengthen or weaken against the U.S. Dollar and the amount of non-U.S. Dollar denominated assets and
liabilities increases or decreases.

Provision for Income Taxes

The effective income tax rate was 32% for the year ended December 31, 2016 compared to 34% for 2015. The more
significant variances in the effective tax rate included a Mexican de-consolidation deferred tax liability adjustment in 2016
which decreased the tax rate by 4% year over year, partially offset by lower domestic production activities deduction on the
U.S. federal return which increased the tax rate by 2% year over year.

Net Income

Net income for the year ended December 31, 2016 was $48.0 million, an increase of $21.7 million, as compared to $26.3

million for 2015, due to the factors described above.

Page 27 of 85

Segment Reporting

The Company's chief executive officer is the chief operating decision maker and, as of the first quarter of 2017, has
determined to assess the Company's performance and allocate the appropriate resources based on the following operating
segments: (1) Food, Health and Nutrition; (2) Industrial Specialties; and (3) Other. The new reporting segments accurately
reflect the underlying business dynamics and align with the strategic direction of the Company. The primary performance
indicators for the chief operating decision maker are sales and EBITDA. The following table sets forth the historical results of
these indicators by segment for the years ended December 31, 2017, 2016 and 2015:

Segment Net Sales
Food, Health and Nutrition
Industrial Specialties
Other
Total
Net Sales % Growth
Food, Health and Nutrition
Industrial Specialties
Other
Total
Segment EBITDA
Food, Health and Nutrition
Industrial Specialties
Other (a) (b)
Total
Segment EBITDA % of net sales
Food, Health and Nutrition
Industrial Specialties
Other (a) (b)
Total
Depreciation and amortization expense
Food, Health and Nutrition
Industrial Specialties
Other
Total

2017

2016

2015

397,298
262,704
62,022
722,024

5.5 %
(5.6)%
(11.9)%
(0.5)%

67,156
33,833
3,060
104,049

16.9 %
12.9 %
4.9 %
14.4 %

24,212
13,863
2,329
40,404

376,672
278,284
70,389
725,345

(4.6)%
(12.9)%
(5.8)%
(8.1)%

78,128
36,029
1,309
115,466

20.7 %
12.9 %
1.9 %
15.9 %

20,269
12,645
4,565
37,479

394,836
319,565
74,746
789,147

67,212
34,028
(15,064)
86,176

17.0 %
10.6 %
(20.2)%
10.9 %

20,186
14,030
4,319
38,535

(a)

(b)

The year ended December 31, 2015 includes a $11.8 million charge to earnings for management transition expenses
and $8.6 million charge to earnings for restructuring reserves.
The year ended December 31, 2016 includes a $1.5 million charge to earnings for restructuring costs.

A reconciliation of net income to EBITDA follows:

Net income

Provision for income taxes

Interest expense, net

Depreciation and amortization

EBITDA

2017
22,445

34,192

7,008

40,404

2016
47,971

22,347

7,669

37,479

2015
26,346

13,777

7,518

38,535

86,176

$ 104,049

$ 115,466

Page 28 of 85

Segment Net Sales:

Food, Health and Nutrition net sales increased 5.5% for the year ended December 31, 2017 compared with the same

period in 2016. Average selling prices decreased by 2.9% while volumes increased 8.4% due to the contribution of the Novel
and NutraGenesis acquisitions. Net sales decreased 4.6% for the year ended December 31, 2016 when compared with the same
period in 2015. Average selling prices decreased by 0.6% and volumes decreased 4.0%.

Industrial Specialties net sales decreased 5.6% for the year ended December 31, 2017 compared with the same period in

2016. Average selling prices decreased 5.6%, due to strong pricing competition in technical grade products, while volumes
were flat with improved mix due to product pruning. Net sales decreased 12.9% for the year ended December 31, 2016 when
compared with the same period in 2015. Selling prices decreased 2.1% and volumes decreased 10.8% due to product pruning.

Other net sales decreased 11.9% for the year ended December 31, 2017 compared with the same period in 2016. Average

selling prices decreased 2.4% and volumes decreased 9.5%. Net sales decreased 5.8% for the year ended December 31, 2016
when compared with the same period in 2015. Volumes increased 14.4% while selling prices decreased 20.2% due to low-value
fertilizer market sales.

Segment EBITDA Percentage of Net Sales:

The 380 basis point decrease in Food, Health and Nutrition EBITDA margins for the year ended December 31, 2017

compared with 2016 is due to lower average selling prices which decreased margins by 240 basis points, higher strategic
project expenses which decreased margins by 110 basis points, higher manufacturing and operating costs which decreased
margins by 80 basis points, and other items such as turnaround costs, sales volume/mix and severance which decreased margins
by a combined 70 basis points. The inclusion of the newly acquired Novel Ingredients and NutraGenesis businesses decreased
margins by 200 basis points, primarily due to a fair value inventory adjustment which decreased margins by 110 basis points.
These decreases were partially offset by decreased raw material costs, mainly phosphate rock and MGA, which increased
margins by 290 basis points and favorable translation and refinancing comparables which increased margins by 30 basis points.

The 370 basis point increase in Food, Health and Nutrition EBITDA margins for the year ended December 31, 2016
compared with 2015 is due to lower operating and manufacturing costs which increased margins 280 basis points, decreased
raw material costs, primarily PPA and MGA, which increased margins 170 basis points, and favorable exchange rate effects
which increased margins by 110 basis points. These increases were partially offset by lower sales volume/mix which decreased
margins by 120 basis points and the combined effects of selling prices, translation and refinancing costs which decreased
margins by 70 basis points.

The EBITDA margins for Industrial Specialties were unchanged for the year ended December 31, 2017 when compared

with 2016. Lower average selling prices decreased margins by 510 basis points, higher strategic project expenses decreased
margins by 70 basis points, and higher operating, turnaround and severance costs decreased margins by 70 basis points. These
decreases were offset by decreased raw material costs, mainly phosphate rock and MGA, which increased margins by 450 basis
points, higher sales volume/mix which increased margins by 140 basis points, and lower manufacturing costs including
translation which increased margins by 50 basis points. Included in 2016 was the costs from the refinancing of our credit
facility which increased margins by 10 basis points in 2017.

The 230 basis point increase in Industrial Specialties EBITDA margins for the year ended December 31, 2016 compared

with the same period in 2015 is due to lower operating and manufacturing cost which increased margins by 270 basis points,
lower raw material costs which increased margins by 220 basis points, and favorable exchange rate effects which increased
margins by 70 basis points. These increases were partially offset by lower average selling prices which decreased margins by
180 basis points, lower sales volume/mix which decreased margins by 130 basis points, unfavorable translation effects and
refinancing costs which decreased margins by 20 basis points.

The 300 basis point increase in Other EBITDA margins for the year ended December 31, 2017 compared with 2016 is

due to decreased raw material costs, mainly phosphate rock and MGA, which increased margins by 1,660 basis points and
lower manufacturing costs including translation which increased margins 130 basis points. These increases were partially offset
by higher strategic project expenses which decreased margins by 840 basis points, lower average selling prices which decreased
margins by 250 basis points, lower sales volume/mix which decreased margins by 240 basis points and higher operating,
turnaround and severance costs which decreased margins by 300 basis points. Included in 2016 was a lower of cost or market
reserve and costs from the refinancing of our credit facility which increased margins by a combined 140 basis points in 2017.

The 2,210 basis point increase in Other EBITDA margins for the year ended December 31, 2016 compared with the same
period in 2015 is due to lower restructuring/management transition costs which increased margins by 2,800 basis points, lower
raw material costs which increased margins by 1,080 basis points, higher sales volume/mix which increased margins by 1,040
Page 29 of 85

basis points and favorable exchange rate and translation effects which increased margins by 620 basis points. These increases
were partially offset by lower selling prices which decreased margins 3,040 basis points, higher operating and manufacturing
costs which decreased margins 830 basis points, and higher severance costs which decreased margins by 180 basis points.
Included in 2015 was higher inventory reserves which increased margins by 450 basis points in 2016 and cost for low
production rates in late 2014 that caused higher cost to be recorded in 2015 which increased margins by 270 basis points in
2016.

Liquidity and Capital Resources

Cash Flow Summary

The following table sets forth a summary of the Company’s cash flows for the periods indicated.

(Dollars in millions)

Operating Activities
Investing Activities
Financing Activities
Effect of foreign exchange rate changes

Year Ended December 31,

2017

2016

2015

80.6
(191.5)
86.5
(0.4)

139.1
(36.6)
(67.1)
0.1

98.9
(31.7)
(86.0)
0.5

Year Ended December 31, 2017 compared to the Year Ended December 31, 2016

Net cash provided by operating activities was $80.6 million for the year ended December 31, 2017 as compared to
$139.1 million for 2016, a decrease of $58.5 million. The decrease in operating activities cash resulted from unfavorable
changes of $25.6 million in net income as described earlier and $47.6 million in working capital due to a significant
improvement in 2016 when working capital as a percent of sales was reduced by 690 basis points, partially offset by
favorable changes of $12.6 million in other long term assets and liabilities and $2.1 million in non-cash adjustments to
income.

The unfavorable change in working capital is derived from it being a use of cash of $6.4 million in 2017 compared to
a source of $41.2 million in 2016, a decrease in cash of $47.6 million. The unfavorable change in working capital was due
to unfavorable changes in inventory of $38.2 million, driven by adjusted inventory levels in the prior year due to customer
demand, accounts receivable of $13.1 million due to the effects of extended payment terms and accounts payable of $11.6
million. These unfavorable effects were partially offset by favorable changes in other current liabilities of $13.2 million,
largely due to U.S. income tax payments in the prior year, and other current assets of $2.1 million. Accounts receivable has
increased as a percent of quarterly sales compared to the last four quarters' average due to pressures on customer payment
terms.

Total inventories as of December 31, 2017 increased $17.4 million from December 31, 2016 levels, due to the
inclusion of $19.8 million of acquisition inventory, resulting in days of inventory on hand increasing to 94 days as of
December 31, 2017. The following chart shows its historical performance:

Inventory Days on Hand

2017

2016

2015

Net cash used for investing activities was $191.5 million for the year ended December 31, 2017, compared to $36.6

million for 2016, an increase in spending of $154.9 million. The change was due to the acquisition of Novel Ingredients and
NutraGenesis for an aggregate purchase price of $151.0 million and a $4.9 million increase in capital spending partially
offset by $1.0 million cash received from the sale of an administrative building.

Approximately 53% of the 2017 capital spending was for strategic growth initiatives and the remaining 47% was for
plant maintenance projects. Approximately half of the strategic growth investments were focused on the deep well injection
system project at our Geismar, Louisiana facility which accounts for approximately 28% of the Company's total capital
expenditures.

Page 30 of 85

Net cash from financing activities for the year ended December 31, 2017 was a source of $86.5 million, compared to
a use of $67.1 million in 2016, an increase in cash of $153.6 million. This increase in cash was largely due to $151.0 million
increased loan borrowings for the Novel Ingredients and NutraGenesis acquisitions.

Year Ended December 31, 2016 compared to the Year Ended December 31, 2015

Net cash provided by operating activities was $139.1 million for the year ended December 31, 2016 as compared to

$98.9 million for 2015, an increase of $40.2 million. The increase in operating activities cash resulted from favorable
changes of $21.7 million in net income as described earlier and $41.3 million in non-cash adjustments to income, primarily
changes in deferred income tax provision, partially offset by unfavorable changes of $16.4 million in working capital and
$6.4 million in other long term assets and liabilities.

The unfavorable change in working capital is derived from it being a source of cash of $41.2 million in 2016
compared to a source of $57.6 million in 2015, a decrease in cash of $16.4 million. The unfavorable change in working
capital was due to unfavorable changes in other current liabilities of $46.8 million, largely due to U.S. income tax payments
of $18.6 million for immediate recognition of revenue for income tax purposes which is not expected to recur and severance
payments of $8.5 million, other current assets of $23.9 million due to lower VAT balances and vendor deposits in 2015
compared to 2014, and accounts receivable of $8.7 million. These unfavorable effects were mostly offset by favorable
changes in inventory of $31.9 million due to lower raw material costs and adjusted inventory levels to align with lower
customer demand, and accounts payable of $31.1 million, which will be paid in the first quarter of 2017. Accounts
receivable as a percent of quarterly sales, when adjusted for GTSP open accounts receivable of $0.1 million, $0.2 million,
$1.8 million, $1.3 million, and $0.3 million as of December 31 2016, September 30, 2016, June 30, 2016, March 31, 2016,
and December 31, 2015, respectively, was consistent with the last four quarters' average.

Total inventories as of December 31, 2016 decreased $44.0 million from December 31, 2015 levels, due to lower raw

material costs and adjusted inventory levels to align with lower customer demand, resulting in days of inventory on hand
decreasing to 81 days as of December 31, 2016. The following chart shows its historical performance:

Inventory Days on Hand

2016

2015

2014

103

Net cash used for investing activities was $36.6 million for the year ended December 31, 2016, compared to $31.7

million for 2015, an increase in spending of $4.9 million.

Approximately 65% of the 2016 capital spending was for plant maintenance projects and the remaining 35% was for

strategic growth initiatives. The majority of the strategic growth investments were focused on improving the capacity and
capability of our North Salt Lake, Utah and Chicago (Waterway), Illinois facilities as well as the preliminary engineering
and equipment investment for the the deep well injection system project at our Geismar, Louisiana facility.

Net cash from financing activities for the year ended December 31, 2016, was a use of $67.1 million, compared to a
use of $86.0 million in 2015, an increase in cash of $18.9 million. This increase in cash was largely due to $125.0 million
decreased stock repurchases and $13.0 million decreased loan repayments, partially offset by $118.0 million decreased loan
borrowings. The loan borrowings in 2015 were largely used to fund the share repurchases in that year.

Page 31 of 85

Liquidity

Indebtedness

Total debt was $310.0 million as of December 31, 2017. Short term and long term debt net of cash was $281.2 million

as of December 31, 2017, an increase of $149.7 million, or 113.8% from the December 31, 2016 level.

In December 2016, Innophos entered into a new senior secured credit facility, or Credit Agreement, with a group of

lenders, or the Lenders, increasing the Company's borrowing capacity. The Credit Agreement replaced the term loan of
$100.0 million and revolving line of credit under the old facility with a $450.0 million revolving line of credit, including a
$20.0 million letter of credit sub-facility and a $20.0 million swingline loan facility, all maturing on December 22, 2021.
Interest accruing on amounts borrowed under the revolving line is based on an applicable margin over LIBOR (London
Interbank Offered Rate) or bank base rate, ranging from 100 to 225 basis points for LIBOR and 0 to 125 basis points for
base rate loans, in each case with loan period and interest alternative as chosen by the Company, which margin is adjusted
quarterly depending on a total leverage ratio (as computed under the Credit Agreement) for the period in question.
Commitment fees on the unused revolving line range from 12.5 to 37.5 basis points, depending on total leverage ratio (as
computed under the Credit Agreement) for the period in question. The current applicable margin for LIBOR based loans,
base rate loans and the commitment fee are 200, 100 and 32.5 basis points, respectively.

The Credit Agreement also provides for possible additional revolving indebtedness under an incremental facility of up

to $150.0 million (for an aggregate of revolving capacity up to $600.0 million) upon future request by the Company to
existing Lenders (and depending on their consent) or from other willing financial institutions invited by the Company and
reasonably acceptable to the administrative agent to join in the Credit Agreement. This revolving credit facility increase, if
implemented, may provide for higher applicable margins to either the increased portion or possibly the entire revolving
credit facility, with limitations, than those in effect for the original revolving commitments under the Credit Agreement.
Refer to Note 10 of Notes to Consolidated Financial Statements in “Item 8. Consolidated Financial Statements and
Supplementary Data”.

Although it had no outstanding debt for the applicable period except attributable to its senior bank credit facilities,

Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt
through public or privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will
depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors
applicable at the time. The amounts involved may be material. Refer to Note 10 of Notes to Consolidated Financial
Statements in “Item 8. Consolidated Financial Statements and Supplementary Data”.

Capital Expenditures

Capital expenditures were $41.5 million for 2017. Approximately 53% of the 2017 capital spending was for strategic

growth initiatives and the remaining 47% was for plant maintenance projects. Approximately half of the strategic growth
investments were focused on the deep well injection system project at our Geismar, Louisiana facility which accounts for
approximately 28% of the Company's total capital expenditures. 2018 capital expenditures are forecasted to be between $45
million and $50 million.

Other Liquidity Matters

As indicated elsewhere, the Company increased the quarterly dividend on its common stock to an annual rate of $1.92

per share starting with the third quarter 2014 payment. That policy may change and is subject to numerous conditions and
variables. See the section entitled “Dividends” in Item 5 of this Form 10-K and "Risk Factors - Certain Financial Risks -
Contingencies Affecting Dividends - Our ability to pay dividends in the future may be compromised."

On December 31, 2017, the Company had cash and cash equivalents outside the United States of $22.8 million, or

79% of the Company's balance. The foreign cash amounts are not restricted by law to be used in other countries.

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act. The legislation significantly changes U.S.
corporate income tax laws by, among other things, reducing the U.S. corporate income tax rate from 35% to 21% effective
for tax years beginning after December 31, 2017 and transitioning U.S. international taxation from a worldwide tax system
to a territorial tax system with a one-time mandatory tax on post-1986 undistributed foreign earnings and profits of U.S.
subsidiaries through the year ended December 31, 2017. We have calculated our best estimate of the impact of this
legislation in our year end income tax provision in accordance with our understanding of the legislation and guidance
available as of the date of this filing and, as a result, have recorded $17.3 million as additional income tax expense in the
fourth quarter of 2017, the period in which the legislation was enacted. This amount consists of two components: (1) a

Page 32 of 85

$13.9 million charge payable over eight years and related to the one-time transition or toll tax on the mandatory deemed
repatriation of foreign earnings of certain non-U.S. subsidiaries owned either wholly or partially by a U.S. subsidiary of the
Company; and (2) a $3.4 million charge related to the remeasurement of certain U.S. deferred tax assets and liabilities,
based on the rates at which they are expected to reverse in the future.

The Company has incurred costs associated with involuntary termination benefits associated with its corporate-related

initiatives, as well as the management transition. During 2015, the Company incurred restructuring and management
transition costs of $8.6 million and $11.8 million, respectively. The amounts recorded within selling, general and
administrative expenses in the statements of operations were $17.1 million and cost of goods sold were $3.3 million. During
2016, we incurred additional amounts in connection with continued restructuring of $1.6 million within selling, general and
administrative expenses and $0.1 million within cost of goods sold. The Company expects to make $1.7 million of
payments associated with these actions within the next twelve months.

The Company’s available financial resources allow for the continuation of dividend payments, pursuit of acquisition
projects and further geographic expansion initiatives. We further believe that on-hand cash combined with cash generated
from operations, including our Mexican operations, and availability under our revolving line of credit in the Credit
Agreement, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working
capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash,
our future operating cash flows and our existing revolving line of credit. However, future operating performance for the
Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the
cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund
our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating
plans.

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred
to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-
balance sheet arrangements or other contractually narrow or limited purposes.

Contractual Obligations and Commercial Commitments

The following table sets forth our long-term contractual cash obligations as of December 31, 2017 (dollars in thousands):

Contractual Obligations
Revolver borrowings (1)

Total
$ 310,000

Future service pension benefits

Years ending December 31,

2018

2019

2020

2021

2022

— $

— $ 310,000

Thereafter
—

— $

U.S. federal transition tax

Other (2)

Operating leases

Total contractual cash
obligations

11,384

13,147

56,745

33,549

883

1,052

56,745

6,654

919

1,052

—

5,591

980

1,052

—

4,434

1,057

1,052

—

4,016

1,130

1,052

—

3,710

6,415

7,887

—

9,144

$ 424,825

65,334

7,562

6,466

$ 316,125

5,892

23,446

______________________
(1)

Amounts exclude interest payments. Interest on the $310.0 million balance of the revolver borrowings at current rates
would be approximately $11.2 million annually.
Represents minimum annual purchase commitments to buy raw materials from suppliers.

(2)

Page 33 of 85

Critical Accounting Estimates and Policies

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial

statements, which have been prepared in accordance with United States generally accepted accounting principles. The
preparation of our financial statements requires us to make estimates, assumptions and judgments that affect the reported
amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our estimates,
including those related to allowance for bad debts, distributor incentives and rebates, the recoverability of long-lived assets,
including amortizable intangible assets, goodwill, depreciation and amortization periods, income taxes and commitments and
contingencies. We base our estimates on historical experience and on various other assumptions that we believe to be
reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of
assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under
different assumptions or conditions. We believe that the following critical accounting policies affect our more significant
judgments and estimates used in the preparation of our consolidated financial statements.

Claims and Legal Proceedings

The categories of asserted or unasserted claims for which the Company has estimated a probable liability and for which

amounts are estimable are critical accounting estimates. Please refer to Part I, Item 3. "Legal Proceedings" and the section
entitled “Commitments and Contingencies” in Note 17 of Notes to Consolidated Financial Statements in “Part II, Item 8.
Consolidated Financial Statements and Supplementary Data” for additional information about such estimates.

Deferred Taxes

Deferred taxes are accounted for by recognizing deferred tax assets and liabilities for the expected future tax

consequences of events that have been recognized in the financial statements. Accordingly, deferred tax assets and liabilities are
determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax
rates in effect for the year in which the differences are expected to reverse.

Deferred tax assets are assessed for recoverability and a valuation allowance is considered necessary if it is more likely

than not that some portion or all of the net deferred tax assets will not be realized. We continue to analyze our current and
future profitability and probability of the realization of our net deferred tax assets in future periods. Please refer to the section
entitled “Income Taxes” (contained in Note 16) of Notes to Consolidated Financial Statements in “Part II, Item 8. Consolidated
Financial Statements and Supplementary Data” for additional information regarding deferred taxes.

Goodwill

Goodwill represents the excess of the acquisition cost over the fair value of net assets of the businesses acquired.
Accounting Standards Codification (ASC) 350, “Intangibles-Goodwill and Other,” requires periodic tests of the impairment of
goodwill. ASC 350 requires a comparison, at least annually, of the net book value of the assets and liabilities associated with a
reporting unit, including goodwill, with the fair value of the reporting unit, which corresponds to the discounted cash flows of
the reporting unit, in the absence of an active market. When this comparison indicates that impairment must be recorded, the
impairment recognized is the amount by which the carrying amount of the assets exceeds the fair value of these assets, not to
exceed the carrying value of the goodwill. The annual goodwill impairment review is conducted during the fourth quarter of
each year. Fair values for goodwill testing are estimated using a discounted cash flow approach. Significant estimates in the
discounted cash flow approach include the cash flow forecasts for each of our reporting units, the discount rate and the terminal
value. The five year cash flow forecasts of the Company’s reporting units is based upon management’s estimate at the date of
the assessment, which incorporates managements long-term view of selling prices, sales volumes for Innophos’ products, key
raw materials and energy costs, and our operating cost structure. The aggregated fair value of our reporting units was reconciled
to our market capitalization at the date of the assessment, plus a suitable control premium. The terminal value was determined
by applying business growth factors for each reporting unit which are in-line with longer term growth rates, to the latest year
for which a forecast exists.

Our market capitalization during fourth quarter of 2017 exceeded the book value of our equity.

Our reporting units for goodwill purposes are Food, Health and Nutrition, Industrial Specialties and Other. These
reporting segments accurately reflect the underlying business dynamics and align with the strategic direction of the Company.

Page 34 of 85

As of October 31, 2017, the Company performed step one of the annual goodwill impairment test for each reporting unit
and concluded that the fair values of all the reporting units were in excess of their carrying values by more than 25%. We used a
discount rate which is commensurate with the risks inherent to each reporting unit and in our cash flow forecasts. The discount
rate used in our 2017 reporting unit valuations is 9.5%.

The development of future cash flow projections requires management estimates related to forecasted sales and expected

costs trends. To the extent that changes in business conditions occur or other management decisions are made that result in
adjusted management projections, impairment losses may occur in future periods.

Long-lived assets

Under ASC 360, “Property, Plant, and Equipment,” long-lived assets including property, plant and equipment and
amortized intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset or asset group may not be recoverable. The review of these long-lived assets is performed
at the individual asset level, asset group level, or the product group level depending on the lowest level for which identifiable
cash flows are largely independent. The Company’s asset groupings or product groupings vary based on the interrelationship of
the long-lived assets and the identifiable cash flows. For example, in certain instances, multiple manufacturing units may work
with one another to produce the lowest identifiable cash flows or in other instances a stand-alone unit may produce the lowest
level of identifiable cash flows. There are other instances where a stand-alone unit may produce multiple products and the
lowest level of identifiable cash flows is at the product group level. Recoverability of assets to be held and used is measured by
a comparison of the carrying amount of the assets to the undiscounted future cash flows expected to be generated by the asset,
asset group or product group. When this comparison indicates that impairment must be recorded, the impairment recognized is
the amount by which the carrying amount of the assets exceeds the fair value of the assets.

The determination of whether or not assets are impaired and the corresponding useful lives of these long-lived assets

requires significant judgment. The development of future cash flow projections requires management estimates related to
forecasted sales and expected costs trends. To the extent that changes in business conditions occur or other management
decisions are made that result in adjusted management projections or alternative use of the assets, impairment losses or
accelerated depreciation may occur in future periods.

Stock-Based Compensation Expense

Our compensation programs can include share-based payments. The primary share-based awards and their general terms

and conditions currently in effect are as follows:

•

Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of
Innophos common stock at an exercise price per share set equal to the market price of Innophos common stock on the
date of grant.

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of
shares of Innophos common stock, and which also entitle the holder to receive dividends paid on such grants
throughout the vesting period.

•

Performance share awards which entitle the holder to receive, at the end of a performance cycle, a number of shares
of Innophos common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated
using a combination of performance indicators as defined solely by reference to the Company’s own activities.
Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards
when vested and distributed.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of

shares of the Company’s common stock equal to a fixed retainer value.

Page 35 of 85

The fair value of the options granted during 2017, 2016 and 2015 was determined using the Black-Scholes option-pricing

model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility
Dividend yield
Risk-free interest rate
Expected term in years
Weighted average grant date fair value of stock options

Year Ended
December 31,
2017

Year Ended
December 31,
2016

Year Ended
December 31,
2015

31.3%
3.6%
2.09%
6.6

33.8%
6.6%
1.4%
6.6

11.54

4.62

40.8%
4.3%
1.7%
6.0
12.14

The expected volatility and the expected term are based on the Company's historical data. The dividend yield is the

expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are
derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term.
The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is
based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based
compensation expense is adjusted accordingly.

Pension and Post-Retirement Costs / Post-Employment Plan

The Company maintains both defined contribution plans and noncontributory defined benefit pension plans that together

cover all U.S. and Canadian employees.

In the United States, salaried and hourly employees are covered by a defined contribution plan with a 401(k) feature. The
plan provides for employee contributions, company matching contributions, and an age-weighted annual company contribution
to eligible employees. Union-represented hourly employees at our Nashville, Tennessee site are covered by a traditional defined
benefit plan providing benefits based on years of service and final average pay whose benefit accruals were frozen as of
August 1, 2007, after which the Nashville union employees began participating in the Company’s existing noncontributory
defined contribution benefit plan. All plans were established by Innophos in 2004.

In Canada, salaried employees are covered by defined contribution plans which provide for company contributions as a

Our pension and post-retirement benefit costs are developed from actuarial valuations. Inherent in these valuations are

key assumptions, including the discount rate and the expected long-term rate on plan assets. These assumptions require
significant judgment and material changes in our pension and post-retirement benefit costs may occur in the future due to
changes in these assumptions, changes in levels of benefits provided, and changes in asset levels. Such assumptions are based
on benchmarks obtained from third party sources.

As a sensitivity measure, the effect of a 25 basis-point decrease in our discount rate assumption would increase our net

periodic benefit cost for our pension and post-retirement plans by approximately $76 thousand. A 1% decrease in our expected
rate of return on plan assets would increase our pension plan expense by $187 thousand.

Recently Issued Accounting Standards

New accounting standards effective in 2017 are described in the Recent Accounting Pronouncements section in Note 1 of

Notes to Consolidated Financial Statements in “Part II, Item 8. Consolidated Financial Statements and Supplementary Data.”

Page 36 of 85

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in
interest rates, as borrowings under our credit agreement will bear interest at floating rates based on LIBOR plus an applicable
borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent
practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows.
Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are
held constant.

At December 31, 2017, we had a $450.0 million revolving credit facility, of which $310.0 million was outstanding, which

approximates fair value (determined using level 2 inputs within the fair value hierarchy). Total remaining availability was
$138.9 million, taking into account $1.1 million in face amount of letters of credit issued under the sub-facility.

Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our

revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds
available for capital investment, operations or other purposes. In addition, a substantial portion of our cash flow has been used
to service debt and fund working capital needs, which may affect our ability to make future acquisitions or capital expenditures.
We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation.
Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest
rate fluctuations. Based on $310.0 million outstanding borrowings as floating rate debt under our credit facility, an immediate
increase of one percentage point would cause an increase to interest expense of approximately $3.1 million per year.

From time to time, we may enter into longer term natural gas and electricity supply contracts in an effort to eliminate

some of the volatility in our energy costs. We did not enter into any economic hedges in the past three years.

We do not currently, but may from time to time, hedge our currency rate risks.

We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are

spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales
in the last 3 years.

Foreign Currency Exchange Rates

The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’
monetary assets and liabilities are remeasured at current exchange rates, non-monetary assets and liabilities are remeasured at
historical exchange rates, and revenue and expenses are remeasured at average exchange rates and at historical exchange rates
for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net
income.

Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses,
which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar
relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely,
a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe
that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses,
and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S.
Dollars and our exchange rate exposure in terms of sales revenues is minimal.

Inflation and changing prices

Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials,

freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to
customers could have a material effect on our financial condition and results of operations. See “Part I, Item 1A. Risk Factors -
Raw Materials Availability and Pricing - The success of our business depends on our ability to successfully source sufficient
amounts of the raw materials used in our products at competitive prices, often from a limited number of suppliers, some of
whom with we do not have a long-term contract in place.” in this Annual Report on Form 10-K for a discussion of the risks
associated with our sourcing raw materials.

Page 37 of 85

ITEM 8.

CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

INDEX TO FINANCIAL STATEMENTS

Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm
Balance Sheets at December 31, 2017 and December 31, 2016
Statements of Comprehensive Income for each of the three years ended December 31, 2017
Statements of Stockholders’ Equity for each of the three years ended December 31, 2017
Statements of Cash Flows for each of the three years ended December 31, 2017
Notes to Consolidated Financial Statements

Page

39
41
42
43
44
45

Page 38 of 85

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Innophos Holdings, Inc.:

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Innophos Holdings, Inc. and its subsidiaries as of
December 31, 2017 and 2016, and the related consolidated statements of comprehensive income, of stockholders’ equity and of
cash flows for each of the three years in the period ended December 31, 2017, including the related notes (collectively referred
to as the “consolidated financial statements”). We also have audited the Company's internal control over financial reporting as
of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial
position of the Company as of December 31, 2017 and 2016, and the results of their operations and their cash flows for each of
the three years in the period ended December 31, 2017 in conformity with accounting principles generally accepted in the
United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over
financial reporting as of December 31, 2017, based on criteria established in Internal Control - Integrated Framework (2013)
issued by the COSO.

Basis for Opinions

The Company's management is responsible for these consolidated financial statements, for maintaining effective internal
control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included
in the accompanying Management's Report on Internal Control over Financial Reporting appearing under Item 9A. Our
responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal control
over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting
Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance
with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and
the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material
misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in
all material respects.

Our audits of the consolidated financial statements included performing procedures to assess the risks of material

misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates
made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of
internal control over financial reporting included obtaining an understanding of internal control over financial reporting,
assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal
control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in
the circumstances. We believe that our audits provide a reasonable basis for our opinions.

As described in Management’s Report on Internal Control over Financial Reporting, management has excluded Novel
Ingredients and NutraGenesis from its assessment of internal control over financial reporting as December 31, 2017 because
they were acquired by the Company in a purchase business combination during 2017. We have also excluded Novel Ingredients
and NutraGenesis from our audit of internal control over financial reporting. Novel Ingredients and NutraGenesis are wholly-
owned subsidiaries whose total assets and total revenues excluded from management’s assessment and our audit of internal
control over financial reporting represent 6% and 5%, respectively, of the related consolidated financial statement amounts as
of and for the year ended December 31, 2017.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to

Page 39 of 85

permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/PricewaterhouseCoopers LLP
Florham Park, New Jersey
March 1, 2018

We have served as the Company’s auditor since 2004.

Page 40 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Consolidated Balance Sheets
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

ASSETS
Current assets:

Cash and cash equivalents
Accounts receivable, net
Inventories
Other current assets

Total current assets

Property, plant and equipment, net
Goodwill
Intangibles and other assets, net
Total assets

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:

Current portion of long-term debt
Accounts payable, trade and other
Other current liabilities

Total current liabilities

Long-term debt
Other long-term liabilities

Total liabilities

Commitments and contingencies (note 17)
Common stock, par value $.001 per share; authorized 100,000,000; issued 22,884,588 and
22,777,690; outstanding 19,537,872 and 19,455,011 shares
Paid-in capital
Common stock held in treasury, at cost (3,346,716 and 3,322,679 shares)
Retained earnings
Accumulated other comprehensive loss

Total stockholders' equity
Total liabilities and stockholders' equity

See notes to consolidated financial statements

December 31,

2017

2016

28,782
100,820
145,685
24,969
300,256
219,297
152,700
112,916
785,169

4
70,445
43,084
113,533
310,005
28,072
451,610

20
137,617
(176,246)
374,366
(2,198)
333,559
785,169

53,487
77,692
128,295
23,894
283,368
205,459
84,373
69,811
643,011

—
51,611
43,605
95,216
185,000
15,569
295,785

19
134,694
(175,051)
389,048
(1,484)
347,226
643,011

Page 41 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

Net sales
Cost of goods sold
Gross profit
Operating expenses:

Selling, general and administrative
Research & development expenses
Total operating expenses

Operating income
Interest expense, net
Foreign exchange (gains) losses
Income before income taxes
Provision for income taxes
Net income

Net income attributable to common shareholders
Per share data (see Note 13):
Income per share:

Basic
Diluted
Weighted average shares outstanding:
Basic
Diluted

Other comprehensive (loss) income, net of tax:
Change in interest rate swaps, (net of tax $5, $24, and $192)
Change in pension and post-retirement plans, (net of tax $236 ($749),
and ($194))
Other comprehensive (loss) income, net of tax
Comprehensive income

Year Ended December 31,

2017
722,024
572,995
149,029

2016
725,345
574,953
150,392

2015
789,147
645,818
143,329

82,229
3,733
85,962
63,067
7,008
(578)
56,637
34,192
22,445
22,369

1.15
1.13

$
$

67,555
3,739
71,294
79,098
7,669
1,111
70,318
22,347
47,971
47,683

2.47
2.44

$
$

87,304
4,502
91,806
51,523
7,518
3,882
40,123
13,777
26,346
26,274

1.31
1.29

19,444,795
19,733,410

19,271,448
19,581,476

20,032,300
20,323,385

(9) $

(39) $

(314)

(705)
(714) $
$

21,731

1,349
1,310
49,281

$
$

333
19
26,365

$
$

See notes to consolidated financial statements

Page 42 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Statements of Stockholders’ Equity
(Dollars and shares in thousands)

Balance, December 31, 2014
Net income
Other comprehensive loss, (net of tax
($2))
Proceeds from stock award exercises
and issuances
Share-based compensation
Excess tax benefits from exercise of
stock options
Common stock repurchases
Restricted stock forfeitures
Dividends declared
Balance, December 31, 2015
Net income
Other comprehensive income, (net of
tax ($725))
Proceeds from stock award exercises
and issuances
Share-based compensation
Excess tax benefits from exercise of
stock options
Restricted stock forfeitures

Dividends declared
Balance, December 31, 2016
Net income
Other comprehensive income, (net of
tax $241) (a)
Effects of U.S. enacted Tax Cuts and
Jobs Act (a)
Proceeds from stock award exercises
and issuances
Share-based compensation
Restricted stock forfeitures

Dividends declared
Balance, December 31, 2017

Number of
Common
Shares

Common
Stock

21,480

Retained
Earnings
(Deficit)
$ 390,525
26,346

Paid-in
Capital

75,274

Accumulated
Other
Comprehensive
Income/(Loss)
$

(2,813) $

Total
Shareholders'
Equity

463,007
26,346

139

(2,319)
(10)

(2)

19,290

(38,550)
$ 378,321
47,971

246
6,618

975
(124,998)
(401)

$ (42,286) $

(2,794) $

1,310

192

(27)

(1,428)
3,732

(9)

(366)

19,455

(37,244)
$ 389,048
22,445

$ (40,357) $

(1,484) $

(714)

293

(900)
3,823
(1,195)

108

(25)

19,538

(37,420)
$ 374,366

$ (38,629) $

(2,198) $

246
6,618

975
(125,000)
(401)
(38,550)
333,260
47,971

1,310

(1,428)
3,732

(9)

(366)
(37,244)
347,226
22,445

(714)

293

(899)
3,823
(1,195)
(37,420)
333,559

(a) Includes the impact of ASU 2018-02, which transferred those amounts from accumulated other comprehensive income (loss) to retained earnings. See
Notes 1 and 18 to the Consolidated Financial Statements.

See notes to consolidated financial statements

Page 43 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Consolidated Statements of Cash Flows
(Dollars in thousands)

Cash flows from operating activities

Net income

Adjustments to reconcile net income to net cash provided from
operating activities:

Year Ended December 31,

2017

2016

2015

22,445

47,971

26,346

Depreciation and amortization

Amortization of deferred financing charges

Deferred income tax provision (benefit)

Gain on sale of building

Share-based compensation

Changes in assets and liabilities:

(Increase) decrease in accounts receivable

Decrease in inventories

Decrease (increase) in other current assets

Increase (decrease) in accounts payable

(Decrease) increase in other current liabilities

Changes in other long-term assets and liabilities

Net cash provided from operating activities

Cash flows used for investing activities:

Capital expenditures

Proceeds from sale of building

Acquisition of businesses, net of cash acquired

Net cash used for investing activities

Cash flows from financing activities:

Proceeds from exercise of stock options

Long-term debt borrowings

Long-term debt repayments

Deferred financing costs

Excess tax benefits from exercise of stock options

Common stock repurchases

Restricted stock forfeitures

Dividends paid

Net cash provided by (used for) financing activities

Effect of foreign exchange rate changes on cash and cash equivalents
Net change in cash

Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period

40,404

429

10,411
(153)
3,823

(11,020)
5,749

1,426

3,131
(5,751)
9,723

80,617

(41,487)
1,028
(150,999)
(191,458)

205

204,000
(79,000)
—

—

—
(1,195)
(37,468)
86,542
(406)
(24,705)
53,487

37,479

680

9,534

—

2,822

2,058

44,012
(634)
14,703
(18,926)
(590)
139,109

(36,599)
—

—
(36,599)

41,000
(69,002)
(1,495)
(9)
—
(366)
(37,217)
(67,072)
144

35,582

17,905

38,535

615
(36,637)
—

6,618

10,784

12,071

23,264
(16,436)
27,932

5,834

98,926

(31,699)
—

—
(31,699)

246

159,000
(82,003)
(277)
975
(125,000)
(401)
(38,558)
(86,018)
489
(18,302)
36,207

28,782

53,487

17,905

See notes to consolidated financial statements

Page 44 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

1. Basis of Statement Presentation:

Summary of Significant Accounting Policies

Fiscal Year

The Company's fiscal year end is December 31.

Description of Business and Principles of Consolidation

Innophos is a leading international producer of specialty ingredient solutions that deliver versatile benefits for the food,
health, nutrition and industrial markets. The Company leverages its expertise in the science and technology of blending and
formulating phosphate, mineral, enzyme and botanical based ingredients to help its customers offer products that are tasty, healthy,
nutritious and economical. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United
States, in Canada, Mexico and China.

Innophos combines more than a century of experience in specialty phosphate manufacturing with a broad range of other
specialty nutritional ingredients. Utilizing its capabilities in consumer insight, research and product development and application
expertise, it partners with its customers to provide differentiated product offerings that respond to consumer preferences and
megatrends. The Company utilizes this collaborative approach in order to attempt to generate market share gains for its customers.

Innophos’ product offering includes a wide array of botanical, enzyme and mineral based nutritional ingredients. These
products have various applications in the food, beverage and dietary supplement end markets and are manufactured to be readily
digestible. Innophos’ 2017 acquisitions of Novel Ingredients and NutraGenesis substantially expanded Innophos’ portfolio of
nutritional ingredients, which is a market that Innophos intends to continue to target for future growth.

Innophos Holdings, Inc. is the parent of Innophos Investments Holdings, Inc., which owns 100% of Innophos, Inc; all are

incorporated under the laws of the State of Delaware. All intercompany transactions are eliminated in consolidation.

Certain prior year balances have been restated to conform to current year presentation.

Use of Estimates

The preparation of financial statements in conformity with United States generally accepted accounting principles
requires the use of judgments and estimates made by management. Actual results could differ from those estimates. Some of the
more significant estimates pertaining to the Company include accruals for contingencies, distributor incentives and rebates, the
valuation of inventories, the allowance for doubtful accounts, income tax valuation allowances, the recoverability of long-lived
assets and goodwill impairment testing analysis and cash flows and assumptions used in the recognition and measurement of
assets acquired in business combinations. Management routinely reviews its estimates and assumptions utilizing currently
available information, changes in facts and circumstances, and historical experience.

Cash Equivalents

All highly liquid investments with original maturities of three months or less are considered to be cash equivalents.

Page 45 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Accounts Receivable and Allowances for Doubtful Accounts

Trade accounts receivable are recorded at the invoiced amount and does not bear interest. The collectability of accounts

receivable is evaluated based on a combination of factors. Allowances for doubtful accounts is evaluated based on the length of
time the receivables are past due, historical experience and financial wherewithal of the customer. In circumstances when it is
probable that a specific customer is unable to meet its financial obligations, an allowance is recorded to reduce the receivable to
the amount that is reasonably expected to be collected.

Inventories

Inventories are valued at the lower of cost or market. Cost is determined on the basis of the first-in, first-out method.
These costs include raw materials, direct labor, manufacturing overhead and depreciation. Spare parts are included in inventory
and are initially recorded at cost.

Inventories, including spare parts, are evaluated for excess quantities, obsolescence or shelf-life expiration. This

evaluation includes an analysis of historical sales levels by product and projections of future demand. To the extent
management determines there are excess, obsolete or expired inventory quantities, valuation reserves are recorded against all or
a portion of the value of the related products with the appropriate charge to cost of goods sold.

Property, Plant and Equipment

Property, plant and equipment are stated at cost less accumulated depreciation. Major renewals and improvements are

capitalized. Maintenance, repairs and minor renewals are expensed as incurred. The cost and related accumulated depreciation
of all property, plant and equipment retired or otherwise disposed of are eliminated from the accounts and any resulting gain or
loss is reflected in net income. Interest is capitalized in connection with the construction of major renewals and improvements.
Capitalized interest is recorded as part of the asset to which it relates and is amortized over the asset’s estimated useful life.
Depreciation is calculated on the straight-line basis over the estimated useful lives of the related assets, typically ranging from
ten to forty years for buildings and improvements, three to twenty years for machinery and equipment, and three to seven years
for capitalized software. Leasehold improvements are amortized over the lease term or the estimated useful life of the
improvement, whichever is less.

External direct costs in developing or obtaining internal use computer software and payroll, and payroll-related costs for

employees dedicated solely to the project, to the extent of the time spent directly on the project and which they meet the
requirements of ASC 350-40, are capitalized.

Long-Lived Assets

Under ASC 360,” Property, Plant, and Equipment,” long-lived assets including property, plant and equipment and
amortizable intangible assets are evaluated and reviewed for impairment whenever events or changes in circumstances indicate
that the carrying amount of an asset or asset group may not be recoverable. The review of these long-lived assets is performed
at the individual asset level, asset group level, or the product group level depending on the lowest level for which identifiable
cash flows are largely independent. The Company’s asset groupings or product groupings vary based on the interrelationship of
the long-lived assets and the identifiable cash flows. For example, in certain instances, multiple manufacturing units may work
with one another to produce the lowest identifiable cash flows or in other instances a stand-alone unit may produce the lowest
level of identifiable cash flows. There are other instances where a stand-alone unit may produce multiple products and the
lowest level of identifiable cash flows is at the product group level. Recoverability of assets to be held and used is measured by
a comparison of the carrying amount of the assets to the undiscounted future cash flows expected to be generated by the asset,
asset group or product group. When this comparison indicates that impairment must be recorded, the impairment recognized is
the amount by which the carrying amount of the assets exceeds the fair value of the assets.

The determination of whether or not assets are impaired and the corresponding useful lives of these long-lived assets

Page 46 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Goodwill

Goodwill represents the excess of the acquisition cost over the fair value of net assets of the businesses acquired. ASC

350, “Intangibles—Goodwill and Other,” requires periodic tests of the impairment of goodwill. ASC 350 requires a
comparison, at least annually, of the net book value of the assets and liabilities associated with a reporting unit, including
goodwill, with the fair value of the reporting unit, which corresponds to the discounted cash flows of the reporting unit, in the
absence of an active market. The development of future cash flow projections requires management estimates related to
forecasted sales and expected costs trends. To the extent that changes in business conditions occur or other management
decisions are made that result in adjusted management projections, impairment losses may occur in future periods. If the entity
determines that it's more likely than not that the fair value of a reporting unit exceeds the carrying amount, then determining an
impairment charge is unnecessary. When the carrying value of the reporting unit exceeds the fair value amount, the impairment
recognized is the amount by which the carrying amount of the assets exceeds the fair value of these assets, not to exceed the
carrying value of the goodwill. The annual goodwill impairment review is conducted during the fourth quarter of each year.

Other Intangible Assets

Other intangible assets, which consist of developed technology, customer relationships, trade names, a non-compete
agreement, patents, licenses and software, are amortized on a straight-line basis over their estimated useful lives which can be
up to twenty years.

Revenue Recognition

Revenue from sales of the Company's products to its customers is recognized when title and risk of loss passes to the
customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers. In the United
States and Canada, the Company records estimated reductions to revenue for distributor incentives and customer incentives
such as rebates, at the time of the initial sale. Distributor and customer incentives in Mexico are immaterial to the financial
statements. The estimated reductions are based on the sales terms, historical experience and trend analysis. Accruals for
distributor incentives are reflected as a direct reduction to accounts receivable and accruals for rebates are recorded as accrued
expenses. This analysis requires a significant amount of judgment from management. Changes in the assumptions used to
calculate these estimates or changes resulting from actual results are recorded against revenue in the period in which the change
occurs.

Shipping and Handling Fees and Costs and Advertising Expenses

Shipping and handling fees and costs invoiced to customers are included in Net sales. Shipping and handling fees and

costs incurred by the Company are included in Cost of goods sold. Advertising expenses, which are not significant, are
expensed as incurred.

Foreign Currency Translation

The U.S. dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations
monetary assets and liabilities are remeasured at current exchange rates, non-monetary assets and liabilities are remeasured at
historical exchange rates. Revenue and expenses related to monetary assets and liabilities are remeasured at average exchange
rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All translation
gains and losses are included in net income.

Research and Development Expenses

Research and development expenditures, including expenditures relating to the development of new products and

processes and significant improvements and refinements to existing products, are expensed as incurred.

Employee Termination Benefits

The Company does not have a written severance plan for its Mexican operations, nor does it offer similar termination

benefits to affected employees in all Mexican restructuring initiatives. However, Mexican law requires payment of certain
minimum termination benefits. Accordingly, in situations where minimum statutory termination benefits must be paid to the
affected employees, the Company records employee severance costs associated with these activities in accordance with ASC
712, Compensation – Nonretirement Post Employment Benefits. The Company does have a written severance plan which is in
accordance with ASC 712 for its U.S. and Canadian operations. The Company has an accrued obligation for post-employment

Page 47 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

benefits for U.S. and Canadian operations when the amounts are probable and reasonably estimated. In all other situations
where the Company pays out termination benefits, including supplemental benefits paid in excess of statutory minimum
amounts and benefits offered to affected employees based on management’s discretion, the Company records these termination
costs in accordance with ASC 420, Exit or Disposal Cost Obligations.

The timing of the recognition of charges for employee severance costs depends on whether the affected employees are

required to render service beyond their legal notification period in order to receive the benefits. If affected employees are
required to render service beyond their legal notification period, charges are recognized ratably over the future service period.
Otherwise, charges are recognized when a specific plan has been confirmed by management and required employee
communication requirements have been met.

Legal Costs

The Company expenses legal costs as incurred, including those legal costs which may be incurred in connection with a

loss contingency.

Income Taxes

The Company’s significant subsidiaries are the Company's United States subsidiaries which file a consolidated U.S. tax

return, the Company's Mexican subsidiaries which filed consolidated Mexico tax returns from 2011 through 2015, but changed
to filing separate tax returns in 2016, the Company's Canadian subsidiary which files a separate Canadian tax return and the
Netherlands files a fiscal unity return for certain Netherlands subsidiaries. The Company accounts for income taxes in
accordance with ASC 740, Income Taxes. Under ASC 740, deferred tax assets and liabilities are determined based on the
differences between the financial statement and tax bases using enacted tax rates applied to those differences.

Deferred tax assets are assessed for realizability and a valuation allowance is provided if a portion of the associated tax

benefit is not expected to be realized.

If any material uncertain tax positions arise, the Company’s policy is to accrue associated penalties in selling, general and

administrative expenses and to accrue interest as part of net interest expense. Other than the assessments disclosed in Note 16,
Income Taxes, as of December 31, 2017, no significant adjustments have been proposed to the Company's tax positions and the
Company currently does not anticipate any adjustments that would result in a material change to its financial position during the
next twelve months.

On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Tax Act”). The Tax Act significantly changes

U.S. corporate income tax laws by, among other things, reducing the U.S. corporate income tax rate from 35% to 21% effective
for tax years beginning after December 31, 2017 and transitioning U.S. international taxation from a worldwide tax system to a
territorial tax system with a one-time mandatory transition or toll tax on post-1986 undistributed foreign earnings and profits of
U.S. subsidiaries through the year ended December 31, 2017. Refer to Note 16 for additional information.

Environmental Costs

Environmental liabilities are recorded undiscounted when it is probable that these liabilities have been incurred and the

amounts can be reasonably estimated. These liabilities are estimated based on an assessment of many factors, including the
amount of remediation costs, the timing and extent of remediation actions required by the applicable governmental authorities,
and the amount of the Company’s liability after considering the liability and financial resources of other potentially responsible
parties. Generally, the recording of these accruals coincides with the assertion of a claim or litigation, completion of a
feasibility study or a commitment to a formal plan of action. Anticipated recoveries from third parties are recorded as a
reduction of expense only when such amounts are realized. Any insurance receivables would be recorded gross of the estimated
liability.

Comprehensive Income (Loss)

Comprehensive income (loss) is composed of net income (loss), adjusted for changes in comprehensive income items

such as changes in defined benefit pension plan funded status.

Page 48 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Share-based Compensation

The Company recognizes compensation expense for its Long-Term Incentive Plans (LTIP). Under applicable accounting
standards, the fair value of share-based compensation is determined at the grant date and the recognition of the related expense
is recorded over the period in which the share-based compensation vests. Refer to Note 12 for additional information.

Business Combinations

An acquired business is included in the consolidated financial statements upon obtaining control of the acquired assets. Assets
acquired and liabilities assumed are recognized at the date of acquisition at their respective fair values. Any excess of the purchase
price over the estimated fair values of the net assets acquired is recognized as goodwill.

Recently Issued Accounting Standards

Adopted

In July 2015, the FASB issued guidance which requires entities to measure most inventory “at the lower of cost and net

realizable value (“NRV”),” thereby simplifying the current guidance under which an entity must measure inventory at the lower
of cost or market. Under the new guidance, inventory is “measured at the lower of cost and net realizable value,” which
eliminates the need to determine replacement cost and evaluate whether it is above the ceiling (NRV) or below the floor (NRV
less a normal profit margin). The guidance defines NRV as the “estimated selling prices in the ordinary course of business, less
reasonably predictable costs of completion, disposal, and transportation.” The guidance is effective for annual periods
beginning after December 15, 2016, and interim periods therein. Early application is permitted. The Company's adoption of this
standard did not have a material impact on its financial position, results of operations and related disclosures.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which
amends Accounting Standards Codification ("ASC") Topic 718, Compensation - Stock Compensation. ASU 2016-09 simplifies
several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of
awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years
beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. The
Company's adoption of this standard did not have a material impact on its financial position, results of operations and related
disclosures.

In January 2017, the FASB issued ASU No. 2017-04, Simplifying the Test for Goodwill Impairment. Under the new

standard, goodwill impairment would be measured as the amount by which a reporting unit’s carrying value exceeds its fair
value, not to exceed the carrying value of goodwill. This ASU eliminates existing guidance that requires an entity to determine
goodwill impairment by calculating the implied fair value of goodwill by hypothetically assigning the fair value of a reporting
unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. The new standard is
effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is
permitted on testing dates after January 1, 2017. The Company has elected to early adopt for testing dates after January 1, 2017
and the adoption of this standard did not have a material impact on its financial position, results of operations and related
disclosures.

In February 2018, the FASB issued amendments to the guidance for reporting comprehensive income through ASU
2018-02, “Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from
Accumulated Other Comprehensive Income.” The ASU allows a reclassification from accumulated other comprehensive
income (loss), or AOCI, to retained earnings for the deferred taxes previously recorded in AOCI that exceed the current federal
tax rate of 21% resulting from the Tax Act. The ASU allows adjustments to reclassification amounts in subsequent periods as a
result of changes to the amounts recorded under SAB 118. If adopted, the ASU is effective in years beginning after December
15, 2018, but permits early adoption in a period for which financial statements have not yet been issued. The Company has
elected to early adopt the ASU. The effect of adopting the ASU resulted in an increase of $0.3 million to retained earnings at
December 31, 2017 due to the reclassification of AOCI to retained earnings.

Issued but not yet adopted

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current

revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize
revenue to depict the transfer of goods or services to customers at an amount that the entity expects to be entitled to in exchange
for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is

Page 49 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

recognized. Other major provisions include capitalization of certain contract costs, consideration of time value of money in the
transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain
circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of
revenue and cash flows arising from an entity’s contracts with customers. In July 2015, the FASB approved the deferral of the
effective date of this guidance by one year (with an option to early adopt at the original effective date), making it effective for
the interim and annual periods beginning on or after December 15, 2017. As a result, this guidance will be effective for the
Company beginning in fiscal year 2018, with an option to early adopt in fiscal year 2017. The guidance permits the use of
either a retrospective or modified retrospective transition method. The Company will adopt the standard using the modified
retrospective transition method on January 1, 2018. Based on the results of the assessment performed to date, though the
Company will provide expanded disclosures as a result, the Company has concluded that revenues are expected to remain
substantially unchanged from the current revenue recognition model and therefore, the adoption of this standard will not have a
material impact on its financial position, results of operations and related disclosures.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) in order to increase transparency and comparability
among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating
leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease
liability) and a right-of-use asset representing its right to use the underlying asset for the lease term on the balance sheet. ASU
2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a
modified retrospective approach and early adoption is permitted. While the Company is continuing to assess the effect of
adoption, it currently believes the most significant changes relate to the recognition of new right-of-use assets and lease
liabilities on its balance sheet for railcar and tank operating leases. The Company will continue to evaluate the impact of
adoption of the ASU on its financial position, results of operations and related disclosures.

In March 2016, the FASB issued ASU 2016-15, Clarification on Classification of Certain Cash Receipts and Cash
Payments on the Statement of Cash Flows. ASU 2016-15 clarifies the classification of certain cash receipts and cash payments
in the statement of cash flows, including debt prepayment or extinguishment costs, settlement of contingent consideration
arising from a business combination, insurance settlement proceeds, and distributions from certain equity method investees.
The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017.
Early adoption is permitted. The Company is evaluating the impact of adopting this new accounting guidance on its
consolidated financial statements.

In October 2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other
Than Inventory, which reduces the complexity in the accounting standards by allowing the recognition of current and deferred
income taxes for an intra-entity asset transfer, other than inventory, when the transfer occurs. Historically, recognition of the
income tax consequence was not recognized until the asset was sold to an outside party. This amendment should be applied on a
modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the
period of adoption. There are no new disclosure requirements. This ASU is effective for annual reporting periods beginning
after December 15, 2017. Early adoption is permitted in the first interim period of 2017. The Company is currently in the
process of evaluating the impact of adoption of the ASU on its financial position, results of operations and related disclosures.

In November 2016, the FASB issued ASU No. 2016-18, Restricted Cash, which clarifies guidance on the classification

and presentation of restricted cash in the statement of cash flows. Under the ASU, changes in restricted cash and restricted cash
equivalents would be included along with those of cash and cash equivalents in the statement of cash flows. As a result, entities
would no longer present transfers between cash/equivalents and restricted cash/equivalents in the statement of cash flows. In
addition, a reconciliation between the balance sheet and the statement of cash flows would be disclosed when the balance sheet
includes more than one line item for cash/equivalents and restricted cash/equivalents. The new standard is effective for fiscal
years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company does not anticipate the
adoption of the new accounting rules will have a material impact on its financial position, results of operations and related
disclosures.

In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business, which narrows the existing

definition of a business and provides a framework for evaluating whether a transaction should be accounted for as an
acquisition (or disposal) of assets or a business. The ASU requires an entity to evaluate if substantially all of the fair value of
the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets; if so, the set of
transferred assets and activities (collectively, the set) is not a business. To be considered a business, the set would need to
include an input and a substantive process that together significantly contribute to the ability to create outputs. The standard
also narrows the definition of outputs. The definition of a business affects areas of accounting such as acquisitions, disposals
and goodwill. Under the new guidance, fewer acquired sets are expected to be considered businesses. The new standard is

Page 50 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company
would apply this guidance to applicable transactions after the adoption date.

In March 2017, the FASB issued ASU No. 2017-07, Improving the Presentation of Net Periodic Pension Cost and Net

Periodic Post-retirement Benefit Cost, which requires that only the service cost component of net periodic benefit costs be
recorded as compensation cost in the operating expense section of the income statement. All other components of net periodic
benefit cost (interest cost, expected return on plan assets and amortization of net loss) will be presented in other income - net.
This standard update is effective beginning with the first quarter 2018 and must be applied retrospectively. the Company is
evaluating the impact of adopting this new accounting guidance on its consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, Stock Compensation - Scope of Modification Accounting, which
requires all modifications to be accounted for as a modification unless the fair value, vesting conditions and classification of the
award as equity or liability are the same as the classification of the original award immediately before the original award is
modified. The amendments in this ASU are effective for fiscal years beginning after December 15, 2017 and for interim periods
therein. The Company's adoption of this guidance is not expected to have a significant effect on its financial position, results of
operations and related disclosures.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and hedging (Topic 815): Targeted improvements to
accounting for hedging activities. This standard more closely aligns the results of cash flow and fair value hedge accounting
with risk management activities through changes to both the designation and measurement guidance for qualifying hedging
relationships and the presentation of hedge results in the financial statements. This standard also addresses specific limitations
in current GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the
measurement of hedge results to better reflect an entity’s hedging strategies. Additionally, by aligning the timing of recognition
of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the
earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged
item is presented, the results of an entity’s hedging program and the cost of executing that program will be more visible to users
of financial statements. The new standard is effective for annual reporting periods beginning after December 15, 2018 with
early adoption permitted. The Company does not anticipate the adoption of this standard will have a material impact on its
financial position, results of operations and related disclosures.

2. Acquisitions

On August 25, 2017, the Company acquired 100 percent of the outstanding shares of GenNx Novel Holding, Inc.
(together with its direct and indirect wholly-owned subsidiaries, "Novel Ingredients"). Novel Ingredients was a privately-held
specialty ingredients supplier of botanicals, proteins, amino acids and other healthy ingredients, as well as branded ingredient
and custom formulated solutions, headquartered in East Hanover, New Jersey. The Company made an initial $125.0 million
cash payment, subsequently adjusted lower by $1.3 million for post-closing working capital adjustments, for total consideration
of $123.7 million. The acquisition was funded by borrowings under its existing credit facility. The addition of Novel
Ingredients grows Innophos' Food, Health, and Nutrition portfolio, expanding its presence in high-growth nutrition end-markets
and positioning the Company to more effectively develop innovative ingredient solutions that better serve its customers. Novel
Ingredients serves attractive end-markets driven by health and wellness consumer trends such as immune health, sports
nutrition, and cognitive health.

On November 3, 2017, the Company acquired 100% of the outstanding equity interests of NutraGenesis LLC, Icon Group

LLC, and Tradeworks Group, Inc. (collectively referred to as "NutraGenesis"). NutraGenesis was a privately-held Vermont-
based marketer of proprietary, branded and science-backed nutraceutical ingredients. The Company made a $27.4 million cash
payment, subject to post-closing working capital adjustments, which was funded by borrowings under its existing credit facility.
NutraGenesis is highly complementary to the Novel Ingredients acquisition and the Company's branded ingredients portfolio.
NutraGenesis serves attractive high-growth end-markets, including stress reduction, weight management, joint health, brain
health and metabolic wellness, that are driven by health and wellness consumer trends.

During the year ended December 31, 2017, the Company's results of operations included revenues of $36.7 million and a

$2.3 million net loss attributable to Novel Ingredients and NutraGenesis.

The excess of purchase price over the fair value amounts assigned to the assets acquired and liabilities assumed represents

the goodwill amount resulting from the acquisitions and will be included in the Food, Health and Nutrition operating segment.

Page 51 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The goodwill of $68.3 million arising from the acquisitions consists of expected revenue and cost synergies, operational know-
how, and acquired workforce. Approximately $24.0 million of the goodwill is deductible for U.S. income tax purposes.

The following table summarizes the estimated fair value of the assets acquired and liabilities assumed (in thousands):

Novel
Ingredients

NutraGenesis

Cash

105

Accounts receivable, net of allowances of $511 and $0 for Novel Ingredients and
NutraGenesis, respectively

Inventory, including fair value adjustment of $4,300 for Novel Ingredients

Other current assets

Property, plant and equipment

Other non-current assets

Goodwill

Intangible assets

Accounts payable

Accrued expenses

Deferred income taxes

Customer Deposits

Total

11,255

23,121

1,655

4,261

187

54,008

52,900
(14,726)
(3,910)
(5,067)
—

123,789

850

—

638

—

14,320

13,699
(793)
(524)
—
(875)
27,397

In preparing the preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management
consulted with an independent third party. The purchase price and related allocation to assets acquired and liabilities assumed is
preliminary pending finalization of the fair values assigned to the intangible assets and the valuation of the working capital
components acquired as of the acquisition date.

Novel Ingredients has Net Operating Loss ("NOL") carryforwards of $16.4 million that are expected to be utilized in

future periods. The deferred income tax balances are preliminary pending management's final analysis and preparation of the
final period tax return.

The intangible assets acquired with Novel Ingredients and NutraGenesis include the following (in thousands):

Customer relationships

Trade names

Useful life
(years)
15-20

5-10

Novel
Ingredients

NutraGenesis

46,200

6,700

52,900

10,499

3,200

13,699

The weighted average useful life (years) of the intangible assets included in the above table is 17.4 years. The weighted
average useful life (years) of the trade names included in the above table is 7.9 years. The weighted average useful life (years)
of the customer relationships included in the above table is 19.1 years.

The following unaudited pro forma information has been prepared as if the acquisitions had occurred on January 1, 2016

(amounts in thousands, excluding EPS figures). The unaudited pro forma results do not reflect any material adjustments,
operating efficiencies and other synergies which may result from the consolidation of operations.

Page 52 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Revenues

Net income

Income per common share - Basic

Income per common share - Diluted

Year Ended December 31,
2016
2017

792,600

22,011

1.13

1.12

812,447

41,711

2.16

2.13

These amounts have been calculated after applying the Company's accounting policies and adjusting the results of Novel

Ingredients and NutraGenesis to reflect the additional depreciation and amortization expense that would have been charged
assuming the fair value adjustments to property, plant and equipment and intangible assets had been applied on January 1, 2016.
Interest expense related to the borrowing for the acquisitions was applied on January 1, 2016. Depreciation and amortization
expense of approximately $5.0 million and interest expense of approximately $4.4 million related to the above were included in
the years ended December 31, 2017 and December 31, 2016. Further, the above pro forma amounts include a fair value
adjustment to inventory of $4.3 million applied on January 1, 2016. The year ended December 31, 2017 include non-recurring
transaction costs of approximately $3.1 million and $2.1 million of integration costs in selling, general and administrative
expense.

3. Restructuring and Management Transition Costs:

During 2015 management evaluated several initiatives to improve the overall operating efficiency of the organization. As

a result of this evaluation the Company launched an initiative to reduce its cost structure by implementing various staff
reduction actions during the third quarter of 2015.

In addition, during the fourth quarter of 2015, the Company experienced a management transition of certain high-level

positions, most notably the Chief Executive Officer and the Chief Financial Officer.

During the third and fourth quarters of 2015, the Company incurred restructuring and management transition costs of $8.6

million and $11.8 million, respectively. The amounts recorded within selling, general and administrative expenses in the
statements of operations were $17.1 million and cost of goods sold were $3.3 million.

During 2016, the Company incurred additional amounts in connection with continued restructuring of $1.6 million
(including accelerated stock compensation of $0.3 million) within selling, general and administrative expenses and $0.1 million
within cost of goods sold. The Company expects to make $1.7 million of payments associated with these actions within the next
twelve months.

The following table summarizes the activities related to severance and benefits for restructuring and management

transition costs:

Balance at beginning of year
Total expense recorded

Accelerated share-based compensation expense (a)

Payments made

Balance at end of year

(a) Accelerated stock-based compensation expense adjustments due to management transition.

2017

2016

6,356

13,389

—

—
(4,427)
1,929

1,718
(254)
(8,497)
6,356

Page 53 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

4. Inventories:

Inventories consist of the following:

Raw materials
Finished products
Spare parts

2017

2016

48,445
83,634
13,606
145,685

33,185
81,369
13,741
128,295

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of December 31, 2017 and December 31,

2016 were $16,168 and $13,422, respectively.

5. Other Current Assets:

Other current assets consist of the following:

Creditable taxes (value added taxes)
Vendor inventory deposits (prepaid)
Prepaid income taxes
Prepaid insurance
Other

2017

2016

7,285
7,807
3,394
2,492
3,991
24,969

9,722
3,750
4,659
2,248
3,515
23,894

Page 54 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

6. Property, Plant and Equipment, net:

Property, plant and equipment, at cost, consist of the following:

2017

2016

— $

Land
Land improvements -
Buildings and improvements -

Machinery & Equipment -

Construction-in-progress

Useful life
(years)
-
3-15
2-9
10
14-16
20
25-34
1-4
5
6
7
8
9
10
11
12-13
15
16-21
-

Gross
18,453
11,861
10,373
17,161
12,080
43,013
21,377
26,409
49,521
49,493
52,955
170,719
26,281
16,856
11,697
9,477
113,062
3,698
31,653
$ 696,139

Accumulated
Depreciation
$

9,855
9,507
10,433
9,699
17,508
7,424
21,325
39,387
49,273
48,937
155,043
26,078
6,992
11,693
9,426
43,061
1,201
—
$ 476,842

Net Book
Value
18,453
2,006
866
6,728
2,381
25,505
13,953
5,084
10,134
220
4,018
15,676
203
9,864
4
51
70,001
2,497
31,653
$ 219,297

Gross
19,053
11,303
9,486
15,526
12,105
39,128
21,687
24,515
46,545
49,493
52,785
167,938
26,413
15,920
11,852
9,478
106,587
1,657
11,594
$ 653,065

Accumulated
Depreciation
$

9,495
9,419
9,079
8,915
15,451
6,741
17,801
34,824
49,216
44,781
150,883
26,140
5,964
11,847
9,419
36,571
1,060
—
$ 447,606

Net Book
Value
19,053
1,808
67
6,447
3,190
23,677
14,946
6,714
11,721
277
8,004
17,055
273
9,956
5
59
70,016
597
11,594
$ 205,459

Depreciation expense, excluding depreciation expense in changes of inventory, was $31,345, $30,142 and $31,594 in
2017, 2016 and 2015, respectively. Depreciation expense in changes of inventory was $678, $113 and $(292), in 2017, 2016
and 2015, respectively. The carrying value of capitalized software, included in machinery and equipment, was $4,749, $8,141
and $10,919 for the years ended December 31, 2017, December 31, 2016 and December 31, 2015, respectively.

7. Goodwill:

Balance: December 31, 2015
Balance: December 31, 2016

Add: Goodwill from Novel Ingredients acquisition
Add: Goodwill from NutraGenesis acquisition

Balance: December 31, 2017

Food,
Health and
Nutrition

$
$

61,090
61,090
54,007
14,320
$ 129,417

Industrial
Specialties
23,283
$
23,283
$
—
—
23,283

$
$

Other

Total
84,373
— $
84,373
— $
54,007
—
—
14,320
— $ 152,700

Page 55 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

8. Intangibles and Other Assets, net:

Intangibles and other assets consist of the following:

Developed technology and application patents, net of accumulated
amortization of $30,716 for 2017 and $27,778 for 2016

Customer relationships, net of accumulated amortization of $22,279 for
2017 and $18,569 for 2016

Trade names and license agreements, net of accumulated amortization of
$12,023 for 2017 and $10,315 for 2016

Non-compete agreement, net of accumulated amortization of $1,293 for
2017 and $1,268 for 2016

Total intangibles

Deferred income taxes
Deferred financing costs, net of accumulated amortization of $3,902 for
2017 and $3,473 for 2016 (see note 10)

Other tax assets
Other assets

Total other assets

Useful life
(years)

2017

2016

7-20

5-20

3-10

15,559

73,232

15,538

40
104,369

5,058

1,721

—

1,768
8,547

112,916

18,497

20,243

7,346

65
46,151

18,432

2,150

997

2,081
23,660

69,811

Amortization expense for intangibles was $8,381, $7,222 and $7,233 in 2017, 2016 and 2015, respectively. Anticipated

amortization expense for the next five years related to intangibles is as follows:

Intangible amortization expense

2018
11,258

2019
10,735

2020
10,117

2021

2022

9,479

9,006

The preceding expected amortization expense is an estimate. Actual amounts of amortization expense may differ from

estimated amounts due to additional intangible asset acquisitions, impairment of intangible assets, accelerated amortization of
intangible assets and other events.

9. Other Current Liabilities:

Other current liabilities consist of the following:

Payroll related
Taxes other than income taxes
Benefits and pensions
Freight and rebates
Income taxes
Restructuring reserve
Other

2017

2016

15,684
2,804
7,730
3,937
4,933
1,719
6,277
43,084

11,852
2,624
5,419
3,579
9,278
4,737
6,116
43,605

Page 56 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

10. Short-term Borrowings, Long-Term Debt, and Interest Expense:

Short-term borrowings and long-term debt consist of the following:

Revolver borrowings under the credit facility due 2021
Capital leases
Total borrowings
Less current portion
Long-term debt

2017
310,000
9
310,009
4
310,005

2016
185,000
—
185,000
—
185,000

In December 2016, Innophos Holdings, Inc. and certain of its directly and/or indirectly wholly-owned subsidiaries
(referred to in this note as the "Company") entered into a senior secured credit facility, or Credit Agreement, with a group of
lenders, or the Lenders, increasing the Company's borrowing capacity. The Credit Agreement replaces the term loan of $100.0
million and revolving line of credit under the prior facility with a $450.0 million revolving line of credit, including a $20.0
million letter of credit sub-facility and a $20.0 million swingline loan facility, all maturing on December 22, 2021. Interest
accruing on amounts borrowed under the revolving line is based on an applicable margin over LIBOR (London Interbank
Offered Rate) or bank base rate, ranging from 100 to 225 basis points for LIBOR and 0 to 125 basis points for base rate loans,
in each case with loan period and interest alternative as chosen by the Company, which margin is adjusted quarterly depending
on a total leverage ratio (as computed under the Credit Agreement) for the period in question. Commitment fees on the unused
revolving line range from 12.5 to 37.5 basis points, depending on total leverage ratio (as computed under the Credit Agreement)
for the period in question. The current applicable margin for LIBOR based loans, base rate loans and the commitment fee are
200, 100 and 32.5 basis points, respectively.

The Credit Agreement also provides for possible additional revolving indebtedness under an incremental facility of up to

$150.0 million (for an aggregate of revolving capacity up to $600.0 million) upon future request by the Company to existing
Lenders (and depending on their consent) or from other willing financial institutions invited by the Company and reasonably
acceptable to the administrative agent to join in the Credit Agreement. This revolving credit facility increase, if implemented,
may provide for higher applicable margins to either the increased portion or possibly the entire revolving credit facility, with
limitations, for interest rates than those in effect for the original revolving commitments under the Credit Agreement.

The obligations of the Company under the Credit Agreement are secured by first priority liens on substantially all the
United States assets of the Company, as well as a pledge of 65% of the voting equity of entities holding the Company's foreign
subsidiaries.

The Credit Agreement contains representations given to the Lenders about the nature and status of the Company's
business that serve as conditions to future borrowings, and affirmative, as well as negative, covenants typical of credit facilities
of this kind that prohibit or limit a variety of actions by the Company and its subsidiaries generally without the Lenders’
approval. These include covenants that affect the ability of those entities, among other things, to (a) incur or guarantee
indebtedness, (b) create liens, (c) enter into mergers, recapitalizations or assets purchases or sales, (d) change names, (e) make
certain changes to their business, (f) make restricted payments that include dividends, purchases and redemptions of equity
(g) make advances, investments or loans, (h) effect sales and leasebacks or (i) enter into transactions with affiliates, (j) allow
negative pledges or limitations on the repayment abilities of subsidiaries or (k) amend subordinated debt. However, subject to
continued compliance with the overall leverage restrictions described in more detail below, the Company retains flexibility
under the Credit Agreement to develop its business and achieve strategic goals by, among other things, being permitted to take
on additional debt, pay dividends (as long as the Total Leverage Ratio shall be .25 less than the then applicable level described
below), re-acquire equity and make domestic acquisitions. Foreign acquisitions and investments are also permitted up to a fixed
limit which is set initially at $213.0 million and can increase with ongoing cash generation up to as high as $425.0 million.

Among its affirmative covenants, the Credit Agreement requires the Company to maintain the following consolidated

ratios (as defined and calculated according to the Credit Agreement) as of the end of each fiscal quarter:

(a) “Total Leverage Ratio” less than or equal to 3.50 to 1.00.

(b) “Interest Coverage Ratio” greater than or equal to 3.00 to 1.00.

Page 57 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

As of December 31, 2017, the Accessible Borrowing Availability was $138.9 million and the Total Leverage Ratio and

Interest Coverage Ratio calculated in accordance with the agreement were 2.45 and 19.32, respectively.

As of December 31, 2017, the Company was in full compliance with all debt covenant requirements.

The Credit Agreement provides for “Events of Default” that, unless waived, can or will lead to acceleration of obligations
upon the occurrence, continuation and/or notice, as applicable, of specified events typical of credit facilities of this kind. These
include (a) failures to pay interest or principal on loans, (b) misrepresentations, (c) failures to observe covenants, (d) cross
defaults of other indebtedness in excess of $20.0 million, (e) uninsured and unsatisfied judgments in excess of $20.0 million or
certain orders or injunctions, (f) bankruptcy and insolvency events, (g) events leading to aggregate liability under the Employee
Retirement Income Security Act of 1974 (ERISA) in excess of $20.0 million, (h) changes of control, (i) invalidity of credit
support /security agreements, and (i) certain disadvantageous changes in Credit Agreement debt compared to subordinated debt.

Fees and expenses incurred in 2016 with the Credit Agreement were approximately $1.5 million. This amount was
recorded as deferred financing costs and is being amortized over the term of the Credit Agreement using the effective interest
method.

As of December 31, 2017, $310.0 million was outstanding under the revolving line of credit, which approximates fair

value (determined using level 2 inputs within the fair value hierarchy), with total availability at 138.9 million, taking into
account $1.1 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate
for all debt is 3.4%.

The Company manages interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent

practicable consistent with the credit status.

Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt
through public or privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend
on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at
the time. The amounts involved may be material.

Total interest paid by the Company for all indebtedness for 2017, 2016 and 2015 was $6.8 million, $8.0 million and $5.9

million, respectively.

Interest expense, net consists of the following:

Interest expense
Deferred financing cost
Interest income
Less: amount capitalized for capital projects
Total interest expense, net

Year Ended December 31,

2017

2016

2015

7,148
429
(124)
(445)
7,008

7,210
680
(53)
(168)
7,669

7,079
615
(65)
(111)
7,518

Page 58 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

11. Other Long-Term Liabilities:

Other long-term liabilities consist of the following:

Deferred income taxes
Long term portion of U.S. transition tax
Pension and post retirement liabilities
Restructuring reserve
Uncertain tax positions
Environmental liabilities
Other liabilities

2017

2016

2,354
12,095
8,886
210
1,974
1,100
1,453
28,072

1,282
—
7,689
1,618
1,974
1,100
1,906
15,569

12. Stockholders’ Equity / Stock-Based Compensation:

The Company's compensation programs include share-based payments. The primary share-based awards and their general

terms and conditions currently in effect are as follows:

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of
shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants
throughout the vesting period. Compensation expense is amortized on a straight-line basis over the requisite vesting
period, generally three years, and accelerated for those employees that are retirement eligible during the vesting
period.

•

Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of
the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common
stock on the date of grant. The stock options generally vest annually over three years with a ten year term from date
of grant.

Performance share awards which entitle the holder to receive, at the end of a performance cycle, a number of shares
of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%),
calculated using a combination of performance indicators as defined by reference to the Company’s own activities.
The performance shares generally vest at the end of a three year performance cycle and the number of shares
distributable depends on the extent to which the Company attains pre-established performance goals. Amounts
equivalent to dividends will accrue over the performance period and are paid on performance share awards when
vested and distributed.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of

shares of the Company’s common stock, which immediately vest, equal to a fixed retainer value.

The following table summarizes the components of stock-based compensation expense, all of which has been classified

as selling, general and administrative expense:

Stock options
Restricted stock
Performance shares
Stock grants
Total stock-based compensation expense (a)

Year Ended December 31,

2017

2016

2015

1,068
1,701
424
630
3,823

994
1,490
(257)
595
2,822

2,521
2,080
1,507
510
6,618

(a) 2016 includes accelerated stock-based compensation expense adjustments of $(254), due to management transition.

Page 59 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

A summary of restricted stock activity during the three years ended December 31, 2017, is presented below:

Outstanding at January 1, 2015

Granted

Released

Forfeited / Surrendered

Outstanding at December 31, 2015

Outstanding at January 1, 2016

Granted

Released

Forfeited / Surrendered

Outstanding at December 31, 2016
Outstanding at January 1, 2017

Granted

Released

Forfeited / Surrendered

Outstanding at December 31, 2017

Weighted
Average
Grant
Date Fair
Value

54.49

34.40

53.84

53.27

40.85

31.47

53.18

40.79

35.27
35.27

52.41

34.71

36.42

38.18

Number
of Shares

50,336

92,433
(7,066)
(10,372)
125,331

125,331

88,836
(7,796)
(29,920)
176,451
176,451

30,723
(32,171)
(24,424)
150,579

$
$

A summary of stock option activity during the three years ended December 31, 2017, is presented below:

Outstanding at January 1, 2015
Granted
Forfeited / Expired / Surrendered
Exercised
Outstanding at December 31, 2015
Exercisable at December 31, 2015
Outstanding at January 1, 2016
Granted
Forfeited / Expired / Surrendered
Exercised
Outstanding at December 31, 2016
Exercisable at December 31, 2016
Outstanding at January 1, 2017
Granted
Forfeited / Expired / Surrendered
Exercised
Outstanding at December 31, 2017
Exercisable at December 31, 2017

Number of
Options

Weighted
Average
Exercise
Price

Weighted
Average Grant
Date Fair Value

625,320
157,961
(37,364)
(53,995)
691,922
543,905
691,922
400,215
(260,913)
(91,029)
740,195
368,159
740,195
102,607
(175,767)
(49,530)
617,505
343,849

$
$
$

$
$

30.87
42.38
31.62
19.78
34.33
31.87
34.33
31.18
33.17
19.55
34.84
37.06
34.84
52.43
37.24
23.40
38.00
38.05

12.14

4.62

11.54

Page 60 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The fair value of the options granted during 2017, 2016 and 2015 was determined using the Black-Scholes option-pricing

model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility
Dividend yield
Risk-free interest rate
Expected term in years
Weighted average grant date fair value of stock options

Year Ended
December 31,
2017

Year Ended
December 31,
2016

Year Ended
December 31,
2015

31.3%
3.6%
2.1%
6.6

33.8%
6.6%
1.4%
6.6

40.8%
4.3%
1.7%
6.0

11.54

4.62

12.14

The expected volatility and the expected term are based on the Company's historical data. The dividend yield is the

A summary of performance share activity is presented below:

Outstanding at January 1, 2015
Granted (at targeted return on invested capital and contribution margin growth)
Forfeited
Vested
Adjustment to estimate of shares to be earned
Outstanding at December 31, 2015
Outstanding at January 1, 2016
Granted (at targeted return on invested capital and contribution margin growth)
Forfeited
Vested
Adjustment to estimate of shares to be earned
Outstanding at December 31, 2016
Outstanding at January 1, 2017
Granted (at targeted return on invested capital and contribution margin growth)
Forfeited
Vested
Adjustment to estimate of shares to be earned
Outstanding at December 31, 2017

Weighted
Average
Grant
Date Fair
Value

Number
of Shares

44,698
62,225
—
(37,835)
(36,671)
32,417
32,417
—
—
(12,401)
(20,016)

$
$

— $
— $

22,958
(2,083)
(353)
401
20,923

55.49
42.31
—
53.05
51.48
37.58
37.58
—
—
54.46
27.12
—
—
52.44
52.44
49.54
49.54
52.43

Page 61 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The total intrinsic value of options exercised and stock grants during 2017, 2016 and 2015 was $4.2 million, $5.9 million
and $4.9 million, respectively. The aggregate intrinsic value of stock options outstanding and exercisable at December 31, 2017
was $5.4 million and $3.0 million, respectively. The total remaining unrecognized compensation expense related to share-based
payments is as follows:

Unrecognized Compensation Expense
Amount
Weighted-average years to be recognized

Restricted
Stock

Stock
Options

Performance
Based

3,698
1.5

1,915
1.5

666
2.3

The Board of Directors authorized a stock repurchase program, commencing January 1, 2015, pursuant to which the
Registrant was authorized to acquire for cash in open market or private transactions from time to time up to $125.0 million of
its common stock over the ensuing 12 months. The timing of repurchases and the exact number of shares of common stock to
be purchased depended upon market conditions and other factors. The repurchase program was funded through existing
liquidity, including borrowings from the Senior Credit Facility, and cash from operations. Treasury stock was recognized at the
cost to reacquire the shares. During 2015, the Company repurchased 2,318,720 shares of its common stock on the open market
at an average price of $53.91 per share or $125.0 million.

13. Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two
calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of
January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as
restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion
of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to
common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends

attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock
outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted
for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted

number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-
class method:

Net income
Less: earnings attributable to unvested shares

Net income available to common shareholders

Weighted average number of common and potential common shares
outstanding:

Basic number of common shares outstanding

Dilutive effect of stock equivalents

Diluted number of weighted average common shares outstanding

Earnings per common share:

Earnings per common share—Basic

Earnings per common share—Diluted

Year Ended December 31,

2017

2016

2015

22,445
(76)
22,369

47,971
(288)
47,683

26,346
(72)
26,274

19,444,795

19,271,448

20,032,300

288,615

310,028

291,085

19,733,410

19,581,476

20,323,385

1.15

1.13

2.47

2.44

1.31

1.29

Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of
diluted earnings per share as the effect would be anti-dilutive are 377,361, 445,303 and 444,334 for the years ended 2017, 2016
and 2015, respectively.

Page 62 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

14. Dividends

The following is the dividend activity for 2017, 2016 and 2015:

Dividends declared – per share
Dividends declared – aggregate
Dividends paid – per share
Dividends paid – aggregate

2017

Quarters ended

March 31

June 30

September 30

December 31

Total

0.48
9,349
0.48
9,349

0.48
9,373
0.48
9,373

1.92
37,468
1.92
37,468

2016

Quarters ended

March 31

June 30

September 30

December 31

Total

0.48
9,256
0.48
9,256

0.48
9,308
0.48
9,308

0.48
9,327
0.48
9,327

0.48
9,326
0.48
9,326

1.92
37,217
1.92
37,217

2015

Quarters ended

March 31

June 30

September 30

December 31

Total

0.48
10,198
0.48
10,198

0.48
9,863
0.48
9,863

0.48
9,261
0.48
9,261

0.48
9,236
0.48
9,236

1.92
38,558
1.92
38,558

The Company is a holding company that does not conduct any business operations of its own. As a result, the Company is

dependent upon cash dividends, distributions and other transfers from its subsidiaries, most directly Innophos, Inc., its primary
operating subsidiary, and Innophos Investments Holdings, Inc., the direct subsidiary of Innophos Holdings, Inc. and the direct
parent company of Innophos, Inc., to make dividend payments on its common stock.

15. Pension Plans and Post-retirement Benefits:

Innophos maintains both defined contribution plans and noncontributory defined benefit pension plans that together cover

substantially all U.S. and Canadian employees.

In the United States, salaried and hourly employees are covered by a defined contribution plan with a 401(k) feature. The
plan provides for employee contributions, company matching contributions, and an age-weighted annual company contribution
to eligible employees. Union-represented hourly employees, at the Company's Nashville, Tennessee site, are covered by a
traditional defined benefit plan providing benefits based on years of service and final average pay. On April 26, 2007, the
Company and the Union for the hourly employees at its Nashville, Tennessee facility agreed that it would freeze its defined
benefit pension plan (the “Plan”) as of August 1, 2007. The accrual of additional benefits or increase in the current level of
benefits under the Plan ceased as of August 1, 2007, after which the Nashville union employees now participate in the
Company’s existing non-contributory defined contribution benefit plan. All plans were established by Innophos in 2004.

In Canada, salaried employees are covered by defined contribution plans which provide for company contributions as a

percent of pay, employee contributions, and company matching contributions. Union-represented hourly employees are covered
by a defined benefit plan providing benefits based on a negotiated benefit level and years of service. The defined contribution
plans were established by the Company in 2004; the defined benefit plan for union-represented hourly employees is a
continuation of the Rhodia Canada Inc.’s pension plan for its Port Maitland, Ontario Canada union employees, which was
included in the acquisition of the Phosphates Business from Rhodia on August 13, 2004.

Page 63 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Innophos also has other post-retirement benefit plans covering substantially all of its U.S. and Canadian employees.
Certain employee groups covered under the plans do not receive benefits post-age 65. In the United States, the health care plans
are contributory with participants’ contributions adjusted annually, and limits on the Company’s share of the costs; the life
insurance plans are noncontributory. The effects of the Medicare Prescription Drug, Improvement and Modernization Act of
2003, or the Act, are not significant. In Canada, the plans are non-contributory.

Innophos uses a December 31 measurement date for all of its plans. For the purposes of the following schedules,

beginning of the year is January 1.

The weighted average discount rate at the measurement dates for the Company’s defined benefit pension plans and the
post-retirement benefit plans is developed using a spot interest yield curve based upon a broad population of corporate bonds
rated AA or higher, adjusted to match the duration of each plan’s projected benefit payment stream.

The expected return is based on a specific asset mix, active management, rebalancing among diversified asset classes

within the portfolio, and a consistent underlying inflation assumption to calculate the appropriate long-term expected
investment return.

As a sensitivity measure, the effect of a 25 basis-point decrease in the Company's discount rate assumption would

increase its net periodic benefit cost for its pension and post-retirement plans by approximately $76. A 1% decrease in the
Company's expected rate of return on plan assets would increase its pension plan expense by $187.

The amounts in accumulated other comprehensive income (loss), or AOCI, for all plans that are expected to be amortized

as components of net periodic benefit cost (benefit) during 2018 are as follows:

Prior service cost
Net actuarial loss (gain)
Transition obligation

Pension

53
194
—

Other
Benefits

Total

— $

(155)
24

53
39
24

The changes in benefit obligations and fair value of plan assets recognized in other comprehensive loss during 2017 and

2016 are as follows:

Pension Benefits

Other Benefits

Total

2017

2016

2017

2016

2017

2016

Change in accumulated other comprehensive
income

Amortization of net (gain) loss
Amortization of prior service cost /
transition obligation

Net (gain) loss

Total change in accumulated other
comprehensive income

Deferred taxes

Net amount recognized

(177) $

(208) $

212

100

(108)

694

409

(88)

321

(106)
(340)

(654)
203
(451) $

(23)
343

532
(148)
384

(23)
(1,521)

(131)
1,037

(1,444)
546
(898) $

941
(236)
705

(129)
(1,861)

(2,098)
749
(1,349)

Page 64 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

U.S. Plans

Obligations and Funded Status—U.S. Plans At December 31

Accumulated benefit obligation at end of year

Change in benefit obligation

Benefit obligation at beginning of year

Service cost

Interest cost

Actuarial loss (gain)

Benefits paid

Benefit obligation at end of year

Change in plan assets

Fair value of plan assets at beginning of year
Actual return on plan assets

Employer contributions

Benefits paid

Fair value of plan assets at end of year

Funded status of the plan

Amounts recognized in the consolidated balance sheets

Noncurrent assets

Current liabilities

Noncurrent liabilities

Net amounts recognized

Amounts recognized in accumulated other comprehensive
income

Prior service (credit) cost

Net actuarial (gain) loss

Total amount recognized
Deferred taxes

Net amount recognized

Pension Benefits

Other Benefits

2017

2016

2017

2016

2,662

2,473

—

100

154
(65)
2,662

2,263
430

—
(65)
2,628

$
(34) $

— $

—
(34)
(34) $

— $
(22)
(22) $
5
(17) $

2,473

2,670

—

114
(250)
(61)
2,473

2,124
200

—
(61)
2,263
$
(210) $

— $

—
(210)
(210) $

— $

114

114
(43)
71

3,250

2,974

123

118

151
(116)
3,250

— $
—

116
(116)

— $
(3,250) $

— $

(151)
(3,099)
(3,250) $

— $

(1,911)
(1,911) $
758
(1,153) $

2,974

4,285

172

165
(1,523)
(125)
2,974

—
—

125
(125)
—
(2,974)

—
(120)
(2,854)
(2,974)

—
(2,274)
(2,274)
864
(1,410)

Page 65 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Components of net periodic benefit cost

Service cost

Interest cost

Expected return on plan assets

Amortization of:

Prior service cost

Actuarial loss (gain)

Net periodic benefit cost

Weighted average assumptions for benefit
obligation

Pension Benefits

Other Benefits

2017

2016

2015

2017

2016

2015

— $

100

(140)

—

(40)

114
(145)

114
(140)

—

—
(31)

—

123

118

—

—
(211)
30

172

165

—

—
(100)
237

292

163

—

—
(48)
407

Discount rate

3.60%

4.16%

4.50%

3.66%

4.22%

4.25%

Expected long-term rate of return on plan
assets

Rate of compensation increase

Weighted average assumptions for net
periodic benefit cost

Discount rate

Expected long-term rate of return on plan
assets

Rate of compensation increase

6.30%

6.20%

6.51%

4.00%

3.75%

4.16%

4.50%

4.00%

4.22%

4.25%

4.00%

6.20%

6.51%

6.65%

3.75%

3.00%

Estimated Future Benefit Payments
Fiscal 2018
Fiscal 2019
Fiscal 2020
Fiscal 2021
Fiscal 2022
Fiscal Years 2023-2027

Pension Benefits
86
$
98
111
118
130
736

Other Benefits
151
$
178
172
177
180
868

Innophos expects to make no contributions to its U.S. defined benefit pension plan in 2018.

The estimated actuarial loss, prior service cost, and transition obligation (asset) for the defined benefit pension plans that
will be amortized from accumulated other comprehensive income into net periodic benefit cost during the 2018 fiscal year are
$0, $0 and $0, respectively.

The estimated actuarial gain, prior service cost, and transition obligation (asset) for the post-retirement plan that will be

amortized from accumulated other comprehensive income into net periodic benefit cost during the 2018 fiscal year are $159, $0
and $0, respectively.

Assumed health care cost trend rates on the U.S. plans do not have a significant effect on the amounts reported for the

health care plans as a result of limits on the Company’s share of the cost.

Page 66 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Plan Assets

The investment policy for the Company’s U.S. defined benefit pension plan is designed to achieve long-term objectives
of return, while mitigating against downside risk and considering expected cash flow. Investment managers appointed by the
Plan are directed to achieve a satisfactory return through a diversified portfolio consistent with acceptable risks and prudent
management. In accordance with the investment and risk philosophy of the Committee, a target asset mix of 90% equities and
10% fixed income instruments has been established. Investment weightings and results are tested regularly against appropriate
benchmark portfolios.

Innophos, Inc.’s defined benefit pension plan invests in mutual funds and commercial paper and the weighted-average

asset allocations at December 31, 2017 and 2016 by asset category are as follows:

Asset Category
Equity securities
Fixed income securities
Total

Plan Assets at
December 31

2017

2016

92.9%
7.1
100.0%

92.7%
7.3
100.0%

The fair values of Innophos, Inc.’s pension plan assets at December 31, 2017 by asset category are as follows:

Equity securities
Fixed income securities

Defined Contribution Plan—U.S.

Total

Level 1

Level 2

Level 3

2,441
187
2,628

— $
—
— $

—
—
—

Innophos Inc.’s expense for the defined contribution plan was $3.2 million, $3.0 million and $3.5 million for 2017, 2016

and 2015, respectively.

Page 67 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Canadian Plans

Obligations and Funded Status—Canadian Plans at December 31

Pension Benefits

Other Benefits

2017

2016

2017

2016

Accumulated benefit obligation at end of year

Change in benefit obligation

Benefit obligation at beginning of year

Service cost

Interest cost

Past service cost

Actuarial (gain) loss

Benefits paid

Foreign currency exchange rate changes

Benefit obligation at end of year

Change in plan assets

Fair value of plan assets at beginning of year

Actual return on plan assets

Employer contributions

Benefits paid

Foreign currency exchange rate changes

Fair value of plan assets at end of year

Funded status of the plan

Amounts recognized in the consolidated balance sheets

Noncurrent assets

Current liabilities

Noncurrent liabilities

Net amounts recognized

Amounts recognized in accumulated other comprehensive
income

Net transition obligation

Prior service cost
Net actuarial loss

Total amount recognized

Deferred taxes

Net amount recognized

15,590

13,128

383

517

153

886
(485)
1,008

15,590

14,798

1,308

—
(485)
1,108

16,729

1,139

—

13,128

12,319

362

489

—

—
(396)
354

13,128

13,864

931

—
(396)
399

14,798

1,670

—

1,139

1,670

— $

158

4,095

4,253
(1,063)
3,190

104

3,604

3,708
(927)
2,781

1,722

1,379

—

181
(53)
109

1,379

1,299

—

—
(58)
38

1,722

1,379

— $

—

53
(53)
—

— $
(1,722) $

— $

(103)
(1,619)
(1,722) $

—

200

237
(59)
178

—

58
(58)
—

—
(1,379)

—
(51)
(1,328)
(1,379)

—

68
(17)
51

Page 68 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Pension Benefits

Other Benefits

2017

2016

2015

2017

2016

2015

Components of net periodic benefit cost

Service cost

Interest cost

Expected return on plan assets

Amortization of:

Actuarial loss

Prior service cost

Net transition obligation

Net periodic benefit cost

Weighted average assumptions for balance
sheet liability at end of year

Discount rate

Rate of compensation increase

Weighted average assumptions for net periodic
benefit cost at end of year

383

517

(819)

177

108

—

366

362

344

489
(768)

507
(773)

207

106

—

396

158

110

—

346

—

129

123

124

3.37%

3.75%

3.37%

3.75%

Discount rate

Expected long-term rate of return

Rate of compensation increase

3.75%

5.50%

3.75%

5.50%

4.00%

5.50%

Accrued health care cost trend rates at end of
year

Health care cost trend rate assumed for
next year (initial rate)

Rate to which the cost trend rate is
assumed to decline (ultimate rate)

Year that the rate reaches the ultimate rate

3.75%

4.00%

2033

Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A one-

percentage-point change in assumed health care cost trend rates would have the following effects:

Effect of a change in the assumed rate of increase in health benefit costs

Effect of a 1% increase on:

Total of service cost and interest cost
Post-retirement benefit obligation

Effect of a 1% decrease on:

Total of service cost and interest cost
Post-retirement benefit obligation

Other Benefits

2017

2016

$
$

24
221

$
$

(18) $
(177) $

15
175

(12)
(143)

The estimated net actuarial loss, prior service cost, and transition obligation (asset) for all defined benefit pension plans

that will be amortized from accumulated other comprehensive income into net periodic benefit cost during the 2018 fiscal year
are $187, $51 and $0, respectively.

The estimated actuarial loss, prior service cost, and transition obligation (asset) for the post-retirement plan that will be
amortized from accumulated other comprehensive income into net periodic benefit cost during the 2018 fiscal year are $0, $0
and $23, respectively.

Page 69 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Plan Assets

Innophos Canada Inc.’s pension plan invests in mutual funds and the weighted-average asset allocations at December 31,

2017 and 2016 by asset category are as follows:

Asset Category
Equity securities
Fixed income securities
Other
Total

2017

2016

51.6%
44.8
3.6
100.0%

50.7%
46.5
2.8
100.0%

The fair values of Innophos Canada, Inc.’s pension plan assets at December 31, 2017 by asset category are as follows:

Equity securities
Fixed income securities
Other

Total

Level 1

Level 2

Level 3

8,636
7,498
595
16,729

8,636
—
595
9,231

— $

7,498
—
7,498

—
—
—
—

The Pension Committee has promulgated a Statement of Investment Policies and Procedures based on the “prudent
person portfolio approach” to ensure investment and administration of the assets of the Plan within the parameters set out in the
Ontario Pension Benefits Act and the Regulations hereunder. Investment managers appointed by the Plan are directed to achieve
a satisfactory return through a diversified portfolio consistent with acceptable risks and prudent management. In accordance
with the investment and risk philosophy of the Committee, a target asset mix of 50% equities and 50% fixed income
instruments has been established. Investment weightings and results are tested regularly against appropriate benchmark
portfolios.

Cash Flows

Contributions

Innophos Canada, Inc. contributed $0.0 million to its pension plan in 2017.

Estimated Future Benefit Payments

The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

Estimated Future Benefit Payments
Fiscal 2018
Fiscal 2019
Fiscal 2020
Fiscal 2021
Fiscal 2022
Fiscal Years 2023-2027

Pension Benefits
543
$
579
619
662
717
4,280

Other Benefits
103
$
64
78
100
103
531

Innophos does not plan to make $0.7 million in contributions to its Canadian pension plan in 2018.

Defined Contribution Plans—Canada

Innophos Canada Inc.’s expense for the defined contribution plans was approximately $0.1 million for 2017, 2016 and

2015, respectively.

Page 70 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Mexico

In accordance with Mexican labor law, a Mexican employee is entitled to certain post-employment payments after
reaching fifteen years of service. In addition, Mexican employees also participate in a statutory profit sharing program based on
10% of adjusted taxable income.

16. Income Taxes:

A reconciliation of the U.S. statutory rate and income taxes follows:

Year Ended December 31,

2017

2016

2015

U.S.
Canada/Mexico/Europe/Asia
Total
Current income taxes
Deferred income taxes
Total

Income
before
income taxes
24,727
$
45,591
70,318

Income
before
income taxes
8,026
$
48,611
56,637

Income tax
expense

$
$

20,230
13,962
34,192
23,781
10,411
34,192

Income
tax expense
10,989
$
11,358
22,347
12,813
9,534
22,347

$
$

Income
before
income taxes
11,574
$
28,549
40,123

Income tax
expense/
(benefit)

$
$

3,474
10,303
13,777
50,414
(36,637)
13,777

Year Ended December 31,

2017

2016

2015

Income tax expense at the U.S. statutory rate
State income taxes
Foreign tax rate differential
Non-taxable interest income
Change in valuation allowance
U.S. Tax Cuts and Jobs Act of 2017
Domestic manufacturing deduction
Mexico entities tax de-consolidation adjustment
Repatriation of foreign earnings
Uncertain tax positions
Foreign tax credits carryforward
Capital loss on note redemption
Other non-deductible permanent items (including translation)
Provision for income taxes

19,824
741
(1,606)
(5,951)
1,984
17,286
—
—
—
—
—
—
1,914
34,192

Net deferred tax balances were reflected on the consolidated balance sheets as follows:

Net noncurrent deferred tax assets
Net noncurrent deferred tax liabilities
Net deferred tax assets

24,611
862
(1,549)
(5,582)
(168)
—
(562)
(472)
496
736
—
—
3,975
22,347

14,044
1,207
(1,163)
(3,903)
3,482
—
(903)
1,470
(645)
306
(1,406)
(1,062)
2,350
13,777

Year Ended December 31,

2017

2016

5,058
(2,354)
2,704

18,432
(1,282)
17,150

Page 71 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The components of the Company’s deferred tax assets/ (liabilities) were as follows:

Deferred tax assets:
Inventories
Accrued liabilities
Prepaid inventory
Tax credits
Tax losses
Total deferred tax assets
Deferred tax liabilities:
Gain on bond retirement
Intangibles
Fixed assets
Accrued liabilities
Total deferred tax liabilities
Total valuation allowances
Net deferred tax assets (liabilities)

Year Ended December 31,

2017

2016

3,427
7,472
—
3,846
22,196
36,941

(170)
(11,012)
(10,809)
(1,800)
(23,791)
(10,446)
2,704

5,089
10,800
13,987
2,535
16,187
48,598

(530)
(7,033)
(15,423)
—
(22,986)
(8,462)
17,150

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows:

Gross unrecognized tax benefits at January 1

Additions for tax positions of prior years

Reductions for tax positions of prior years

Reductions due to settlements

Gross unrecognized tax benefits at December 31

Year Ended December 31,

2017

2016

2015

2,679

3,121

2,798

—

2,679

973

—
(1,415)
2,679

470
(147)
—

3,121

Net uncertain tax benefits, that if recognized would impact the effective tax
rate, at December 31

2,116

1,741

1,311

The U.S. operations have deferred tax assets for federal tax loss carry forwards of $13.9 million and $9.3 million and

state tax loss carry forwards of $1.6 million and $1.1 million as of December 31, 2017 and 2016, respectively. These tax loss
carry forwards will expire in the years 2026 through 2036. The Company realized tax benefits of $0.8 million and $0.0 million
from stock options exercised in 2017 and 2016, respectively.

The Company maintains full valuation allowances of $10.4 million and $8.5 million at December 31, 2017 and 2016,

respectively, on its capital loss on note redemptions, foreign withholding tax credits and foreign net operating loss
carryforwards as it is more likely than not that these tax benefits will not be realized. The increase in valuation allowances
during 2017 is primarily a result of the generation of current year foreign tax withholding credits and foreign net operating
losses which are not anticipated to be utilized in future years. Certain of these foreign tax attributes, approximately $4.6 million,
do not expire, while the remaining tax attributes will expire in the years 2018 through 2037.

On December 22, 2017, the U.S. enacted the Tax Act. The Tax Act significantly changes U.S. corporate income tax laws

by, among other things, reducing the U.S. corporate income tax rate from 35% to 21% effective for tax years beginning after
December 31, 2017 and transitioning U.S. international taxation from a worldwide tax system to a territorial tax system with a
one-time mandatory transition or toll tax on post-1986 undistributed foreign earnings and profits of U.S. subsidiaries through
the year ended December 31, 2017. The Company has calculated its best estimate of the impact of the Tax Act in its year end
income tax provision in accordance with the Company's understanding of the Tax Act and guidance available as of the date of
Page 72 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

this filing and, as a result, have recorded $17.3 million as additional income tax expense in the fourth quarter of 2017, the
period in which the legislation was enacted. This amount consists of two components: (1) a $13.9 million charge payable over
eight years and related to the one-time transition tax on the mandatory deemed repatriation of foreign earnings of certain non-
U.S. subsidiaries owned either wholly or partially by a U.S. subsidiary of the Company, and (2) a $3.4 million charge related to
the remeasurement of certain U.S. deferred tax assets and liabilities, based on the rates at which they are expected to reverse in
the future.

On December 22, 2017, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of

U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including
computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with
SAB 118, the Company has recognized the provisional tax impacts related to deemed repatriated earnings and the revaluation
of deferred tax assets and liabilities and included these reasonably estimated amounts in its consolidated financial statements for
the year ended December 31, 2017. The ultimate impact may differ from these provisional amounts, possibly materially, due to,
among other things, additional analysis, changes in interpretations and assumptions the Company has made, additional
regulatory guidance that may be issued, and actions the Company may take as a result of the Tax Act. Any subsequent
adjustment to these amounts will be recorded within the one year measurement period allowed by SAB 118.

Beginning in 2018, the Tax Act includes two new U.S. tax base erosion provisions, the GILTI provisions and the base-

erosion and anti-abuse tax (“BEAT”) provisions.

The GILTI provisions require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess

of an allowable return on the foreign subsidiary’s tangible assets. The Company expects that it will be subject to incremental
U.S. tax on GILTI income beginning in 2018 due to expense allocations required by the U.S. foreign tax credit rules. The
Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred
tax impacts of GILTI in its consolidated financial statements for the year ended December 31, 2017.

The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign

corporations, and impose a minimum tax if greater than regular tax. The Company does not expect it will be subject to this tax
and therefore has not included any tax impacts of BEAT in its consolidated financial statements for the year ended December
31, 2017.

As of December 31, 2017, the Company is in the process of evaluating the impact of the Tax Act on its permanent
reinvestment assertion. With respect to accumulated earnings of foreign subsidiaries, no additional U.S. income taxes or foreign
withholding taxes have been provided as all accumulated earnings of foreign subsidiaries are deemed to have been remitted as
part of the one-time transition tax. The Company continues to evaluate its permanent reinvestment assertion in light of the Tax
Act. The accounting is expected to be completed within the one-year measurement period as allowed by SAB 118.

Business is conducted in various countries throughout the world and is subject to tax in numerous jurisdictions. A
significant number of tax returns are filed and subject to examination by various federal, state and local tax authorities. Tax
examinations are often complex, as tax authorities may disagree with the treatment of items reported requiring several years to
resolve. As such, the Company maintains liabilities for possible assessments by tax authorities resulting from known tax
exposures for uncertain income tax positions. The Company’s policy is to accrue associated penalties in selling, general and
administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has
been contacted for examination on income tax returns for the years 2009 through 2015. Certain state income tax assessments
are under protest and the Company believes its financial position is sustainable. The Company estimates the liability for
unrecognized tax benefits may decrease by approximately $0.7 million during the next twelve months as a result of possible
settlements of income tax authority examinations. The Company has recorded an immaterial amount for interest and penalties
in the statement of operations. Interest and penalties related to uncertain tax positions of $0.8 million and $0.7 million are
accrued in other long-term liabilities as of December 31, 2017 and December 31, 2016, respectively. Other than the items
mentioned above, as of December 31, 2017, no significant adjustments have been proposed to the Company's tax positions and
the Company currently does not anticipate any adjustments that would result in a material change to its financial position during
the next twelve months.

Income taxes paid (net of refunds) were $14.9 million, $27.9 million and $17.0 million for 2017, 2016 and 2015,

respectively.

Page 73 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

17. Commitments and Contingencies:

Leases

Under agreements expiring through 2020, the Company leases railcars and other equipment under various operating

leases. Rental expense for 2017, 2016 and 2015 was $7,287, $6,930 and $6,858, respectively. Minimum annual rentals for all
operating leases are:

Year Ending
2018
2019
2020
2021
2022
Thereafter

Lease Payments
6,654
$
5,591
4,434
4,016
3,710
9,144

Purchase Commitments and Supplier Concentration

The Company has multiple raw material supply contracts which prices are established annually based on a formula. The
minimum annual purchase obligation for several of these raw material supply contracts, at current prices, approximates $56.7
million for 2018.

The Company's business activities depend on long-term or renewable contracts to supply materials or products. In

particular, the Company relies to a significant degree on single-source supply contracts and some of these contractual
relationships may be with a relatively limited number of suppliers. Although most of the supplier relationships are typically the
result of multiple contractual arrangements of varying terms, in any given year, one or more of these contracts may come up for
renewal. As such, on June 23, 2016, the Company received written notice from PCS Purified Phosphates, or PCSPP, an affiliate
of Potash Corporation of Saskatchewan, now Nutrien as of January 1, 2018, that PCSPP does not wish to extend the term of the
Amended and Restated Purified Wet Phosphoric Acid Supply Agreement, dated March 23, 2000, beyond July 29, 2018, the end
of the current renewal term. The Company currently purchases purified phosphoric acid supply from PCSPP under the
agreement and it will continue to qualify and develop additional sources for future supply needs after July 29, 2018. In addition,
from time to time, the Company enters into toll manufacturing agreements or other arrangements to produce minimum
quantities of product for a certain duration. If the Company experience delays in delivering contracted production, the Company
may be subject to contractual liabilities to the buyers to whom the Company has promised the products.

Environmental

The Company's operations are subject to extensive and changing federal, state, local and international environmental

laws, rules and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and
groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites,

discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology,
changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the
involvement of and the financial capability of other potentially responsible parties and the extended time periods over which
remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are
probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible
that amounts may need to be accrued. However, management does not believe, based on current information, that
environmental remediation requirements will have a material impact on the Company's results of operations, financial position
or cash flows.

Future environmental spending is probable at the Company's site in Nashville, Tennessee, the eastern portion of which
had been used historically as a landfill, and a western parcel therein, previously acquired from a third party, which reportedly
had housed, but no longer does, a fertilizer and pesticide manufacturing facility. The Company has an estimated liability with a
range of $0.9 million-$1.3 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has
recorded a liability, which represents the Company's best estimate, of $1.1 million as of December 31, 2017.

Page 74 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Litigation

2008 RCRA Civil Enforcement - Geismar, Louisiana plant

On January 12, 2017, the Company entered into a settlement with the United States Environmental Protection Agency, or
EPA, and the Louisiana Department of Environmental Quality, or LDEQ, with respect to certain manufacturing processes at the
Company’s Geismar, Louisiana plant, including the Company’s handling of (i) filter material from an enclosed intermediate
filtration step to further process merchant green phosphoric acid, or MGA, that the Company receives as raw material via
pipeline from the adjacent site operated by Nutrien and (ii) the Company’s raffinate co-product that is separated in connection
with its PPA production at the plant. The EPA and LDEQ, collectively with the United States Department of Justice, or DOJ, are
collectively referred to as the Government Parties. This settlement resulted from years of negotiations between the Company
and the Government Parties following inspections of the plant by the Government Parties in which they raised certain violations
of the federal Resource, Conservation and Recovery Act. Prior to this settlement, in the course of discussions with the
Government Parties, the EPA and the DOJ required that the Company undertake, as an interim measure, the construction of a
new filter unit to replace the enclosed system and allow the removal and separate handling of the filter material. The Company
built that unit, which has been operating since 2012. As part of the settlement, Innophos is implementing a deep well injection
system, a solution approved by the EPA and LDEQ to handle the raffinate separated at the plant. Such system has been
completed, subject to regulatory approvals and permitting. The Company previously returned the raffinate to Nutrien under a
long-term contract it has with Nutrien and can continue to do so until the Company receives the necessary approvals and
permits to operate its deep well system. In connection with this settlement, the Company paid a $1.4 million civil penalty in
November 2017 which was previously accrued in other current liabilities.

Other Legal Matters

In addition, the Company is party to legal proceedings and contractual disputes that arise in the ordinary course of its

business. Except as to the matters specifically discussed, management believes the likelihood that the ultimate disposition of
these matters will have a material adverse effect on its business, results of operations, financial condition and/or cash flows is
remote. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could
have a material adverse effect on the Company's business, results of operations, financial condition, and/or cash flows.

18. Changes in Accumulated Other Comprehensive Income (Loss) by Component:

Pension and
Other Post-
retirement
Adjustments

Changes in
Fair Value of
Effective Cash
Flow Hedges

Total

Balance at December 31, 2015

Other comprehensive income (loss) before reclassifications

Amounts reclassified from accumulated other comprehensive income (loss)
Net current period other comprehensive income (loss)

Balance at December 31, 2016

Other comprehensive income (loss) before reclassifications

Amounts reclassified from accumulated other comprehensive income (loss)

Net current period other comprehensive income (loss)

Balance at December 31, 2017

(2,842) $
1,349

—
1,349
(1,493)
(412)
(293)
(705)
(2,198) $

48
(39)
—
(39)
9
(9)
—
(9)
— $

(2,794)
1,310

—
1,310
(1,484)
(421)
(293)
(714)
(2,198)

19. Financial Instruments and Concentration of Credit Risks:

The Company believes that its concentration of credit risk related to trade accounts receivable is limited since these
receivables are spread among a number of customers and are geographically dispersed. The ten largest customers accounted for
26%, 35% and 33%, respectively, of net sales for 2017, 2016 and 2015. No customer accounted for more than 10% of the
Company's sales in the last three years.

Page 75 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

20. Valuation Allowances:

Valuation allowances as of December 31, 2017, 2016 and 2015, and the changes in the valuation allowances for the year

ended December 31, 2017, 2016 and 2015 are as follows:

Balance,
January, 1 2017
8,462
$

Balance,
January, 1 2016
8,630
$

Balance,
January, 1 2015
5,148
$

Charged/
(credited)
to costs
and
expenses

Deductions
(Bad debts)

(Credited)
to Goodwill

Balance,
December 31,
2017

1,984

— $

10,446

Charged/
(credited)
to costs
and
expenses

Deductions
(Bad debts)

(Credited)
to Goodwill

Balance,
December 31,
2016

(168) $

— $

8,462

Charged/
(credited)
to costs
and
expenses

Deductions
(Bad debts)

(Credited)
to Goodwill

Balance,
December 31,
2015

3,482

— $

8,630

Deferred taxes valuation allowances

21. Segment Reporting:

The Company discloses certain financial and supplementary information about its reportable segments, revenue by

products and revenues by geographic area. Operating segments are defined as components of an enterprise about which
separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to
allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales
and EBITDA (defined as net income (loss) before interest, income taxes, depreciation and amortization). All references to sales
in this Annual Report on Form 10-K are recognized when title and risk of loss passes to the customer, which occurs either upon
shipment or delivery, depending upon the agreed sales terms with customers.

Page 76 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the year ended December 31, 2017
Sales

EBITDA

Depreciation and amortization expense

Other data
Capital expenditures

Long-lived assets

Total assets (c)

For the year ended December 31, 2016
Sales

EBITDA (a)

Depreciation and amortization expense

Other data
Capital expenditures

Long-lived assets

Total assets

For the year ended December 31, 2015
Sales
EBITDA (b)
Depreciation and amortization expense
Other data
Capital expenditures
Long-lived assets
Total assets

Food, Health
and Nutrition

Industrial
Specialties

Other

Total

$
$
$

397,298

67,156

24,212

27,537

130,705

556,479

Food, Health
and Nutrition

376,672

78,128

20,269

19,181

124,664

397,575

Food, Health
and Nutrition

394,836
67,212
20,186

17,507
114,549
401,660

$
$
$

262,704

33,833

13,863

13,331

71,925

190,700

Industrial
Specialties

278,284

36,029

12,645

15,866

72,727

210,680

Industrial
Specialties

319,565
34,028
14,030

13,137
66,819
221,386

$
$
$

62,022

3,060

2,329

619

16,667

37,990

Other

70,389

1,309

4,565

1,552

8,068

34,756

722,024

104,049

40,404

41,487

219,297

785,169

Total

725,345

115,466

37,479

36,599

205,459

643,011

Other

Total

74,746
$
(15,064) $
$
4,319

1,055
18,126
46,507

$
$
$

789,147
86,176
38,535

31,699
199,494
669,553

(a)
(b)

(c)

The year ended December 31, 2016 includes a $1.5 million charge to earnings for restructuring reserves in Other.
The year ended December 31, 2015 includes an $11.8 million charge to earnings for management transition expenses
and an $8.6 million charge to earnings for restructuring reserves in Other.
The increase in total assets in the Food, Health and Nutrition segment is largely due to the Novel Ingredients and
NutraGenesis acquisitions.

A reconciliation of net income to EBITDA follows:

Net income

Provision for income taxes

Interest expense, net

Depreciation and amortization

EBITDA

2017

2016

2015

22,445

47,971

34,192

7,008

40,404

22,347

7,669

37,479

104,049

115,466

26,346

13,777

7,518

38,535

86,176

Page 77 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Year Ended December 31,

Product Revenues
Specialty Ingredients
Core Ingredients
Co-Products and Other
Total

Geographic Revenues
U.S.
Mexico
Canada
Other foreign countries
Total

Geographic Long-lived Assets
U.S.
Mexico
Canada
Other foreign countries
Total

2017
490,256
174,819
56,949
722,024

2016
456,465
200,560
68,320
725,345

$
Year Ended December 31,

2017
450,171
125,116
31,993
114,744
722,024

2016
418,411
123,885
32,391
150,658
725,345

Year Ended December 31,

2017
113,795
91,414
12,293
1,795
219,297

2016
104,118
85,698
13,575
2,068
205,459

2015
499,047
216,787
73,313
789,147

2015
469,263
119,080
33,456
167,348
789,147

2015
101,001
82,132
13,868
2,493
199,494

Revenues for the geographic information are attributed to geographic areas based on the destination of the sale.

Long-lived assets include property, plant and equipment.

Page 78 of 85

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Consolidated Financial Statements
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

22. Quarterly information (unaudited):

2017

Quarters ended

Net sales
Gross profit
Net income (loss) (a)
Per share data:

Income per share:

Basic
Diluted

Net sales
Gross profit (b)
Net income (c)
Per share data:

Income per share:

Basic
Diluted

March 31

165,944
36,543
10,923

0.56
0.55

March 31

189,630
40,716
12,842

0.67
0.66

$
$

June 30
179,140
39,076
11,223

September 30 December 31
$

183,839 $

193,101 $

40,969
11,582

32,441
(11,283)

Total
722,024
149,029
22,445

0.58
0.57

$
$

2016

0.59
0.58

$
$

(0.58)
(0.58)

Quarters ended

June 30
181,888
36,150
12,104

September 30 December 31
167,790
$
32,986
9,382

186,037
40,540
13,643

Total
725,345
150,392
47,971

0.62
0.61

$
$

0.70
0.69

$
$

0.48
0.47

(a) The three months ended December 31, 2017 include a $17.3 million charge to income taxes for the impacts of the Tax

Act.

(b) The three months ended September 30, 2016 include a $0.2 million charge to earnings for restructuring costs,

recorded in Other.

expenses for restructuring costs, recorded in Other.

Page 79 of 85

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Disclosure Control and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Exchange
Act) that are designed to provide reasonable assurance that information required to be reported in the Company’s consolidated
financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and
forms of the SEC and that such information is accumulated and communicated to the Company’s management, including its
principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required
disclosure. The Principal Executive Officer and Principal Financial Officer, with the participation of management, concluded
that the Company’s disclosure controls and procedures are effective at the reasonable assurance level as of December 31, 2017.

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Management is responsible for establishing and maintaining adequate internal control over financial reporting. The

Company’s internal control framework and processes are designed to provide reasonable assurance to management and the
Board of Directors regarding the reliability of financial reporting and the preparation of the Company’s consolidated financial
statements in accordance with United States generally accepted accounting principles.

As of December 31, 2017, management conducted an assessment of the Company’s internal control over financial
reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission in
Internal Control — Integrated Framework (2013). Based on the assessment, management concluded that, as of December 31,
2017, the Company’s internal control over financial reporting is effective at the reasonable assurance level.

The Company acquired Novel Ingredients on August 25, 2017 and NutraGenesis on November 3, 2017, both wholly

owned subsidiaries, and is in the process of evaluating and integrating these companies into the Company’s existing internal
control over financial reporting. The combined revenue of these two companies as a percentage of total revenue is 5% and their
combined assets as a percentage of total Company assets is 6%. The Management’s Report on Internal Control Over Financial
Reporting included in this Annual Report on Form 10-K excludes Novel Ingredients and NutraGenesis, and the Company will
disclose any material changes in its internal controls over financial reporting with respect to Novel Ingredients and
NutraGenesis in the Annual Report on Form 10-K for the year ending December 31, 2018.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

PricewaterhouseCoopers LLP, an independent registered public accounting firm, has audited the Company’s financial
statements included in this Annual Report on Form 10-K and issued its report on the effectiveness of the Company’s internal
control over financial reporting as of December 31, 2017, which is included in “Part II, Item 8. Consolidated Financial
Statements and Supplementary Data”.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during or with respect to the
fourth quarter of 2017 that have materially affected, or are reasonably likely to materially affect, the Company's internal control
over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

Page 80 of 85

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Information relating to our executive officers appears in "Part 1, Item 1. Business" appearing elsewhere in this Annual

Report on Form 10-K. Additional information required by this Item is incorporated herein by reference to the 2018 Proxy
Statement.

ITEM 11. EXECUTIVE COMPENSATION

The information required by this Item is incorporated herein by reference to the 2018 Proxy Statement.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND

RELATED STOCKHOLDER MATTERS

Equity Compensation Plans

The following information is provided for our most recently completed fiscal year for certain plans providing

compensation in the form of equity securities.

Equity Compensation Plan Information

Number of securities to be
issued upon exercise of
outstanding options,
warrants and rights

Weighted average exercise
price of outstanding
options, warrants and right
s

Number of securities
remaining available for
future issuance under
equity
compensation plans
(excluding securities
reflected in column (a))

(a)

(b) *

(c)

789,007

— $
$

789,007

38.42

—
38.42

639,613 * *

—
639,613

Plan category

Equity compensation plans approved by
security holders

Equity compensation plans not approved
by security holders
Total

______________________

In column (b), the weighted average exercise price is only applicable to stock options.

In column (c), the shares shown are attributable to the 2009 Long Term Incentive Plan.

Additional information required by this Item is incorporated herein by reference to the 2018 Proxy Statement.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

The information required by this Item is incorporated herein by reference to the 2018 Proxy Statement.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this Item is incorporated herein by reference to the 2018 Proxy Statement.

Page 81 of 85

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

PART IV

(a)(1) Financial Statements. The financial statements filed as part of this Annual Report on Form 10-K are listed on the
Index to Financial Statements in “Part II, Item 8. Consolidated Financial Statements and Supplementary Data.”

(a)(2) Financial Statement Schedules. Schedules are omitted because they are not required or because the information
is provided elsewhere in the financial statements noted in (a)(1) above.

(a)(3) Exhibits required by Item 601 of Regulation S-K. The information required by this Section (a)(3) of Item 15 is
set forth on the Exhibit Index that follows the signatures page of this Annual Report on Form 10-K.

ITEM 16. FORM 10-K SUMMARY

Optional disclosure, not included in this Annual Report on Form 10-K.

Page 82 of 85

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, Innophos Holdings, Inc. has

duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized on the 1st day of March, 2018.

SIGNATURES

INNOPHOS HOLDINGS, INC.

By:

/S/ KIM ANN MINK
Kim Ann Mink

Chief Executive Officer and President
(Principal Executive Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons

on behalf of Innophos Holdings, Inc. and in the capacities and on the dates indicated.

Signatures

Title

Dates

/S/ KIM ANN MINK

Chairman, Chief Executive Officer and President

March 1, 2018

Kim Ann Mink

(Principal Executive Officer)

/S/ HAN KIEFTENBELD

Senior Vice President and Chief Financial Officer

March 1, 2018

Han Kieftenbeld

(Principal Financial Officer)

/S/ CHARLES BRODHEIM

Vice President, Corporate Controller and Chief
Accounting Officer

March 1, 2018

Charles Brodheim

(Principal Accounting Officer)

/S/ GARY CAPPELINE

Director

Gary Cappeline

March 1, 2018

/S/ LINDA MYRICK

Director

March 1, 2018

Linda Myrick

/S/ KAREN OSAR

Karen Osar

/S/ JOHN STEITZ

John Steitz

Director

/S/ PETER THOMAS

Director

Peter Thomas

/S/ JAMES ZALLIE

Director

James Zallie

/S/ ROBERT ZATTA

Director

Robert Zatta

Page 83 of 85

March 1, 2018

EXHIBIT INDEX

Exhibit No.

Description

3.1 Second Amended and Restated Certificate of Incorporation of Innophos Holdings, Inc. incorporated by

reference to Exhibit 3.1 of Amendment No. 4 to Registration Statement 333-135851 on Form S-1 of Innophos
Holdings, Inc. filed October 30, 2006

3.2 Amended and Restated By-Laws of Innophos Holdings, Inc. as of February 8, 2018, incorporated by

reference to Exhibit 3.1 of the Current report on Form 8-K of Innophos Holdings, Inc. filed February 12, 2018

4.1 Form of Common Stock certificate, incorporated by reference to Exhibit 4.1 of Amendment No. 4 to
Registration Statement 333-135851 on Form S-1 of Innophos Holdings, Inc. filed October 30, 2006
10.1 Supply Agreement (Sulphuric Acid) dated as of August 13, 2004 between Rhodia, Inc. (now part of Solvay

S.A.) and Innophos, Inc. (filed in redacted form per confidential treatment order), incorporated by reference to
Exhibit 10.3 of Annual Report on Form 10-K of Innophos Holdings, Inc. filed on March 14, 2008

10.2 Amended and Restated Purified Wet Phosphoric Acid Supply Agreement dated as of March 23, 2000 by and

between Rhodia, Inc. (assigned to Innophos) and PCS Purified Phosphates (now part of Nutrien), incorporated
by reference to Exhibit 10.15 to Amendment No. 4 of Registration Statement 333-129951 on Form S-4 of
Innophos, Inc. (filed in redacted form per confidential treatment order) filed February 14, 2006

10.3 Amended and Restated Acid Purchase Agreement dated as of March 23, 2000 among Rhodia, Inc. (assigned
to Innophos), PCS Sales (USA), Inc. and PCS Nitrogen Fertilizer L.P. (now part of Nutrien), incorporated by
reference to Exhibit 10.16 to Amendment No. 4 of Registration Statement 333-129951 on Form S-4 of
Innophos, Inc. (filed in redacted form per confidential treatment order) filed February 14, 2006

10.4 Purchase and Sale Agreement of Anhydrous Ammonia dated as of February 15, 2008 , by and between Pemex
Petroquimica (assigned to Pemex Fertilizantes), and Innophos Fosfatados De Mexico, S. de R.L. de C.V.
(filed in redacted form per confidential treatment order), incorporated by reference to Exhibit 10.8 of Annual
Report on Form 10-K/A of Innophos Holdings, Inc. filed on May 8, 2009

10.5 Assignment, Assumption, and Consent, concerning the Purchase and Sale Agreement of Anhydrous

Ammonia, to be effective May 1, 2009, incorporated by reference to Exhibit 10.2 of Annual Report on Form
10-K of Innophos Holdings, Inc. filed on February 28, 2011

10.6 Letter Update, dated February 22, 2011, concerning the Purchase and Sale Agreement of Anhydrous

Ammonia, incorporated by reference to Exhibit 10.6 of the Annual Report on Form 10-K of Innophos
Holdings, Inc. filed on February 26, 2016

10.7 Sulfur Supply Contract dated as of January 1, 2011 by and Between Pemex Gas Y Petroquimica Basica

(assigned to Pemex Transformacion Industrial) and Innophos Fosfatados de Mexico, S. de R.L. de C.V. (filed
in redacted form per confidential treatment order), incorporated by reference to Exhibit 10.7 of Annual Report
on Form 10-K of Innophos Holdings, Inc. filed on February 28, 2011

10.8 Partial Assignment of Rights and Obligations Agreement dated November 1, 2012, by and between

Administracion Portuaria Integral de Coatzacoalcos, S.A. de C.V. and Innophos Fosfatados de Mexico, S. de
R.L. de C.V (in redacted form per confidential treatment order), incorporated by reference to Exhibit 99.1 to
Form 8-K of Innophos Holdings, Inc. filed November 9, 2012

10.9 Addendum to Partial Assignment of Rights and Obligations agreement, dated May 31, 2016, incorporated by

reference to Exhibit 10.9 of the Annual Report on Form 10-K of Innophos Holdings, Inc. filed on February
28, 2017

10.10+ Innophos Holdings, Inc. Amended and Restated 2005 Executive Stock Option Plan, incorporated by reference
to Exhibit 10.28 to Amendment No. 4 of Registration Statement 333-135851 on Form S-1 of Innophos
Holdings, Inc. filed October 30, 2006

10.11+ Form of 2006 Long-Term Equity Incentive Plan, incorporated by reference to Exhibit 10.37 to Amendment
No. 4 of Registration Statement 333-135851 on Form S-1 of Innophos, Inc. filed October 30, 2006

10.12+ Form of 2009 Long-Term Incentive Plan (2009 LTIP), incorporated by reference to Exhibit 99.1 of the

Current Report on Form 8-K of Innophos Holdings, Inc. filed June 4, 2009

10.13+ Form of Award Agreement under the 2009 LTIP, incorporated by reference to Exhibit 10.1 of the Current

Report on Form 8-K of Innophos Holdings, Inc. filed on April 7, 2017

10.14+ Form of Innophos, Inc. Retirement Savings Restoration Plan effective as of January 1, 2006, incorporated by
reference to Exhibit 10.29 of Annual Report on Form 10-K of Innophos Holdings, Inc. filed March 22, 2007

10.15+ Innophos, Inc. 2015 Executive, Management and Sales Incentive Plan effective January 1, 2015, incorporated

by reference to Exhibit 99.1 of Form 8-K of Innophos Holdings, Inc. filed May 27, 2015

10.16+ Form of Indemnification Agreement, by and among Innophos Holdings, Inc. and certain Directors and

Executive Officers, incorporated by reference to Exhibit 99.2 of Form 8-K of Innophos Holdings, Inc. filed
January 31, 2007

Page 84 of 85

10.17+ Executive Employment Agreement, dated November 10, 2015, by and between Innophos Holdings, Inc. and

Kim Ann Mink, incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K of Innophos
Holdings, Inc. filed on November 16, 2015

10.18+* Executive Employment Agreement, dated April 1,2016, by and between Innophos Holdings, Inc. and Han

Kieftenbeld (being filed solely to fix a typographical error included in the agreement previously filed as
Exhibit 10.1 of the Current Report on Form 8-K filed by Innophos Holdings, Inc. on April 6, 2016)

10.19+* Executive Employment Agreement, dated as of October 7, 2016, by and between Innophos Holdings, Inc. and

Joshua Horenstein

10.20+* Change in Control Agreement, dated July 15, 2016, by and between Innophos Holdings, Inc. and Sherry Duff
10.21+ Change in Control Agreement, dated June 1, 2017, by and between Innophos Holdings, Inc. and Amy

Hartzell, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed by Innophos
Holdings, Inc. on June 6, 2017

10.22 Credit Agreement, dated December 22, 2016, between the Company and a group of Lenders, including Wells

Fargo Bank, National Association, as administrative agent, incorporated by reference to exhibit 10.1 of the
Current Report on Form 8-K filed by Innophos Holdings, Inc. on December 22, 2016

12.1* Statement re: Calculation of Ratio of Earnings to Fixed Charges
21.1* Subsidiaries of Registrant
23.1* Consent of PricewaterhouseCoopers LLP
31.1* Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2* Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1** Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2** Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

Pursuant to rules of the Securities and Exchange Commission, agreements and instruments evidencing the rights of

holders of debt whose total amount does not exceed 10% of the total assets of the registrant and its subsidiaries on a
consolidated basis are not being filed as exhibits to this report. The registrant has agreed to furnish a copy of such agreements
and instruments to the Commission upon its request.

* Filed herewith.
** Furnished herewith.
+ Management contract or compensatory plan or arrangement.

Page 85 of 85

[THIS PAGE INTENTIONALLY LEFT BLANK]

Ofﬁcers & Directors

Innophos Executive Ofﬁcers

Board of Directors

Corporate Information

Kim Ann Mink, Ph.D.
Chairman of the Board

Gary Cappeline
Lead Independent Director;
Chair, Strategic Advisory Committee

Linda Myrick
Director; Chair, Nominating &
Corporate Governance Committee

Karen Osar
Director

John Steitz
Director; Chair,
Compensation Committee

Peter Thomas
Director

James Zallie
Director

Robert Zatta
Director; Chair, Audit Committee

Kim Ann Mink, Ph.D.
Chairman, President and
Chief Executive Ofﬁcer

Han Kieftenbeld
Senior Vice President and
Chief Financial Ofﬁcer

Charles Brodheim
Vice President, Corporate Controller
and Chief Accounting Ofﬁcer

Sherry Duff
Senior Vice President, Chief
Marketing and Technology Ofﬁcer

Amy Hartzell
Senior Vice President, Supply Chain
and Purchasing

Joshua Horenstein
Senior Vice President, Chief Legal
Ofﬁcer and Corporate Secretary

Mark Santangelo
Senior Vice President,
Manufacturing, Engineering,
and EH&S

Robert Sklans
Senior Vice President and
Chief Human Resources Ofﬁcer

TRANSFER AGENT AND REGISTRAR
EQ Shareowner Services

INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM
PricewaterhouseCoopers LLP

CORPORATE LOCATIONS
USA (Corporate Headquarters)
Innophos Holdings, Inc.
259 Prospect Plains Rd, Bldg A
Cranbury, NJ 08512-3706 USA
609-495-2495

Mexico
Innophos Mexicana S. de R.L. de C.V.
Bosques de los Ciruelos 186
Piso 11
Colonia Bosques de las Lomas
Delegacion Miguel Hidalgo
11700 Mexico, D.F.
+ (52) 55 5322 4808

www.innophos.com

INNOPHOS MANUFACTURING
FACILITIES
Port Maitland, Ontario, Canada
Chicago Heights, Illinois
Chicago (Waterway), Illinois
East Hanover, New Jersey
Ogden, Utah
North Salt Lake, Utah
Nashville, Tennessee
Green Pond, South Carolina
Geismar, Louisiana
San Jose de Iturbide (Mission Hills),
Guanajuato, Mexico
Coatzacoalcos, Veracruz, Mexico
Taicang, China

INVESTOR RELATIONS CONTACTS
investor.relations@innophos.com
609-366-1299
or Ryan Flaim
Sharon Merrill Associates
617-542-5300
IPHS@investorrelations.com

Innophos Holdings, Inc.
259 Prospect Plains Rd, Bldg A
Cranbury, NJ 08512-3706 USA